6	DYSPORT.xml:S1:4:1	O
ADVERSE	DYSPORT.xml:S1:6:7	O
REACTIONS	DYSPORT.xml:S1:14:9	O

The	DYSPORT.xml:S1:27:3	O
following	DYSPORT.xml:S1:31:9	O
serious	DYSPORT.xml:S1:41:7	O
adverse	DYSPORT.xml:S1:49:7	O
reactions	DYSPORT.xml:S1:57:9	O
are	DYSPORT.xml:S1:67:3	O
discussed	DYSPORT.xml:S1:71:9	O
below	DYSPORT.xml:S1:81:5	O
and	DYSPORT.xml:S1:87:3	O
elsewhere	DYSPORT.xml:S1:91:9	O
in	DYSPORT.xml:S1:101:2	O
labeling	DYSPORT.xml:S1:104:8	O
:	DYSPORT.xml:S1:112:1	O

Distant	DYSPORT.xml:S1:121:7	B-AdverseReaction
Spread	DYSPORT.xml:S1:129:6	I-AdverseReaction
of	DYSPORT.xml:S1:136:2	I-AdverseReaction
Toxin	DYSPORT.xml:S1:139:5	I-AdverseReaction
Effect	DYSPORT.xml:S1:145:6	I-AdverseReaction
[	DYSPORT.xml:S1:152:1	O
seeBoxed	DYSPORT.xml:S1:153:8	O
Warning	DYSPORT.xml:S1:162:7	O
]	DYSPORT.xml:S1:169:1	O

Lack	DYSPORT.xml:S1:177:4	O
of	DYSPORT.xml:S1:182:2	O
Interchangeability	DYSPORT.xml:S1:185:18	O
between	DYSPORT.xml:S1:204:7	O
Botulinum	DYSPORT.xml:S1:212:9	O
Toxin	DYSPORT.xml:S1:222:5	O
Products	DYSPORT.xml:S1:228:8	O
[	DYSPORT.xml:S1:237:1	O
seeWarnings	DYSPORT.xml:S1:238:11	O
and	DYSPORT.xml:S1:250:3	O
Precautions	DYSPORT.xml:S1:254:11	O
(	DYSPORT.xml:S1:266:1	O
5.1	DYSPORT.xml:S1:267:3	O
)]	DYSPORT.xml:S1:270:2	O

Spread	DYSPORT.xml:S1:279:6	B-AdverseReaction
of	DYSPORT.xml:S1:286:2	I-AdverseReaction
Effects	DYSPORT.xml:S1:289:7	I-AdverseReaction
from	DYSPORT.xml:S1:297:4	I-AdverseReaction
Toxin	DYSPORT.xml:S1:302:5	I-AdverseReaction
[	DYSPORT.xml:S1:308:1	O
seeWarnings	DYSPORT.xml:S1:310:11	O
and	DYSPORT.xml:S1:322:3	O
Precautions	DYSPORT.xml:S1:326:11	O
(	DYSPORT.xml:S1:338:1	O
5.2	DYSPORT.xml:S1:339:3	O
)	DYSPORT.xml:S1:342:1	O
]	DYSPORT.xml:S1:344:1	O

Dysphagia	DYSPORT.xml:S1:351:9	B-AdverseReaction
and	DYSPORT.xml:S1:361:3	O
Breathing	DYSPORT.xml:S1:365:9	B-AdverseReaction
Difficulties	DYSPORT.xml:S1:375:12	I-AdverseReaction
[	DYSPORT.xml:S1:388:1	O
seeWarnings	DYSPORT.xml:S1:389:11	O
and	DYSPORT.xml:S1:401:3	O
Precautions	DYSPORT.xml:S1:405:11	O
(	DYSPORT.xml:S1:417:1	O
5.3	DYSPORT.xml:S1:418:3	O
)]	DYSPORT.xml:S1:421:2	O

Facial	DYSPORT.xml:S1:430:6	O
Anatomy	DYSPORT.xml:S1:437:7	O
in	DYSPORT.xml:S1:445:2	O
the	DYSPORT.xml:S1:448:3	O
Treatment	DYSPORT.xml:S1:452:9	O
of	DYSPORT.xml:S1:462:2	O
Glabellar	DYSPORT.xml:S1:465:9	O
Lines	DYSPORT.xml:S1:475:5	O
[	DYSPORT.xml:S1:481:1	O
seeWarnings	DYSPORT.xml:S1:482:11	O
and	DYSPORT.xml:S1:494:3	O
Precautions	DYSPORT.xml:S1:498:11	O
(	DYSPORT.xml:S1:510:1	O
5.4	DYSPORT.xml:S1:511:3	O
)]	DYSPORT.xml:S1:514:2	O

Pre	DYSPORT.xml:S1:523:3	O
-	DYSPORT.xml:S1:526:1	O
existing	DYSPORT.xml:S1:527:8	O
Neuromuscular	DYSPORT.xml:S1:536:13	O
Disorders	DYSPORT.xml:S1:550:9	O
[	DYSPORT.xml:S1:560:1	O
seeWarnings	DYSPORT.xml:S1:561:11	O
and	DYSPORT.xml:S1:573:3	O
Precautions	DYSPORT.xml:S1:577:11	O
(	DYSPORT.xml:S1:589:1	O
5.5	DYSPORT.xml:S1:590:3	O
)]	DYSPORT.xml:S1:593:2	O

Human	DYSPORT.xml:S1:602:5	O
Albumin	DYSPORT.xml:S1:608:7	O
[	DYSPORT.xml:S1:616:1	O
seeWarnings	DYSPORT.xml:S1:617:11	O
and	DYSPORT.xml:S1:629:3	O
Precautions	DYSPORT.xml:S1:633:11	O
(	DYSPORT.xml:S1:645:1	O
5.6	DYSPORT.xml:S1:646:3	O
)]	DYSPORT.xml:S1:649:2	O

Intradermal	DYSPORT.xml:S1:658:11	B-AdverseReaction
Immune	DYSPORT.xml:S1:670:6	I-AdverseReaction
Reaction	DYSPORT.xml:S1:677:8	I-AdverseReaction
[	DYSPORT.xml:S1:686:1	O
seeWarnings	DYSPORT.xml:S1:687:11	O
and	DYSPORT.xml:S1:699:3	O
Precautions	DYSPORT.xml:S1:703:11	O
(	DYSPORT.xml:S1:715:1	O
5	DYSPORT.xml:S1:716:1	O
.	DYSPORT.xml:S1:717:1	O

7	DYSPORT.xml:S1:719:1	O
)]	DYSPORT.xml:S1:720:2	O

EXCERPT	DYSPORT.xml:S1:731:7	O
:	DYSPORT.xml:S1:738:1	O
Cervical	DYSPORT.xml:S1:744:8	O
Dystonia	DYSPORT.xml:S1:753:8	O

Most	DYSPORT.xml:S1:768:4	O

commonly	DYSPORT.xml:S1:773:8	O
observed	DYSPORT.xml:S1:782:8	O
adverse	DYSPORT.xml:S1:791:7	O
reactions	DYSPORT.xml:S1:799:9	O
(	DYSPORT.xml:S1:809:1	O
5%	DYSPORT.xml:S1:812:2	O
of	DYSPORT.xml:S1:815:2	O
patients	DYSPORT.xml:S1:818:8	O
)	DYSPORT.xml:S1:826:1	O
are	DYSPORT.xml:S1:828:3	O
:	DYSPORT.xml:S1:831:1	O
muscular	DYSPORT.xml:S1:833:8	B-AdverseReaction
weakness	DYSPORT.xml:S1:842:8	I-AdverseReaction
,	DYSPORT.xml:S1:850:1	O
dysphagia	DYSPORT.xml:S1:852:9	B-AdverseReaction
,	DYSPORT.xml:S1:861:1	O
dry	DYSPORT.xml:S1:863:3	B-AdverseReaction
mouth	DYSPORT.xml:S1:867:5	I-AdverseReaction
,	DYSPORT.xml:S1:872:1	O
injection	DYSPORT.xml:S1:874:9	B-AdverseReaction
site	DYSPORT.xml:S1:884:4	I-AdverseReaction
discomfort	DYSPORT.xml:S1:889:10	I-AdverseReaction
,	DYSPORT.xml:S1:899:1	O
fatigue	DYSPORT.xml:S1:901:7	B-AdverseReaction
,	DYSPORT.xml:S1:908:1	O
headache	DYSPORT.xml:S1:910:8	B-AdverseReaction
,	DYSPORT.xml:S1:918:1	O
neck	DYSPORT.xml:S1:920:4	B-AdverseReaction
pain	DYSPORT.xml:S1:925:4	I-AdverseReaction
,	DYSPORT.xml:S1:929:1	O
musculoskeletal	DYSPORT.xml:S1:931:15	B-AdverseReaction
pain	DYSPORT.xml:S1:947:4	I-AdverseReaction
,	DYSPORT.xml:S1:951:1	O
dysphonia	DYSPORT.xml:S1:953:9	B-AdverseReaction
,	DYSPORT.xml:S1:962:1	O
injection	DYSPORT.xml:S1:964:9	B-AdverseReaction
site	DYSPORT.xml:S1:974:4	I-AdverseReaction
pain	DYSPORT.xml:S1:979:4	I-AdverseReaction
,	DYSPORT.xml:S1:983:1	O
and	DYSPORT.xml:S1:985:3	O
eye	DYSPORT.xml:S1:989:3	B-AdverseReaction
disorders	DYSPORT.xml:S1:993:9	I-AdverseReaction
.	DYSPORT.xml:S1:1002:1	O

(	DYSPORT.xml:S1:1004:1	O
6.1	DYSPORT.xml:S1:1005:3	O
)	DYSPORT.xml:S1:1008:1	O

Glabellar	DYSPORT.xml:S1:1016:9	O
Lines	DYSPORT.xml:S1:1026:5	O

The	DYSPORT.xml:S1:1038:3	O
most	DYSPORT.xml:S1:1042:4	O
frequently	DYSPORT.xml:S1:1047:10	O
reported	DYSPORT.xml:S1:1058:8	O
adverse	DYSPORT.xml:S1:1067:7	O
reactions	DYSPORT.xml:S1:1075:9	O
(	DYSPORT.xml:S1:1085:1	O
2%	DYSPORT.xml:S1:1088:2	O
)	DYSPORT.xml:S1:1090:1	O
are	DYSPORT.xml:S1:1092:3	O
:	DYSPORT.xml:S1:1095:1	O
nasopharyngitis	DYSPORT.xml:S1:1097:15	B-AdverseReaction
,	DYSPORT.xml:S1:1112:1	O
headache	DYSPORT.xml:S1:1114:8	B-AdverseReaction
,	DYSPORT.xml:S1:1122:1	O
injection	DYSPORT.xml:S1:1124:9	B-AdverseReaction
site	DYSPORT.xml:S1:1134:4	I-AdverseReaction
pain	DYSPORT.xml:S1:1139:4	I-AdverseReaction
,	DYSPORT.xml:S1:1143:1	O
injection	DYSPORT.xml:S1:1145:9	B-AdverseReaction
site	DYSPORT.xml:S1:1155:4	I-AdverseReaction
reaction	DYSPORT.xml:S1:1160:8	I-AdverseReaction
,	DYSPORT.xml:S1:1168:1	O
upper	DYSPORT.xml:S1:1170:5	B-AdverseReaction
respiratory	DYSPORT.xml:S1:1176:11	I-AdverseReaction
tract	DYSPORT.xml:S1:1188:5	I-AdverseReaction
infection	DYSPORT.xml:S1:1194:9	I-AdverseReaction
,	DYSPORT.xml:S1:1203:1	O
eyelid	DYSPORT.xml:S1:1205:6	B-AdverseReaction
edema	DYSPORT.xml:S1:1212:5	I-AdverseReaction
,	DYSPORT.xml:S1:1217:1	O
eyelid	DYSPORT.xml:S1:1219:6	B-AdverseReaction
ptosis	DYSPORT.xml:S1:1226:6	I-AdverseReaction
,	DYSPORT.xml:S1:1232:1	O
sinusitis	DYSPORT.xml:S1:1234:9	B-AdverseReaction
,	DYSPORT.xml:S1:1243:1	O
and	DYSPORT.xml:S1:1245:3	O
nausea	DYSPORT.xml:S1:1249:6	B-AdverseReaction
.	DYSPORT.xml:S1:1255:1	O

(	DYSPORT.xml:S1:1257:1	O
6.1	DYSPORT.xml:S1:1258:3	O
)	DYSPORT.xml:S1:1261:1	O

Upper	DYSPORT.xml:S1:1269:5	O
Limb	DYSPORT.xml:S1:1275:4	O
Spasticity	DYSPORT.xml:S1:1280:10	O

The	DYSPORT.xml:S1:1297:3	O
most	DYSPORT.xml:S1:1301:4	O
frequently	DYSPORT.xml:S1:1306:10	O
reported	DYSPORT.xml:S1:1317:8	O
adverse	DYSPORT.xml:S1:1326:7	O
reactions	DYSPORT.xml:S1:1334:9	O
(	DYSPORT.xml:S1:1344:1	O
2%	DYSPORT.xml:S1:1347:2	O
)	DYSPORT.xml:S1:1349:1	O
are	DYSPORT.xml:S1:1351:3	O
:	DYSPORT.xml:S1:1354:1	O
urinary	DYSPORT.xml:S1:1356:7	B-AdverseReaction
tract	DYSPORT.xml:S1:1364:5	I-AdverseReaction
infection	DYSPORT.xml:S1:1370:9	I-AdverseReaction
,	DYSPORT.xml:S1:1379:1	O
nasopharyngitis	DYSPORT.xml:S1:1381:15	B-AdverseReaction
,	DYSPORT.xml:S1:1396:1	O
muscular	DYSPORT.xml:S1:1398:8	B-AdverseReaction
weakness	DYSPORT.xml:S1:1407:8	I-AdverseReaction
,	DYSPORT.xml:S1:1415:1	O
musculoskeletal	DYSPORT.xml:S1:1417:15	B-AdverseReaction
pain	DYSPORT.xml:S1:1433:4	I-AdverseReaction
,	DYSPORT.xml:S1:1437:1	O
dizziness	DYSPORT.xml:S1:1439:9	B-AdverseReaction
,	DYSPORT.xml:S1:1448:1	O
fall	DYSPORT.xml:S1:1450:4	B-AdverseReaction
and	DYSPORT.xml:S1:1455:3	O
depression	DYSPORT.xml:S1:1459:10	B-AdverseReaction
.	DYSPORT.xml:S1:1469:1	O

(	DYSPORT.xml:S1:1470:1	O
6.1	DYSPORT.xml:S1:1471:3	O
)	DYSPORT.xml:S1:1474:1	O

To	DYSPORT.xml:S1:1482:2	O
report	DYSPORT.xml:S1:1485:6	O
SUSPECTED	DYSPORT.xml:S1:1492:9	O
ADVERSE	DYSPORT.xml:S1:1502:7	O
REACTIONS	DYSPORT.xml:S1:1510:9	O
,	DYSPORT.xml:S1:1519:1	O
contact	DYSPORT.xml:S1:1521:7	O
Ipsen	DYSPORT.xml:S1:1529:5	O
Biopharmaceuticals	DYSPORT.xml:S1:1535:18	O
,	DYSPORT.xml:S1:1553:1	O
Inc	DYSPORT.xml:S1:1555:3	O
.	DYSPORT.xml:S1:1558:1	O

at	DYSPORT.xml:S1:1560:2	O
877	DYSPORT.xml:S1:1563:3	O
-	DYSPORT.xml:S1:1566:1	O
397	DYSPORT.xml:S1:1567:3	O
-	DYSPORT.xml:S1:1570:1	O
7671	DYSPORT.xml:S1:1571:4	O
or	DYSPORT.xml:S1:1576:2	O
FDA	DYSPORT.xml:S1:1579:3	O
at	DYSPORT.xml:S1:1583:2	O
1	DYSPORT.xml:S1:1586:1	O
-	DYSPORT.xml:S1:1587:1	O
800	DYSPORT.xml:S1:1588:3	O
-	DYSPORT.xml:S1:1591:1	O
FDA	DYSPORT.xml:S1:1592:3	O
-	DYSPORT.xml:S1:1595:1	O
1088	DYSPORT.xml:S1:1596:4	O
or	DYSPORT.xml:S1:1601:2	O
www	DYSPORT.xml:S1:1604:3	O
.	DYSPORT.xml:S1:1607:1	O
fda	DYSPORT.xml:S1:1608:3	O
.	DYSPORT.xml:S1:1611:1	O
gov	DYSPORT.xml:S1:1612:3	O
medwatch	DYSPORT.xml:S1:1616:8	O

6.1	DYSPORT.xml:S1:1635:3	O

Clinical	DYSPORT.xml:S1:1639:8	O
Trials	DYSPORT.xml:S1:1648:6	O
Experience	DYSPORT.xml:S1:1655:10	O

Because	DYSPORT.xml:S1:1669:7	O
clinical	DYSPORT.xml:S1:1677:8	O
trials	DYSPORT.xml:S1:1686:6	O
are	DYSPORT.xml:S1:1693:3	O
conducted	DYSPORT.xml:S1:1697:9	O
under	DYSPORT.xml:S1:1707:5	O
widely	DYSPORT.xml:S1:1713:6	O
varying	DYSPORT.xml:S1:1720:7	O
conditions	DYSPORT.xml:S1:1728:10	O
,	DYSPORT.xml:S1:1738:1	O
adverse	DYSPORT.xml:S1:1740:7	O
reaction	DYSPORT.xml:S1:1748:8	O
rates	DYSPORT.xml:S1:1757:5	O
observed	DYSPORT.xml:S1:1763:8	O
in	DYSPORT.xml:S1:1772:2	O
the	DYSPORT.xml:S1:1775:3	O
clinical	DYSPORT.xml:S1:1779:8	O
trials	DYSPORT.xml:S1:1788:6	O
of	DYSPORT.xml:S1:1795:2	O
a	DYSPORT.xml:S1:1798:1	O
drug	DYSPORT.xml:S1:1800:4	O
cannot	DYSPORT.xml:S1:1805:6	O
be	DYSPORT.xml:S1:1812:2	O
directly	DYSPORT.xml:S1:1815:8	O
compared	DYSPORT.xml:S1:1824:8	O
to	DYSPORT.xml:S1:1833:2	O
rates	DYSPORT.xml:S1:1836:5	O
in	DYSPORT.xml:S1:1842:2	O
the	DYSPORT.xml:S1:1845:3	O
clinical	DYSPORT.xml:S1:1849:8	O
trials	DYSPORT.xml:S1:1858:6	O
of	DYSPORT.xml:S1:1865:2	O
another	DYSPORT.xml:S1:1868:7	O
drug	DYSPORT.xml:S1:1876:4	O
and	DYSPORT.xml:S1:1881:3	O
may	DYSPORT.xml:S1:1885:3	O
not	DYSPORT.xml:S1:1889:3	O
reflect	DYSPORT.xml:S1:1893:7	O
the	DYSPORT.xml:S1:1901:3	O
rates	DYSPORT.xml:S1:1905:5	O
observed	DYSPORT.xml:S1:1911:8	O
in	DYSPORT.xml:S1:1920:2	O
practice	DYSPORT.xml:S1:1923:8	O
.	DYSPORT.xml:S1:1931:1	O

Cervical	DYSPORT.xml:S1:1941:8	O
Dystonia	DYSPORT.xml:S1:1950:8	O

The	DYSPORT.xml:S1:1965:3	O
data	DYSPORT.xml:S1:1969:4	O
described	DYSPORT.xml:S1:1974:9	O
below	DYSPORT.xml:S1:1984:5	O
reflect	DYSPORT.xml:S1:1990:7	O
exposure	DYSPORT.xml:S1:1998:8	O
to	DYSPORT.xml:S1:2007:2	O
DYSPORT	DYSPORT.xml:S1:2010:7	O
(	DYSPORT.xml:S1:2021:1	O
r	DYSPORT.xml:S1:2022:1	O
)	DYSPORT.xml:S1:2023:1	O
in	DYSPORT.xml:S1:2028:2	O
357	DYSPORT.xml:S1:2031:3	O
cervical	DYSPORT.xml:S1:2035:8	O
dystonia	DYSPORT.xml:S1:2044:8	O
patients	DYSPORT.xml:S1:2053:8	O
in	DYSPORT.xml:S1:2062:2	O
6	DYSPORT.xml:S1:2065:1	O
studies	DYSPORT.xml:S1:2067:7	O
.	DYSPORT.xml:S1:2074:1	O

Of	DYSPORT.xml:S1:2076:2	O
these	DYSPORT.xml:S1:2079:5	O
,	DYSPORT.xml:S1:2084:1	O
two	DYSPORT.xml:S1:2086:3	O
studies	DYSPORT.xml:S1:2090:7	O
were	DYSPORT.xml:S1:2098:4	O
randomized	DYSPORT.xml:S1:2103:10	O
,	DYSPORT.xml:S1:2113:1	O
double	DYSPORT.xml:S1:2115:6	O
-	DYSPORT.xml:S1:2121:1	O
blind	DYSPORT.xml:S1:2122:5	O
,	DYSPORT.xml:S1:2127:1	O
single	DYSPORT.xml:S1:2129:6	O
treatment	DYSPORT.xml:S1:2136:9	O
,	DYSPORT.xml:S1:2145:1	O
placebo	DYSPORT.xml:S1:2147:7	O
controlled	DYSPORT.xml:S1:2155:10	O
studies	DYSPORT.xml:S1:2166:7	O
with	DYSPORT.xml:S1:2174:4	O
subsequent	DYSPORT.xml:S1:2179:10	O
optional	DYSPORT.xml:S1:2190:8	O
open	DYSPORT.xml:S1:2199:4	O
label	DYSPORT.xml:S1:2204:5	O
treatment	DYSPORT.xml:S1:2210:9	O
in	DYSPORT.xml:S1:2220:2	O
which	DYSPORT.xml:S1:2223:5	O
dose	DYSPORT.xml:S1:2229:4	O
optimization	DYSPORT.xml:S1:2234:12	O
(	DYSPORT.xml:S1:2247:1	O
250	DYSPORT.xml:S1:2248:3	O
to	DYSPORT.xml:S1:2252:2	O
1000	DYSPORT.xml:S1:2255:4	O
Units	DYSPORT.xml:S1:2260:5	O
per	DYSPORT.xml:S1:2266:3	O
treatment	DYSPORT.xml:S1:2270:9	O
)	DYSPORT.xml:S1:2279:1	O
over	DYSPORT.xml:S1:2281:4	O
the	DYSPORT.xml:S1:2286:3	O
course	DYSPORT.xml:S1:2290:6	O
of	DYSPORT.xml:S1:2297:2	O
5	DYSPORT.xml:S1:2300:1	O
treatment	DYSPORT.xml:S1:2302:9	O
cycles	DYSPORT.xml:S1:2312:6	O
was	DYSPORT.xml:S1:2319:3	O
allowed	DYSPORT.xml:S1:2323:7	O
.	DYSPORT.xml:S1:2330:1	O

The	DYSPORT.xml:S1:2336:3	O
population	DYSPORT.xml:S1:2340:10	O
was	DYSPORT.xml:S1:2351:3	O
almost	DYSPORT.xml:S1:2355:6	O
entirely	DYSPORT.xml:S1:2362:8	O
Caucasian	DYSPORT.xml:S1:2371:9	O
(	DYSPORT.xml:S1:2381:1	O
99%	DYSPORT.xml:S1:2382:3	O
)	DYSPORT.xml:S1:2385:1	O
with	DYSPORT.xml:S1:2387:4	O
a	DYSPORT.xml:S1:2392:1	O
median	DYSPORT.xml:S1:2394:6	O
age	DYSPORT.xml:S1:2401:3	O
of	DYSPORT.xml:S1:2405:2	O
51	DYSPORT.xml:S1:2408:2	O
years	DYSPORT.xml:S1:2411:5	O
(	DYSPORT.xml:S1:2417:1	O
range	DYSPORT.xml:S1:2418:5	O
18	DYSPORT.xml:S1:2424:2	O
-	DYSPORT.xml:S1:2426:1	O
82	DYSPORT.xml:S1:2427:2	O
years	DYSPORT.xml:S1:2430:5	O
)	DYSPORT.xml:S1:2435:1	O
.	DYSPORT.xml:S1:2436:1	O

Most	DYSPORT.xml:S1:2438:4	O
patients	DYSPORT.xml:S1:2443:8	O
(	DYSPORT.xml:S1:2452:1	O
87%	DYSPORT.xml:S1:2453:3	O
)	DYSPORT.xml:S1:2456:1	O
were	DYSPORT.xml:S1:2458:4	O
less	DYSPORT.xml:S1:2463:4	O
than	DYSPORT.xml:S1:2468:4	O
65	DYSPORT.xml:S1:2473:2	O
years	DYSPORT.xml:S1:2476:5	O
of	DYSPORT.xml:S1:2482:2	O
age	DYSPORT.xml:S1:2485:3	O
;	DYSPORT.xml:S1:2488:1	O
58.4%	DYSPORT.xml:S1:2490:5	O
were	DYSPORT.xml:S1:2496:4	O
women	DYSPORT.xml:S1:2501:5	O
.	DYSPORT.xml:S1:2506:1	O

Common	DYSPORT.xml:S1:2516:6	O
Adverse	DYSPORT.xml:S1:2523:7	O
Reactions	DYSPORT.xml:S1:2531:9	O

The	DYSPORT.xml:S1:2547:3	O
most	DYSPORT.xml:S1:2551:4	O
commonly	DYSPORT.xml:S1:2556:8	O
reported	DYSPORT.xml:S1:2565:8	O
adverse	DYSPORT.xml:S1:2574:7	O
reactions	DYSPORT.xml:S1:2582:9	O
(	DYSPORT.xml:S1:2592:1	O
occurring	DYSPORT.xml:S1:2593:9	O
in	DYSPORT.xml:S1:2603:2	O
more	DYSPORT.xml:S1:2606:4	O
than	DYSPORT.xml:S1:2611:4	O
5%	DYSPORT.xml:S1:2616:2	O
of	DYSPORT.xml:S1:2619:2	O
patients	DYSPORT.xml:S1:2622:8	O
who	DYSPORT.xml:S1:2631:3	O
received	DYSPORT.xml:S1:2635:8	O
500	DYSPORT.xml:S1:2644:3	O
Units	DYSPORT.xml:S1:2648:5	O
of	DYSPORT.xml:S1:2654:2	O
DYSPORT	DYSPORT.xml:S1:2657:7	O
(	DYSPORT.xml:S1:2668:1	O
r	DYSPORT.xml:S1:2669:1	O
)	DYSPORT.xml:S1:2670:1	O
in	DYSPORT.xml:S1:2675:2	O
the	DYSPORT.xml:S1:2678:3	O
placebo	DYSPORT.xml:S1:2682:7	O
controlled	DYSPORT.xml:S1:2690:10	O
clinical	DYSPORT.xml:S1:2701:8	O
trials	DYSPORT.xml:S1:2710:6	O
)	DYSPORT.xml:S1:2716:1	O
in	DYSPORT.xml:S1:2718:2	O
cervical	DYSPORT.xml:S1:2721:8	O
dystonia	DYSPORT.xml:S1:2730:8	O
patients	DYSPORT.xml:S1:2739:8	O
were	DYSPORT.xml:S1:2748:4	O
:	DYSPORT.xml:S1:2752:1	O
muscular	DYSPORT.xml:S1:2754:8	B-AdverseReaction
weakness	DYSPORT.xml:S1:2763:8	I-AdverseReaction
,	DYSPORT.xml:S1:2771:1	O
dysphagia	DYSPORT.xml:S1:2773:9	B-AdverseReaction
,	DYSPORT.xml:S1:2782:1	O
dry	DYSPORT.xml:S1:2784:3	B-AdverseReaction
mouth	DYSPORT.xml:S1:2788:5	I-AdverseReaction
,	DYSPORT.xml:S1:2793:1	O
injection	DYSPORT.xml:S1:2795:9	B-AdverseReaction
site	DYSPORT.xml:S1:2805:4	I-AdverseReaction
discomfort	DYSPORT.xml:S1:2810:10	I-AdverseReaction
,	DYSPORT.xml:S1:2820:1	O
fatigue	DYSPORT.xml:S1:2822:7	B-AdverseReaction
,	DYSPORT.xml:S1:2829:1	O
headache	DYSPORT.xml:S1:2831:8	B-AdverseReaction
,	DYSPORT.xml:S1:2839:1	O
neck	DYSPORT.xml:S1:2841:4	B-AdverseReaction
pain	DYSPORT.xml:S1:2846:4	I-AdverseReaction
,	DYSPORT.xml:S1:2850:1	O
musculoskeletal	DYSPORT.xml:S1:2852:15	B-AdverseReaction
pain	DYSPORT.xml:S1:2868:4	I-AdverseReaction
,	DYSPORT.xml:S1:2872:1	O
dysphonia	DYSPORT.xml:S1:2874:9	B-AdverseReaction
,	DYSPORT.xml:S1:2883:1	O
injection	DYSPORT.xml:S1:2885:9	B-AdverseReaction
site	DYSPORT.xml:S1:2895:4	I-AdverseReaction
pain	DYSPORT.xml:S1:2900:4	I-AdverseReaction
,	DYSPORT.xml:S1:2904:1	O
and	DYSPORT.xml:S1:2906:3	O
eye	DYSPORT.xml:S1:2910:3	B-AdverseReaction
disorders	DYSPORT.xml:S1:2914:9	I-AdverseReaction
(	DYSPORT.xml:S1:2924:1	O
consisting	DYSPORT.xml:S1:2925:10	O
of	DYSPORT.xml:S1:2936:2	O
blurred	DYSPORT.xml:S1:2939:7	B-AdverseReaction
vision	DYSPORT.xml:S1:2947:6	I-AdverseReaction
,	DYSPORT.xml:S1:2953:1	O
diplopia	DYSPORT.xml:S1:2955:8	B-AdverseReaction
,	DYSPORT.xml:S1:2963:1	O
and	DYSPORT.xml:S1:2965:3	O
reduced	DYSPORT.xml:S1:2969:7	B-AdverseReaction
visual	DYSPORT.xml:S1:2977:6	I-AdverseReaction
acuity	DYSPORT.xml:S1:2984:6	I-AdverseReaction
and	DYSPORT.xml:S1:2991:3	O
accommodation	DYSPORT.xml:S1:2995:13	I-AdverseReaction
)	DYSPORT.xml:S1:3008:1	O
.	DYSPORT.xml:S1:3009:1	O

Other	DYSPORT.xml:S1:3011:5	O
than	DYSPORT.xml:S1:3017:4	O
injection	DYSPORT.xml:S1:3022:9	B-AdverseReaction
site	DYSPORT.xml:S1:3032:4	I-AdverseReaction
reactions	DYSPORT.xml:S1:3037:9	I-AdverseReaction
,	DYSPORT.xml:S1:3046:1	O
most	DYSPORT.xml:S1:3048:4	O
adverse	DYSPORT.xml:S1:3053:7	O
reactions	DYSPORT.xml:S1:3061:9	O
became	DYSPORT.xml:S1:3071:6	O
noticeable	DYSPORT.xml:S1:3078:10	O
about	DYSPORT.xml:S1:3089:5	O
one	DYSPORT.xml:S1:3095:3	O
week	DYSPORT.xml:S1:3099:4	O
after	DYSPORT.xml:S1:3104:5	O
treatment	DYSPORT.xml:S1:3110:9	O
and	DYSPORT.xml:S1:3120:3	O
lasted	DYSPORT.xml:S1:3124:6	O
several	DYSPORT.xml:S1:3131:7	O
weeks	DYSPORT.xml:S1:3139:5	O
.	DYSPORT.xml:S1:3144:1	O

The	DYSPORT.xml:S1:3150:3	O
rates	DYSPORT.xml:S1:3154:5	O
of	DYSPORT.xml:S1:3160:2	O
adverse	DYSPORT.xml:S1:3163:7	O
reactions	DYSPORT.xml:S1:3171:9	O
were	DYSPORT.xml:S1:3181:4	O
higher	DYSPORT.xml:S1:3186:6	O
in	DYSPORT.xml:S1:3193:2	O
the	DYSPORT.xml:S1:3196:3	O
combined	DYSPORT.xml:S1:3200:8	O
controlled	DYSPORT.xml:S1:3209:10	O
and	DYSPORT.xml:S1:3220:3	O
open	DYSPORT.xml:S1:3224:4	O
-	DYSPORT.xml:S1:3228:1	O
label	DYSPORT.xml:S1:3229:5	O
experience	DYSPORT.xml:S1:3235:10	O
than	DYSPORT.xml:S1:3246:4	O
in	DYSPORT.xml:S1:3251:2	O
the	DYSPORT.xml:S1:3254:3	O
placebo	DYSPORT.xml:S1:3258:7	O
-	DYSPORT.xml:S1:3265:1	O
controlled	DYSPORT.xml:S1:3266:10	O
trials	DYSPORT.xml:S1:3277:6	O
.	DYSPORT.xml:S1:3283:1	O

During	DYSPORT.xml:S1:3285:6	O
the	DYSPORT.xml:S1:3292:3	O
clinical	DYSPORT.xml:S1:3296:8	O
studies	DYSPORT.xml:S1:3305:7	O
,	DYSPORT.xml:S1:3312:1	O
two	DYSPORT.xml:S1:3314:3	O
patients	DYSPORT.xml:S1:3318:8	O
(	DYSPORT.xml:S1:3327:1	O
1%	DYSPORT.xml:S1:3329:2	O
)	DYSPORT.xml:S1:3331:1	O
experienced	DYSPORT.xml:S1:3333:11	O
adverse	DYSPORT.xml:S1:3345:7	O
reactions	DYSPORT.xml:S1:3353:9	O
leading	DYSPORT.xml:S1:3363:7	O
to	DYSPORT.xml:S1:3371:2	O
withdrawal	DYSPORT.xml:S1:3374:10	O
.	DYSPORT.xml:S1:3384:1	O

One	DYSPORT.xml:S1:3386:3	O
patient	DYSPORT.xml:S1:3390:7	O
experienced	DYSPORT.xml:S1:3398:11	O
disturbance	DYSPORT.xml:S1:3410:11	B-AdverseReaction
in	DYSPORT.xml:S1:3422:2	I-AdverseReaction
attention	DYSPORT.xml:S1:3425:9	I-AdverseReaction
,	DYSPORT.xml:S1:3434:1	O
eyelid	DYSPORT.xml:S1:3436:6	B-AdverseReaction
disorder	DYSPORT.xml:S1:3443:8	I-AdverseReaction
,	DYSPORT.xml:S1:3451:1	O
feeling	DYSPORT.xml:S1:3453:7	B-AdverseReaction
abnormal	DYSPORT.xml:S1:3461:8	I-AdverseReaction
and	DYSPORT.xml:S1:3470:3	O
headache	DYSPORT.xml:S1:3474:8	B-AdverseReaction
,	DYSPORT.xml:S1:3482:1	O
and	DYSPORT.xml:S1:3484:3	O
one	DYSPORT.xml:S1:3488:3	O
patient	DYSPORT.xml:S1:3492:7	O
experienced	DYSPORT.xml:S1:3500:11	O
dysphagia	DYSPORT.xml:S1:3512:9	B-AdverseReaction
.	DYSPORT.xml:S1:3521:1	O

Table	DYSPORT.xml:S1:3527:5	O
3	DYSPORT.xml:S1:3533:1	O
compares	DYSPORT.xml:S1:3535:8	O
the	DYSPORT.xml:S1:3544:3	O
incidence	DYSPORT.xml:S1:3548:9	O
of	DYSPORT.xml:S1:3558:2	O
the	DYSPORT.xml:S1:3561:3	O
most	DYSPORT.xml:S1:3565:4	O
frequent	DYSPORT.xml:S1:3570:8	O
adverse	DYSPORT.xml:S1:3579:7	O
reactions	DYSPORT.xml:S1:3587:9	O
from	DYSPORT.xml:S1:3597:4	O
a	DYSPORT.xml:S1:3602:1	O
single	DYSPORT.xml:S1:3604:6	O
treatment	DYSPORT.xml:S1:3611:9	O
cycle	DYSPORT.xml:S1:3621:5	O
of	DYSPORT.xml:S1:3627:2	O
500	DYSPORT.xml:S1:3630:3	O
Units	DYSPORT.xml:S1:3634:5	O
of	DYSPORT.xml:S1:3640:2	O
DYSPORT	DYSPORT.xml:S1:3643:7	O
(	DYSPORT.xml:S1:3654:1	O
r	DYSPORT.xml:S1:3655:1	O
)	DYSPORT.xml:S1:3656:1	O
compared	DYSPORT.xml:S1:3661:8	O
to	DYSPORT.xml:S1:3670:2	O
placebo	DYSPORT.xml:S1:3673:7	O
[	DYSPORT.xml:S1:3681:1	O
seeClinical	DYSPORT.xml:S1:3684:11	O
Studies	DYSPORT.xml:S1:3696:7	O
(	DYSPORT.xml:S1:3704:1	O
14.1	DYSPORT.xml:S1:3705:4	O
)	DYSPORT.xml:S1:3709:1	O
]	DYSPORT.xml:S1:3712:1	O
.	DYSPORT.xml:S1:3713:1	O

Table	DYSPORT.xml:S1:3719:5	O
3	DYSPORT.xml:S1:3725:1	O
:	DYSPORT.xml:S1:3726:1	O
Most	DYSPORT.xml:S1:3728:4	O
Common	DYSPORT.xml:S1:3733:6	O
Adverse	DYSPORT.xml:S1:3740:7	O
Reactions	DYSPORT.xml:S1:3748:9	O
(	DYSPORT.xml:S1:3758:1	O
5%	DYSPORT.xml:S1:3760:2	O
)	DYSPORT.xml:S1:3762:1	O
and	DYSPORT.xml:S1:3764:3	O
Greater	DYSPORT.xml:S1:3768:7	O
than	DYSPORT.xml:S1:3776:4	O
Placebo	DYSPORT.xml:S1:3781:7	O
in	DYSPORT.xml:S1:3789:2	O
the	DYSPORT.xml:S1:3792:3	O
Pooled	DYSPORT.xml:S1:3796:6	O
,	DYSPORT.xml:S1:3802:1	O
Double	DYSPORT.xml:S1:3804:6	O
-	DYSPORT.xml:S1:3810:1	O
blind	DYSPORT.xml:S1:3811:5	O
Phase	DYSPORT.xml:S1:3817:5	O
of	DYSPORT.xml:S1:3823:2	O
Clinical	DYSPORT.xml:S1:3826:8	O
Trials	DYSPORT.xml:S1:3835:6	O
in	DYSPORT.xml:S1:3842:2	O
Patients	DYSPORT.xml:S1:3845:8	O
with	DYSPORT.xml:S1:3854:4	O
Cervical	DYSPORT.xml:S1:3859:8	O
Dystonia	DYSPORT.xml:S1:3868:8	O

Adverse	DYSPORT.xml:S1:3879:7	O
Reaction	DYSPORT.xml:S1:3887:8	O
Preferred	DYSPORT.xml:S1:3897:9	O
Term	DYSPORT.xml:S1:3907:4	O
DYSPORT	DYSPORT.xml:S1:3931:7	O
(	DYSPORT.xml:S1:3940:1	O
r	DYSPORT.xml:S1:3941:1	O
)	DYSPORT.xml:S1:3942:1	O
500	DYSPORT.xml:S1:3945:3	O
Units	DYSPORT.xml:S1:3949:5	O
(	DYSPORT.xml:S1:3954:1	O
N	DYSPORT.xml:S1:3955:1	O
173	DYSPORT.xml:S1:3957:3	O
)	DYSPORT.xml:S1:3960:1	O
Placebo	DYSPORT.xml:S1:3968:7	O
(	DYSPORT.xml:S1:3975:1	O
N	DYSPORT.xml:S1:3976:1	O
182	DYSPORT.xml:S1:3978:3	O
)	DYSPORT.xml:S1:3981:1	O

Any	DYSPORT.xml:S1:4107:3	O

Adverse	DYSPORT.xml:S1:4111:7	O

Reaction	DYSPORT.xml:S1:4119:8	O
61	DYSPORT.xml:S1:4168:2	O
51	DYSPORT.xml:S1:4195:2	O

General	DYSPORT.xml:S1:4216:7	O
disorders	DYSPORT.xml:S1:4224:9	O
and	DYSPORT.xml:S1:4234:3	O
administration	DYSPORT.xml:S1:4238:14	O
site	DYSPORT.xml:S1:4253:4	O
conditions	DYSPORT.xml:S1:4258:10	O
30	DYSPORT.xml:S1:4283:2	O
23	DYSPORT.xml:S1:4310:2	O

Injection	DYSPORT.xml:S1:4331:9	B-AdverseReaction
site	DYSPORT.xml:S1:4341:4	I-AdverseReaction
discomfort	DYSPORT.xml:S1:4346:10	I-AdverseReaction
13	DYSPORT.xml:S1:4392:2	O
8	DYSPORT.xml:S1:4420:1	O

Fatigue	DYSPORT.xml:S1:4440:7	B-AdverseReaction
12	DYSPORT.xml:S1:4501:2	O
10	DYSPORT.xml:S1:4528:2	O

Injection	DYSPORT.xml:S1:4549:9	B-AdverseReaction
site	DYSPORT.xml:S1:4559:4	I-AdverseReaction
pain	DYSPORT.xml:S1:4564:4	I-AdverseReaction
5	DYSPORT.xml:S1:4611:1	O
4	DYSPORT.xml:S1:4638:1	O

Musculoskeletal	DYSPORT.xml:S1:4658:15	O
and	DYSPORT.xml:S1:4674:3	O
connective	DYSPORT.xml:S1:4678:10	O
tissue	DYSPORT.xml:S1:4689:6	O
disorders	DYSPORT.xml:S1:4696:9	O
30	DYSPORT.xml:S1:4720:2	O
18	DYSPORT.xml:S1:4747:2	O

Muscular	DYSPORT.xml:S1:4768:8	B-AdverseReaction
weakness	DYSPORT.xml:S1:4777:8	I-AdverseReaction
16	DYSPORT.xml:S1:4829:2	O
4	DYSPORT.xml:S1:4857:1	O

Musculoskeletal	DYSPORT.xml:S1:4877:15	B-AdverseReaction
pain	DYSPORT.xml:S1:4893:4	I-AdverseReaction
7	DYSPORT.xml:S1:4939:1	O
3	DYSPORT.xml:S1:4966:1	O

Gastrointestinal	DYSPORT.xml:S1:4986:16	O
disorders	DYSPORT.xml:S1:5003:9	O
28	DYSPORT.xml:S1:5047:2	O
15	DYSPORT.xml:S1:5074:2	O

Dysphagia	DYSPORT.xml:S1:5095:9	B-AdverseReaction
15	DYSPORT.xml:S1:5156:2	O
4	DYSPORT.xml:S1:5184:1	O

Dry	DYSPORT.xml:S1:5204:3	B-AdverseReaction
mouth	DYSPORT.xml:S1:5208:5	I-AdverseReaction
13	DYSPORT.xml:S1:5265:2	O
7	DYSPORT.xml:S1:5293:1	O

Nervous	DYSPORT.xml:S1:5313:7	O
system	DYSPORT.xml:S1:5321:6	O
disorders	DYSPORT.xml:S1:5328:9	O
16	DYSPORT.xml:S1:5374:2	O
13	DYSPORT.xml:S1:5401:2	O

Headache	DYSPORT.xml:S1:5422:8	B-AdverseReaction
11	DYSPORT.xml:S1:5483:2	O
9	DYSPORT.xml:S1:5511:1	O

Infections	DYSPORT.xml:S1:5531:10	O
and	DYSPORT.xml:S1:5542:3	O
infestations	DYSPORT.xml:S1:5546:12	O
13	DYSPORT.xml:S1:5592:2	O
9	DYSPORT.xml:S1:5620:1	O

Respiratory	DYSPORT.xml:S1:5640:11	O
,	DYSPORT.xml:S1:5651:1	O
thoracic	DYSPORT.xml:S1:5653:8	O
and	DYSPORT.xml:S1:5662:3	O
mediastinal	DYSPORT.xml:S1:5666:11	O
disorders	DYSPORT.xml:S1:5678:9	O
12	DYSPORT.xml:S1:5702:2	O
8	DYSPORT.xml:S1:5730:1	O

Dysphonia	DYSPORT.xml:S1:5750:9	B-AdverseReaction
6	DYSPORT.xml:S1:5812:1	O
2	DYSPORT.xml:S1:5839:1	O

Eye	DYSPORT.xml:S1:5859:3	O
Disorders	DYSPORT.xml:S1:5863:9	O
7	DYSPORT.xml:S1:5921:1	O
2	DYSPORT.xml:S1:5948:1	O

Dose	DYSPORT.xml:S1:5974:4	O
-	DYSPORT.xml:S1:5978:1	O
response	DYSPORT.xml:S1:5979:8	O
relationships	DYSPORT.xml:S1:5988:13	O
for	DYSPORT.xml:S1:6002:3	O
common	DYSPORT.xml:S1:6006:6	O
adverse	DYSPORT.xml:S1:6013:7	O
reactions	DYSPORT.xml:S1:6021:9	O
in	DYSPORT.xml:S1:6031:2	O
a	DYSPORT.xml:S1:6034:1	O
randomized	DYSPORT.xml:S1:6036:10	O
multiple	DYSPORT.xml:S1:6047:8	O
fixed	DYSPORT.xml:S1:6056:5	O
-	DYSPORT.xml:S1:6061:1	O
dose	DYSPORT.xml:S1:6062:4	O
study	DYSPORT.xml:S1:6067:5	O
in	DYSPORT.xml:S1:6073:2	O
which	DYSPORT.xml:S1:6076:5	O
the	DYSPORT.xml:S1:6082:3	O
total	DYSPORT.xml:S1:6086:5	O
dose	DYSPORT.xml:S1:6092:4	O
was	DYSPORT.xml:S1:6097:3	O
divided	DYSPORT.xml:S1:6101:7	O
between	DYSPORT.xml:S1:6109:7	O
two	DYSPORT.xml:S1:6117:3	O
muscles	DYSPORT.xml:S1:6121:7	O
(	DYSPORT.xml:S1:6129:1	O
the	DYSPORT.xml:S1:6130:3	O
sternocleidomastoid	DYSPORT.xml:S1:6134:19	O
and	DYSPORT.xml:S1:6154:3	O
splenius	DYSPORT.xml:S1:6158:8	O
capitis	DYSPORT.xml:S1:6167:7	O
)	DYSPORT.xml:S1:6174:1	O
are	DYSPORT.xml:S1:6176:3	O
shown	DYSPORT.xml:S1:6180:5	O
in	DYSPORT.xml:S1:6186:2	O
Table	DYSPORT.xml:S1:6189:5	O
4	DYSPORT.xml:S1:6195:1	O
.	DYSPORT.xml:S1:6196:1	O

Table	DYSPORT.xml:S1:6202:5	O

4	DYSPORT.xml:S1:6208:1	O
:	DYSPORT.xml:S1:6209:1	O
Common	DYSPORT.xml:S1:6211:6	O
Adverse	DYSPORT.xml:S1:6218:7	O
Reactions	DYSPORT.xml:S1:6226:9	O
by	DYSPORT.xml:S1:6236:2	O
Dose	DYSPORT.xml:S1:6239:4	O
in	DYSPORT.xml:S1:6244:2	O
Fixed	DYSPORT.xml:S1:6247:5	O
-	DYSPORT.xml:S1:6252:1	O
dose	DYSPORT.xml:S1:6253:4	O
Study	DYSPORT.xml:S1:6258:5	O
in	DYSPORT.xml:S1:6264:2	O
Patients	DYSPORT.xml:S1:6267:8	O
with	DYSPORT.xml:S1:6276:4	O
Cervical	DYSPORT.xml:S1:6281:8	O
Dystonia	DYSPORT.xml:S1:6290:8	O

Adverse	DYSPORT.xml:S1:6301:7	O
Reaction	DYSPORT.xml:S1:6309:8	O
Preferred	DYSPORT.xml:S1:6319:9	O
Term	DYSPORT.xml:S1:6329:4	O
DYSPORT	DYSPORT.xml:S1:6343:7	O
(	DYSPORT.xml:S1:6352:1	O
r	DYSPORT.xml:S1:6353:1	O
)	DYSPORT.xml:S1:6354:1	O
Dose	DYSPORT.xml:S1:6357:4	O

Placebo	DYSPORT.xml:S1:6366:7	O
250	DYSPORT.xml:S1:6411:3	O
Units	DYSPORT.xml:S1:6415:5	O
500	DYSPORT.xml:S1:6428:3	O
Units	DYSPORT.xml:S1:6432:5	O
1000	DYSPORT.xml:S1:6444:4	O
Units	DYSPORT.xml:S1:6449:5	O

Any	DYSPORT.xml:S1:6467:3	O

Adverse	DYSPORT.xml:S1:6471:7	O
Event	DYSPORT.xml:S1:6479:5	O
30%	DYSPORT.xml:S1:6513:3	O
37%	DYSPORT.xml:S1:6530:3	O
65%	DYSPORT.xml:S1:6547:3	O
83%	DYSPORT.xml:S1:6564:3	O

Dysphagia	DYSPORT.xml:S1:6580:9	B-AdverseReaction
5%	DYSPORT.xml:S1:6626:2	O
21%	DYSPORT.xml:S1:6643:3	O
29%	DYSPORT.xml:S1:6660:3	O
39%	DYSPORT.xml:S1:6677:3	O

Dry	DYSPORT.xml:S1:6693:3	B-AdverseReaction
Mouth	DYSPORT.xml:S1:6697:5	I-AdverseReaction
10%	DYSPORT.xml:S1:6739:3	O
21%	DYSPORT.xml:S1:6756:3	O
18%	DYSPORT.xml:S1:6773:3	O
39%	DYSPORT.xml:S1:6790:3	O

Muscular	DYSPORT.xml:S1:6806:8	B-AdverseReaction
Weakness	DYSPORT.xml:S1:6815:8	I-AdverseReaction
0%	DYSPORT.xml:S1:6852:2	O
11%	DYSPORT.xml:S1:6869:3	O
12%	DYSPORT.xml:S1:6886:3	O
56%	DYSPORT.xml:S1:6903:3	O

Injection	DYSPORT.xml:S1:6919:9	B-AdverseReaction
Site	DYSPORT.xml:S1:6929:4	I-AdverseReaction
Discomfort	DYSPORT.xml:S1:6934:10	I-AdverseReaction
10%	DYSPORT.xml:S1:6965:3	O
5%	DYSPORT.xml:S1:6982:2	O
18%	DYSPORT.xml:S1:6999:3	O
22%	DYSPORT.xml:S1:7016:3	O

Dysphonia	DYSPORT.xml:S1:7032:9	B-AdverseReaction
0%	DYSPORT.xml:S1:7078:2	O
0%	DYSPORT.xml:S1:7095:2	O
18%	DYSPORT.xml:S1:7112:3	O
28%	DYSPORT.xml:S1:7129:3	O

Facial	DYSPORT.xml:S1:7145:6	B-AdverseReaction
Paresis	DYSPORT.xml:S1:7152:7	I-AdverseReaction
0%	DYSPORT.xml:S1:7191:2	O
5%	DYSPORT.xml:S1:7208:2	O
0%	DYSPORT.xml:S1:7225:2	O
11%	DYSPORT.xml:S1:7242:3	O

Eye	DYSPORT.xml:S1:7258:3	O
Disorders	DYSPORT.xml:S1:7262:9	O
0%	DYSPORT.xml:S1:7304:2	O
0%	DYSPORT.xml:S1:7321:2	O
6%	DYSPORT.xml:S1:7338:2	O
17%	DYSPORT.xml:S1:7355:3	O

Injection	DYSPORT.xml:S1:7383:9	O
Site	DYSPORT.xml:S1:7393:4	O
Reactions	DYSPORT.xml:S1:7398:9	O

Injection	DYSPORT.xml:S1:7414:9	B-AdverseReaction

site	DYSPORT.xml:S1:7424:4	I-AdverseReaction
discomfort	DYSPORT.xml:S1:7429:10	I-AdverseReaction
and	DYSPORT.xml:S1:7440:3	O
injection	DYSPORT.xml:S1:7444:9	B-AdverseReaction
site	DYSPORT.xml:S1:7454:4	I-AdverseReaction
pain	DYSPORT.xml:S1:7459:4	I-AdverseReaction
were	DYSPORT.xml:S1:7464:4	O
common	DYSPORT.xml:S1:7469:6	O
adverse	DYSPORT.xml:S1:7476:7	O
reactions	DYSPORT.xml:S1:7484:9	O
following	DYSPORT.xml:S1:7494:9	O
DYSPORT	DYSPORT.xml:S1:7504:7	O
(	DYSPORT.xml:S1:7515:1	O
r	DYSPORT.xml:S1:7516:1	O
)	DYSPORT.xml:S1:7517:1	O
administration	DYSPORT.xml:S1:7522:14	O
.	DYSPORT.xml:S1:7536:1	O

Less	DYSPORT.xml:S1:7546:4	O
Common	DYSPORT.xml:S1:7551:6	O
Adverse	DYSPORT.xml:S1:7558:7	O
Reactions	DYSPORT.xml:S1:7566:9	O

The	DYSPORT.xml:S1:7582:3	O
following	DYSPORT.xml:S1:7586:9	O
adverse	DYSPORT.xml:S1:7596:7	O
reactions	DYSPORT.xml:S1:7604:9	O
were	DYSPORT.xml:S1:7614:4	O
reported	DYSPORT.xml:S1:7619:8	O
less	DYSPORT.xml:S1:7628:4	O
frequently	DYSPORT.xml:S1:7633:10	O
(	DYSPORT.xml:S1:7644:1	O
5%	DYSPORT.xml:S1:7646:2	O
)	DYSPORT.xml:S1:7648:1	O
.	DYSPORT.xml:S1:7649:1	O

Breathing	DYSPORT.xml:S1:7659:9	O
Difficulty	DYSPORT.xml:S1:7669:10	O

Breathing	DYSPORT.xml:S1:7686:9	B-AdverseReaction
difficulties	DYSPORT.xml:S1:7696:12	I-AdverseReaction
were	DYSPORT.xml:S1:7709:4	O
reported	DYSPORT.xml:S1:7714:8	O
by	DYSPORT.xml:S1:7723:2	O
approximately	DYSPORT.xml:S1:7726:13	O
3%	DYSPORT.xml:S1:7740:2	O
of	DYSPORT.xml:S1:7743:2	O
patients	DYSPORT.xml:S1:7746:8	O
following	DYSPORT.xml:S1:7755:9	O
DYSPORT	DYSPORT.xml:S1:7765:7	O
(	DYSPORT.xml:S1:7776:1	O
r	DYSPORT.xml:S1:7777:1	O
)	DYSPORT.xml:S1:7778:1	O
administration	DYSPORT.xml:S1:7783:14	O
and	DYSPORT.xml:S1:7798:3	O
in	DYSPORT.xml:S1:7802:2	O
1%	DYSPORT.xml:S1:7805:2	O
of	DYSPORT.xml:S1:7808:2	O
placebo	DYSPORT.xml:S1:7811:7	O
patients	DYSPORT.xml:S1:7819:8	O
in	DYSPORT.xml:S1:7828:2	O
clinical	DYSPORT.xml:S1:7831:8	O
trials	DYSPORT.xml:S1:7840:6	O
during	DYSPORT.xml:S1:7847:6	O
the	DYSPORT.xml:S1:7854:3	O
double	DYSPORT.xml:S1:7858:6	O
-	DYSPORT.xml:S1:7864:1	O
blind	DYSPORT.xml:S1:7865:5	O
phase	DYSPORT.xml:S1:7871:5	O
.	DYSPORT.xml:S1:7876:1	O

These	DYSPORT.xml:S1:7878:5	O
consisted	DYSPORT.xml:S1:7884:9	O
mainly	DYSPORT.xml:S1:7894:6	O
of	DYSPORT.xml:S1:7901:2	O
dyspnea	DYSPORT.xml:S1:7904:7	B-AdverseReaction
.	DYSPORT.xml:S1:7911:1	O

The	DYSPORT.xml:S1:7913:3	O
median	DYSPORT.xml:S1:7917:6	O
time	DYSPORT.xml:S1:7924:4	O
to	DYSPORT.xml:S1:7929:2	O
onset	DYSPORT.xml:S1:7932:5	O
from	DYSPORT.xml:S1:7938:4	O
last	DYSPORT.xml:S1:7943:4	O
dose	DYSPORT.xml:S1:7948:4	O
of	DYSPORT.xml:S1:7953:2	O
DYSPORT	DYSPORT.xml:S1:7956:7	O
(	DYSPORT.xml:S1:7967:1	O
r	DYSPORT.xml:S1:7968:1	O
)	DYSPORT.xml:S1:7969:1	O
was	DYSPORT.xml:S1:7974:3	O
approximately	DYSPORT.xml:S1:7978:13	O
one	DYSPORT.xml:S1:7992:3	O
week	DYSPORT.xml:S1:7996:4	O
,	DYSPORT.xml:S1:8000:1	O
and	DYSPORT.xml:S1:8002:3	O
the	DYSPORT.xml:S1:8006:3	O
median	DYSPORT.xml:S1:8010:6	O
duration	DYSPORT.xml:S1:8017:8	O
was	DYSPORT.xml:S1:8026:3	O
approximately	DYSPORT.xml:S1:8030:13	O
three	DYSPORT.xml:S1:8044:5	O
weeks	DYSPORT.xml:S1:8050:5	O
.	DYSPORT.xml:S1:8055:1	O

Other	DYSPORT.xml:S1:8061:5	O
adverse	DYSPORT.xml:S1:8067:7	O
reactions	DYSPORT.xml:S1:8075:9	O
with	DYSPORT.xml:S1:8085:4	O
incidences	DYSPORT.xml:S1:8090:10	O
of	DYSPORT.xml:S1:8101:2	O
less	DYSPORT.xml:S1:8104:4	O
than	DYSPORT.xml:S1:8109:4	O
5%	DYSPORT.xml:S1:8114:2	O
in	DYSPORT.xml:S1:8117:2	O
the	DYSPORT.xml:S1:8120:3	O
DYSPORT	DYSPORT.xml:S1:8124:7	O
(	DYSPORT.xml:S1:8135:1	O
r	DYSPORT.xml:S1:8136:1	O
)	DYSPORT.xml:S1:8137:1	O
500	DYSPORT.xml:S1:8142:3	O
Units	DYSPORT.xml:S1:8146:5	O
group	DYSPORT.xml:S1:8152:5	O
in	DYSPORT.xml:S1:8158:2	O
the	DYSPORT.xml:S1:8161:3	O
double	DYSPORT.xml:S1:8165:6	O
-	DYSPORT.xml:S1:8171:1	O
blind	DYSPORT.xml:S1:8172:5	O
phase	DYSPORT.xml:S1:8178:5	O
of	DYSPORT.xml:S1:8184:2	O
clinical	DYSPORT.xml:S1:8187:8	O
trials	DYSPORT.xml:S1:8196:6	O
included	DYSPORT.xml:S1:8203:8	O
dizziness	DYSPORT.xml:S1:8212:9	B-AdverseReaction
in	DYSPORT.xml:S1:8222:2	O
3.5%	DYSPORT.xml:S1:8225:4	O
of	DYSPORT.xml:S1:8230:2	O
DYSPORT	DYSPORT.xml:S1:8233:7	O
(	DYSPORT.xml:S1:8244:1	O
r	DYSPORT.xml:S1:8245:1	O
)	DYSPORT.xml:S1:8246:1	O
-	DYSPORT.xml:S1:8251:1	O
treated	DYSPORT.xml:S1:8252:7	O
patients	DYSPORT.xml:S1:8260:8	O
and	DYSPORT.xml:S1:8269:3	O
1%	DYSPORT.xml:S1:8273:2	O
of	DYSPORT.xml:S1:8276:2	O
placebo	DYSPORT.xml:S1:8279:7	O
-	DYSPORT.xml:S1:8286:1	O
treated	DYSPORT.xml:S1:8287:7	O
patients	DYSPORT.xml:S1:8295:8	O
,	DYSPORT.xml:S1:8303:1	O
and	DYSPORT.xml:S1:8305:3	O
muscle	DYSPORT.xml:S1:8309:6	B-AdverseReaction
atrophy	DYSPORT.xml:S1:8316:7	I-AdverseReaction
in	DYSPORT.xml:S1:8324:2	O
1%	DYSPORT.xml:S1:8327:2	O
of	DYSPORT.xml:S1:8330:2	O
DYSPORT	DYSPORT.xml:S1:8333:7	O
(	DYSPORT.xml:S1:8344:1	O
r	DYSPORT.xml:S1:8345:1	O
)	DYSPORT.xml:S1:8346:1	O
-	DYSPORT.xml:S1:8351:1	O
treated	DYSPORT.xml:S1:8352:7	O
patients	DYSPORT.xml:S1:8360:8	O
and	DYSPORT.xml:S1:8369:3	O
in	DYSPORT.xml:S1:8373:2	O
none	DYSPORT.xml:S1:8376:4	O
of	DYSPORT.xml:S1:8381:2	O
the	DYSPORT.xml:S1:8384:3	O
placebo	DYSPORT.xml:S1:8388:7	O
-	DYSPORT.xml:S1:8395:1	O
treated	DYSPORT.xml:S1:8396:7	O
patients	DYSPORT.xml:S1:8404:8	O
.	DYSPORT.xml:S1:8412:1	O

Laboratory	DYSPORT.xml:S1:8422:10	O
Findings	DYSPORT.xml:S1:8433:8	O

Patients	DYSPORT.xml:S1:8448:8	O
treated	DYSPORT.xml:S1:8457:7	O
with	DYSPORT.xml:S1:8465:4	O
DYSPORT	DYSPORT.xml:S1:8470:7	O
(	DYSPORT.xml:S1:8481:1	O
r	DYSPORT.xml:S1:8482:1	O
)	DYSPORT.xml:S1:8483:1	O
exhibited	DYSPORT.xml:S1:8488:9	O
a	DYSPORT.xml:S1:8498:1	O
small	DYSPORT.xml:S1:8500:5	B-Severity
increase	DYSPORT.xml:S1:8506:8	B-AdverseReaction
from	DYSPORT.xml:S1:8515:4	O
baseline	DYSPORT.xml:S1:8520:8	O
(	DYSPORT.xml:S1:8529:1	O
0.23	DYSPORT.xml:S1:8530:4	O
mol	DYSPORT.xml:S1:8535:3	O
L	DYSPORT.xml:S1:8539:1	O
)	DYSPORT.xml:S1:8540:1	O
in	DYSPORT.xml:S1:8542:2	I-AdverseReaction
mean	DYSPORT.xml:S1:8545:4	I-AdverseReaction
blood	DYSPORT.xml:S1:8550:5	I-AdverseReaction
glucose	DYSPORT.xml:S1:8556:7	I-AdverseReaction
relative	DYSPORT.xml:S1:8564:8	O
to	DYSPORT.xml:S1:8573:2	O
placebo	DYSPORT.xml:S1:8576:7	O
-	DYSPORT.xml:S1:8583:1	O
treated	DYSPORT.xml:S1:8585:7	O
patients	DYSPORT.xml:S1:8593:8	O
.	DYSPORT.xml:S1:8601:1	O

This	DYSPORT.xml:S1:8603:4	O
was	DYSPORT.xml:S1:8608:3	O
not	DYSPORT.xml:S1:8612:3	O
clinically	DYSPORT.xml:S1:8616:10	O
significant	DYSPORT.xml:S1:8627:11	O
among	DYSPORT.xml:S1:8639:5	O
patients	DYSPORT.xml:S1:8645:8	O
in	DYSPORT.xml:S1:8654:2	O
the	DYSPORT.xml:S1:8657:3	O
development	DYSPORT.xml:S1:8661:11	O
program	DYSPORT.xml:S1:8673:7	O
but	DYSPORT.xml:S1:8681:3	O
could	DYSPORT.xml:S1:8685:5	O
be	DYSPORT.xml:S1:8691:2	O
a	DYSPORT.xml:S1:8694:1	O
factor	DYSPORT.xml:S1:8696:6	O
in	DYSPORT.xml:S1:8703:2	O
patients	DYSPORT.xml:S1:8706:8	O
whose	DYSPORT.xml:S1:8715:5	O
diabetes	DYSPORT.xml:S1:8721:8	O
is	DYSPORT.xml:S1:8730:2	O
difficult	DYSPORT.xml:S1:8733:9	O
to	DYSPORT.xml:S1:8743:2	O
control	DYSPORT.xml:S1:8746:7	O
.	DYSPORT.xml:S1:8753:1	O

Electrocardiographic	DYSPORT.xml:S1:8763:20	O
Findings	DYSPORT.xml:S1:8784:8	O

ECG	DYSPORT.xml:S1:8799:3	O
measurements	DYSPORT.xml:S1:8803:12	O
were	DYSPORT.xml:S1:8816:4	O
only	DYSPORT.xml:S1:8821:4	O
recorded	DYSPORT.xml:S1:8826:8	O
in	DYSPORT.xml:S1:8835:2	O
a	DYSPORT.xml:S1:8838:1	O
limited	DYSPORT.xml:S1:8840:7	O
number	DYSPORT.xml:S1:8848:6	O
of	DYSPORT.xml:S1:8855:2	O
patients	DYSPORT.xml:S1:8858:8	O
in	DYSPORT.xml:S1:8867:2	O
an	DYSPORT.xml:S1:8870:2	O
open	DYSPORT.xml:S1:8873:4	O
-	DYSPORT.xml:S1:8877:1	O
label	DYSPORT.xml:S1:8878:5	O
study	DYSPORT.xml:S1:8884:5	O
without	DYSPORT.xml:S1:8890:7	O
a	DYSPORT.xml:S1:8898:1	O
placebo	DYSPORT.xml:S1:8900:7	O
or	DYSPORT.xml:S1:8908:2	O
active	DYSPORT.xml:S1:8911:6	O
control	DYSPORT.xml:S1:8918:7	O
.	DYSPORT.xml:S1:8925:1	O

This	DYSPORT.xml:S1:8927:4	O
study	DYSPORT.xml:S1:8932:5	O
showed	DYSPORT.xml:S1:8938:6	O
a	DYSPORT.xml:S1:8945:1	O
statistically	DYSPORT.xml:S1:8947:13	O
significant	DYSPORT.xml:S1:8961:11	O
reduction	DYSPORT.xml:S1:8973:9	B-AdverseReaction
in	DYSPORT.xml:S1:8983:2	I-AdverseReaction
heart	DYSPORT.xml:S1:8986:5	I-AdverseReaction
rate	DYSPORT.xml:S1:8992:4	I-AdverseReaction
compared	DYSPORT.xml:S1:8997:8	O
to	DYSPORT.xml:S1:9006:2	O
baseline	DYSPORT.xml:S1:9009:8	O
,	DYSPORT.xml:S1:9017:1	O
averaging	DYSPORT.xml:S1:9019:9	O
about	DYSPORT.xml:S1:9029:5	O
three	DYSPORT.xml:S1:9035:5	O
beats	DYSPORT.xml:S1:9041:5	O
per	DYSPORT.xml:S1:9047:3	O
minute	DYSPORT.xml:S1:9051:6	O
,	DYSPORT.xml:S1:9057:1	O
observed	DYSPORT.xml:S1:9059:8	O
thirty	DYSPORT.xml:S1:9068:6	O
minutes	DYSPORT.xml:S1:9075:7	O
after	DYSPORT.xml:S1:9083:5	O
injection	DYSPORT.xml:S1:9089:9	O
.	DYSPORT.xml:S1:9098:1	O

Glabellar	DYSPORT.xml:S1:9108:9	O
Lines	DYSPORT.xml:S1:9118:5	O

In	DYSPORT.xml:S1:9130:2	O
placebo	DYSPORT.xml:S1:9133:7	O
-	DYSPORT.xml:S1:9140:1	O
controlled	DYSPORT.xml:S1:9141:10	O
clinical	DYSPORT.xml:S1:9152:8	O
trials	DYSPORT.xml:S1:9161:6	O
of	DYSPORT.xml:S1:9168:2	O
DYSPORT	DYSPORT.xml:S1:9171:7	O
(	DYSPORT.xml:S1:9182:1	O
r	DYSPORT.xml:S1:9183:1	O
)	DYSPORT.xml:S1:9184:1	O
,	DYSPORT.xml:S1:9189:1	O
the	DYSPORT.xml:S1:9191:3	O
most	DYSPORT.xml:S1:9195:4	O
common	DYSPORT.xml:S1:9200:6	O
adverse	DYSPORT.xml:S1:9207:7	O
reactions	DYSPORT.xml:S1:9215:9	O
(	DYSPORT.xml:S1:9224:1	O
2%	DYSPORT.xml:S1:9227:2	O
)	DYSPORT.xml:S1:9229:1	O
following	DYSPORT.xml:S1:9231:9	O
injection	DYSPORT.xml:S1:9241:9	O
of	DYSPORT.xml:S1:9251:2	O
DYSPORT	DYSPORT.xml:S1:9254:7	O
(	DYSPORT.xml:S1:9265:1	O
r	DYSPORT.xml:S1:9266:1	O
)	DYSPORT.xml:S1:9267:1	O
were	DYSPORT.xml:S1:9272:4	O
nasopharyngitis	DYSPORT.xml:S1:9277:15	B-AdverseReaction
,	DYSPORT.xml:S1:9292:1	O
headache	DYSPORT.xml:S1:9294:8	B-AdverseReaction
,	DYSPORT.xml:S1:9302:1	O
injection	DYSPORT.xml:S1:9304:9	B-AdverseReaction
site	DYSPORT.xml:S1:9314:4	I-AdverseReaction
pain	DYSPORT.xml:S1:9319:4	I-AdverseReaction
,	DYSPORT.xml:S1:9323:1	O
injection	DYSPORT.xml:S1:9325:9	B-AdverseReaction
site	DYSPORT.xml:S1:9335:4	I-AdverseReaction
reaction	DYSPORT.xml:S1:9340:8	I-AdverseReaction
,	DYSPORT.xml:S1:9348:1	O
upper	DYSPORT.xml:S1:9350:5	B-AdverseReaction
respiratory	DYSPORT.xml:S1:9356:11	I-AdverseReaction
tract	DYSPORT.xml:S1:9368:5	I-AdverseReaction
infection	DYSPORT.xml:S1:9374:9	I-AdverseReaction
,	DYSPORT.xml:S1:9383:1	O
eyelid	DYSPORT.xml:S1:9385:6	B-AdverseReaction
edema	DYSPORT.xml:S1:9392:5	I-AdverseReaction
,	DYSPORT.xml:S1:9397:1	O
eyelid	DYSPORT.xml:S1:9399:6	B-AdverseReaction
ptosis	DYSPORT.xml:S1:9406:6	I-AdverseReaction
,	DYSPORT.xml:S1:9412:1	O
sinusitis	DYSPORT.xml:S1:9414:9	B-AdverseReaction
,	DYSPORT.xml:S1:9423:1	O
and	DYSPORT.xml:S1:9425:3	O
nausea	DYSPORT.xml:S1:9429:6	B-AdverseReaction
.	DYSPORT.xml:S1:9435:1	O

Table	DYSPORT.xml:S1:9441:5	O
5	DYSPORT.xml:S1:9447:1	O
reflects	DYSPORT.xml:S1:9449:8	O
exposure	DYSPORT.xml:S1:9458:8	O
to	DYSPORT.xml:S1:9467:2	O
DYSPORT	DYSPORT.xml:S1:9470:7	O
(	DYSPORT.xml:S1:9481:1	O
r	DYSPORT.xml:S1:9482:1	O
)	DYSPORT.xml:S1:9483:1	O
in	DYSPORT.xml:S1:9488:2	O
398	DYSPORT.xml:S1:9491:3	O
patients	DYSPORT.xml:S1:9495:8	O
19	DYSPORT.xml:S1:9504:2	O
to	DYSPORT.xml:S1:9507:2	O
75	DYSPORT.xml:S1:9510:2	O
years	DYSPORT.xml:S1:9513:5	O
of	DYSPORT.xml:S1:9519:2	O
age	DYSPORT.xml:S1:9522:3	O
who	DYSPORT.xml:S1:9526:3	O
were	DYSPORT.xml:S1:9530:4	O
evaluated	DYSPORT.xml:S1:9535:9	O
in	DYSPORT.xml:S1:9545:2	O
the	DYSPORT.xml:S1:9548:3	O
randomized	DYSPORT.xml:S1:9552:10	O
,	DYSPORT.xml:S1:9562:1	O
placebo	DYSPORT.xml:S1:9564:7	O
-	DYSPORT.xml:S1:9571:1	O
controlled	DYSPORT.xml:S1:9573:10	O
clinical	DYSPORT.xml:S1:9584:8	O
studies	DYSPORT.xml:S1:9593:7	O
that	DYSPORT.xml:S1:9601:4	O
assessed	DYSPORT.xml:S1:9606:8	O
the	DYSPORT.xml:S1:9615:3	O
use	DYSPORT.xml:S1:9619:3	O
of	DYSPORT.xml:S1:9623:2	O
DYSPORT	DYSPORT.xml:S1:9626:7	O
(	DYSPORT.xml:S1:9637:1	O
r	DYSPORT.xml:S1:9638:1	O
)	DYSPORT.xml:S1:9639:1	O
for	DYSPORT.xml:S1:9644:3	O
the	DYSPORT.xml:S1:9648:3	O
temporary	DYSPORT.xml:S1:9652:9	O
improvement	DYSPORT.xml:S1:9662:11	O
in	DYSPORT.xml:S1:9674:2	O
the	DYSPORT.xml:S1:9677:3	O
appearance	DYSPORT.xml:S1:9681:10	O
of	DYSPORT.xml:S1:9692:2	O
glabellar	DYSPORT.xml:S1:9695:9	O
lines	DYSPORT.xml:S1:9705:5	O
[	DYSPORT.xml:S1:9711:1	O
seeClinical	DYSPORT.xml:S1:9714:11	O
Studies	DYSPORT.xml:S1:9726:7	O
(	DYSPORT.xml:S1:9734:1	O
14	DYSPORT.xml:S1:9735:2	O
)	DYSPORT.xml:S1:9737:1	O
]	DYSPORT.xml:S1:9740:1	O
.	DYSPORT.xml:S1:9741:1	O

Adverse	DYSPORT.xml:S1:9743:7	O
reactions	DYSPORT.xml:S1:9751:9	O
of	DYSPORT.xml:S1:9761:2	O
any	DYSPORT.xml:S1:9764:3	O
cause	DYSPORT.xml:S1:9768:5	O
occurred	DYSPORT.xml:S1:9774:8	O
in	DYSPORT.xml:S1:9783:2	O
48%	DYSPORT.xml:S1:9786:3	O
of	DYSPORT.xml:S1:9790:2	O
the	DYSPORT.xml:S1:9793:3	O
DYSPORT	DYSPORT.xml:S1:9797:7	O
(	DYSPORT.xml:S1:9808:1	O
r	DYSPORT.xml:S1:9809:1	O
)	DYSPORT.xml:S1:9810:1	O
-	DYSPORT.xml:S1:9815:1	O
treated	DYSPORT.xml:S1:9816:7	O
patients	DYSPORT.xml:S1:9824:8	O
and	DYSPORT.xml:S1:9833:3	O
33%	DYSPORT.xml:S1:9837:3	O
of	DYSPORT.xml:S1:9841:2	O
the	DYSPORT.xml:S1:9844:3	O
placebo	DYSPORT.xml:S1:9848:7	O
-	DYSPORT.xml:S1:9855:1	O
treated	DYSPORT.xml:S1:9857:7	O
patients	DYSPORT.xml:S1:9865:8	O
.	DYSPORT.xml:S1:9873:1	O

Table	DYSPORT.xml:S1:9879:5	O
5	DYSPORT.xml:S1:9885:1	O
:	DYSPORT.xml:S1:9886:1	O
Most	DYSPORT.xml:S1:9888:4	O
Common	DYSPORT.xml:S1:9893:6	O
Adverse	DYSPORT.xml:S1:9900:7	O
Reactions	DYSPORT.xml:S1:9908:9	O
with	DYSPORT.xml:S1:9918:4	O
1%	DYSPORT.xml:S1:9925:2	O
Incidence	DYSPORT.xml:S1:9928:9	O
in	DYSPORT.xml:S1:9938:2	O
Pooled	DYSPORT.xml:S1:9941:6	O
,	DYSPORT.xml:S1:9947:1	O
Placebo	DYSPORT.xml:S1:9949:7	O
-	DYSPORT.xml:S1:9956:1	O
Controlled	DYSPORT.xml:S1:9957:10	O
Trials	DYSPORT.xml:S1:9968:6	O
for	DYSPORT.xml:S1:9975:3	O
Glabellar	DYSPORT.xml:S1:9979:9	O
Lines	DYSPORT.xml:S1:9989:5	O

Adverse	DYSPORT.xml:S1:9997:7	O
Reactions	DYSPORT.xml:S1:10005:9	O
by	DYSPORT.xml:S1:10015:2	O
Body	DYSPORT.xml:S1:10018:4	O
System	DYSPORT.xml:S1:10023:6	O
DYSPORT	DYSPORT.xml:S1:10050:7	O
(	DYSPORT.xml:S1:10059:1	O
r	DYSPORT.xml:S1:10060:1	O
)	DYSPORT.xml:S1:10061:1	O
n	DYSPORT.xml:S1:10064:1	O
398	DYSPORT.xml:S1:10066:3	O
(	DYSPORT.xml:S1:10070:1	O
)	DYSPORT.xml:S1:10072:1	O
Placebon	DYSPORT.xml:S1:10080:8	O
496	DYSPORT.xml:S1:10089:3	O
(	DYSPORT.xml:S1:10093:1	O
)	DYSPORT.xml:S1:10095:1	O

Any	DYSPORT.xml:S1:10111:3	O

Adverse	DYSPORT.xml:S1:10115:7	O
Reaction	DYSPORT.xml:S1:10123:8	O
48	DYSPORT.xml:S1:10172:2	O
33	DYSPORT.xml:S1:10199:2	O

Eye	DYSPORT.xml:S1:10220:3	O
Disorders	DYSPORT.xml:S1:10224:9	O

Eyelid	DYSPORT.xml:S1:10329:6	B-AdverseReaction
Edema	DYSPORT.xml:S1:10336:5	I-AdverseReaction
2	DYSPORT.xml:S1:10391:1	O
0	DYSPORT.xml:S1:10418:1	O

Eyelid	DYSPORT.xml:S1:10438:6	B-AdverseReaction
Ptosis	DYSPORT.xml:S1:10445:6	I-AdverseReaction
2	DYSPORT.xml:S1:10500:1	O
1	DYSPORT.xml:S1:10527:1	O

Gastrointestinal	DYSPORT.xml:S1:10547:16	O
Disorders	DYSPORT.xml:S1:10564:9	O

Nausea	DYSPORT.xml:S1:10656:6	B-AdverseReaction
2	DYSPORT.xml:S1:10718:1	O
1	DYSPORT.xml:S1:10745:1	O

General	DYSPORT.xml:S1:10765:7	O
Disorders	DYSPORT.xml:S1:10773:9	O
and	DYSPORT.xml:S1:10783:3	O
Administration	DYSPORT.xml:S1:10787:14	O
Site	DYSPORT.xml:S1:10802:4	O
Conditions	DYSPORT.xml:S1:10807:10	O

Injection	DYSPORT.xml:S1:10880:9	B-AdverseReaction
Site	DYSPORT.xml:S1:10890:4	I-AdverseReaction
Pain	DYSPORT.xml:S1:10895:4	I-AdverseReaction
3	DYSPORT.xml:S1:10942:1	O
2	DYSPORT.xml:S1:10969:1	O

Injection	DYSPORT.xml:S1:10989:9	B-AdverseReaction
Site	DYSPORT.xml:S1:10999:4	I-AdverseReaction
Reaction	DYSPORT.xml:S1:11004:8	I-AdverseReaction
3	DYSPORT.xml:S1:11051:1	O
1	DYSPORT.xml:S1:11078:1	O

Infections	DYSPORT.xml:S1:11098:10	O
and	DYSPORT.xml:S1:11109:3	O
Infestations	DYSPORT.xml:S1:11113:12	O

Nasopharyngitis	DYSPORT.xml:S1:11207:15	B-AdverseReaction
10	DYSPORT.xml:S1:11268:2	O
4	DYSPORT.xml:S1:11296:1	O

Upper	DYSPORT.xml:S1:11316:5	B-AdverseReaction
Respiratory	DYSPORT.xml:S1:11322:11	I-AdverseReaction
Tract	DYSPORT.xml:S1:11334:5	I-AdverseReaction
Infection	DYSPORT.xml:S1:11340:9	I-AdverseReaction
3	DYSPORT.xml:S1:11378:1	O
2	DYSPORT.xml:S1:11405:1	O

Sinusitis	DYSPORT.xml:S1:11425:9	B-AdverseReaction
2	DYSPORT.xml:S1:11487:1	O
1	DYSPORT.xml:S1:11514:1	O

Investigations	DYSPORT.xml:S1:11534:14	O

Blood	DYSPORT.xml:S1:11643:5	B-AdverseReaction
Present	DYSPORT.xml:S1:11649:7	I-AdverseReaction
in	DYSPORT.xml:S1:11657:2	I-AdverseReaction
Urine	DYSPORT.xml:S1:11660:5	I-AdverseReaction
2	DYSPORT.xml:S1:11705:1	O
1	DYSPORT.xml:S1:11732:1	O

Nervous	DYSPORT.xml:S1:11752:7	O
System	DYSPORT.xml:S1:11760:6	O
Disorders	DYSPORT.xml:S1:11767:9	O

Headache	DYSPORT.xml:S1:11861:8	B-AdverseReaction
9	DYSPORT.xml:S1:11923:1	O
5	DYSPORT.xml:S1:11950:1	O

In	DYSPORT.xml:S1:11976:2	O
the	DYSPORT.xml:S1:11979:3	O
overall	DYSPORT.xml:S1:11983:7	O
safety	DYSPORT.xml:S1:11991:6	O
database	DYSPORT.xml:S1:11998:8	O
,	DYSPORT.xml:S1:12006:1	O
where	DYSPORT.xml:S1:12008:5	O
some	DYSPORT.xml:S1:12014:4	O
patients	DYSPORT.xml:S1:12019:8	O
received	DYSPORT.xml:S1:12028:8	O
up	DYSPORT.xml:S1:12037:2	O
to	DYSPORT.xml:S1:12040:2	O
twelve	DYSPORT.xml:S1:12043:6	O
treatments	DYSPORT.xml:S1:12050:10	O
with	DYSPORT.xml:S1:12061:4	O
DYSPORT	DYSPORT.xml:S1:12066:7	O
(	DYSPORT.xml:S1:12077:1	O
r	DYSPORT.xml:S1:12078:1	O
)	DYSPORT.xml:S1:12079:1	O
,	DYSPORT.xml:S1:12084:1	O
adverse	DYSPORT.xml:S1:12086:7	O
reactions	DYSPORT.xml:S1:12094:9	O
were	DYSPORT.xml:S1:12104:4	O
reported	DYSPORT.xml:S1:12109:8	O
for	DYSPORT.xml:S1:12118:3	O
57%	DYSPORT.xml:S1:12122:3	O
(	DYSPORT.xml:S1:12126:1	O
1425	DYSPORT.xml:S1:12127:4	O
2491	DYSPORT.xml:S1:12132:4	O
)	DYSPORT.xml:S1:12136:1	O
of	DYSPORT.xml:S1:12138:2	O
patients	DYSPORT.xml:S1:12141:8	O
.	DYSPORT.xml:S1:12149:1	O

The	DYSPORT.xml:S1:12151:3	O
most	DYSPORT.xml:S1:12155:4	O
frequently	DYSPORT.xml:S1:12160:10	O
reported	DYSPORT.xml:S1:12171:8	O
of	DYSPORT.xml:S1:12180:2	O
these	DYSPORT.xml:S1:12183:5	O
adverse	DYSPORT.xml:S1:12189:7	O
reactions	DYSPORT.xml:S1:12197:9	O
were	DYSPORT.xml:S1:12207:4	O
headache	DYSPORT.xml:S1:12212:8	B-AdverseReaction
,	DYSPORT.xml:S1:12220:1	O
nasopharyngitis	DYSPORT.xml:S1:12222:15	B-AdverseReaction
,	DYSPORT.xml:S1:12237:1	O
injection	DYSPORT.xml:S1:12239:9	B-AdverseReaction
site	DYSPORT.xml:S1:12249:4	I-AdverseReaction
pain	DYSPORT.xml:S1:12254:4	I-AdverseReaction
,	DYSPORT.xml:S1:12258:1	O
sinusitis	DYSPORT.xml:S1:12260:9	B-AdverseReaction
,	DYSPORT.xml:S1:12269:1	O
URI	DYSPORT.xml:S1:12271:3	B-AdverseReaction
,	DYSPORT.xml:S1:12274:1	O
injection	DYSPORT.xml:S1:12276:9	B-AdverseReaction
site	DYSPORT.xml:S1:12286:4	I-AdverseReaction
bruising	DYSPORT.xml:S1:12291:8	I-AdverseReaction
,	DYSPORT.xml:S1:12299:1	O
and	DYSPORT.xml:S1:12301:3	O
injection	DYSPORT.xml:S1:12305:9	B-AdverseReaction
site	DYSPORT.xml:S1:12315:4	I-AdverseReaction
reaction	DYSPORT.xml:S1:12320:8	I-AdverseReaction
(	DYSPORT.xml:S1:12329:1	O
numbness	DYSPORT.xml:S1:12330:8	I-AdverseReaction
,	DYSPORT.xml:S1:12338:1	O
discomfort	DYSPORT.xml:S1:12340:10	I-AdverseReaction
,	DYSPORT.xml:S1:12350:1	O
erythema	DYSPORT.xml:S1:12352:8	I-AdverseReaction
,	DYSPORT.xml:S1:12360:1	O
tenderness	DYSPORT.xml:S1:12362:10	I-AdverseReaction
,	DYSPORT.xml:S1:12372:1	O
tingling	DYSPORT.xml:S1:12374:8	I-AdverseReaction
,	DYSPORT.xml:S1:12382:1	O
itching	DYSPORT.xml:S1:12384:7	I-AdverseReaction
,	DYSPORT.xml:S1:12391:1	O
stinging	DYSPORT.xml:S1:12393:8	I-AdverseReaction
,	DYSPORT.xml:S1:12401:1	O
warmth	DYSPORT.xml:S1:12403:6	I-AdverseReaction
,	DYSPORT.xml:S1:12409:1	O
irritation	DYSPORT.xml:S1:12411:10	I-AdverseReaction
,	DYSPORT.xml:S1:12421:1	O
tightness	DYSPORT.xml:S1:12423:9	I-AdverseReaction
,	DYSPORT.xml:S1:12432:1	O
swelling	DYSPORT.xml:S1:12434:8	I-AdverseReaction
)	DYSPORT.xml:S1:12442:1	O
.	DYSPORT.xml:S1:12443:1	O

Adverse	DYSPORT.xml:S1:12449:7	O

reactions	DYSPORT.xml:S1:12457:9	O
that	DYSPORT.xml:S1:12467:4	O
occurred	DYSPORT.xml:S1:12472:8	O
after	DYSPORT.xml:S1:12481:5	O
repeated	DYSPORT.xml:S1:12487:8	O
injections	DYSPORT.xml:S1:12496:10	O
in	DYSPORT.xml:S1:12507:2	O
2	DYSPORT.xml:S1:12510:1	O
-	DYSPORT.xml:S1:12511:1	O
3%	DYSPORT.xml:S1:12512:2	O
of	DYSPORT.xml:S1:12515:2	O
the	DYSPORT.xml:S1:12518:3	O
population	DYSPORT.xml:S1:12522:10	O
included	DYSPORT.xml:S1:12533:8	O
bronchitis	DYSPORT.xml:S1:12542:10	B-AdverseReaction
,	DYSPORT.xml:S1:12552:1	O
influenza	DYSPORT.xml:S1:12554:9	B-AdverseReaction
,	DYSPORT.xml:S1:12563:1	O
pharyngolaryngeal	DYSPORT.xml:S1:12565:17	B-AdverseReaction
pain	DYSPORT.xml:S1:12583:4	I-AdverseReaction
,	DYSPORT.xml:S1:12587:1	O
cough	DYSPORT.xml:S1:12589:5	B-AdverseReaction
,	DYSPORT.xml:S1:12594:1	O
contact	DYSPORT.xml:S1:12596:7	B-AdverseReaction
dermatitis	DYSPORT.xml:S1:12604:10	I-AdverseReaction
,	DYSPORT.xml:S1:12614:1	O
injection	DYSPORT.xml:S1:12616:9	B-AdverseReaction
site	DYSPORT.xml:S1:12626:4	I-AdverseReaction
swelling	DYSPORT.xml:S1:12631:8	I-AdverseReaction
,	DYSPORT.xml:S1:12639:1	O
and	DYSPORT.xml:S1:12641:3	O
injection	DYSPORT.xml:S1:12645:9	B-AdverseReaction
site	DYSPORT.xml:S1:12655:4	I-AdverseReaction
discomfort	DYSPORT.xml:S1:12660:10	I-AdverseReaction
.	DYSPORT.xml:S1:12670:1	O

The	DYSPORT.xml:S1:12676:3	O
incidence	DYSPORT.xml:S1:12680:9	O
of	DYSPORT.xml:S1:12690:2	O
eyelid	DYSPORT.xml:S1:12693:6	B-AdverseReaction
ptosis	DYSPORT.xml:S1:12700:6	I-AdverseReaction
did	DYSPORT.xml:S1:12707:3	O
not	DYSPORT.xml:S1:12711:3	O
increase	DYSPORT.xml:S1:12715:8	O
in	DYSPORT.xml:S1:12724:2	O
the	DYSPORT.xml:S1:12727:3	O
long	DYSPORT.xml:S1:12731:4	O
-	DYSPORT.xml:S1:12735:1	O
term	DYSPORT.xml:S1:12736:4	O
safety	DYSPORT.xml:S1:12741:6	O
studies	DYSPORT.xml:S1:12748:7	O
with	DYSPORT.xml:S1:12756:4	O
multiple	DYSPORT.xml:S1:12761:8	O
re	DYSPORT.xml:S1:12770:2	O
-	DYSPORT.xml:S1:12772:1	O
treatments	DYSPORT.xml:S1:12773:10	O
at	DYSPORT.xml:S1:12784:2	O
intervals	DYSPORT.xml:S1:12787:9	O
three	DYSPORT.xml:S1:12800:5	O
months	DYSPORT.xml:S1:12806:6	O
.	DYSPORT.xml:S1:12812:1	O

The	DYSPORT.xml:S1:12814:3	O
majority	DYSPORT.xml:S1:12818:8	O
of	DYSPORT.xml:S1:12827:2	O
the	DYSPORT.xml:S1:12830:3	O
reports	DYSPORT.xml:S1:12834:7	O
of	DYSPORT.xml:S1:12842:2	O
eyelid	DYSPORT.xml:S1:12845:6	B-AdverseReaction
ptosis	DYSPORT.xml:S1:12852:6	I-AdverseReaction
were	DYSPORT.xml:S1:12859:4	O
mild	DYSPORT.xml:S1:12864:4	B-Severity
to	DYSPORT.xml:S1:12869:2	O
moderate	DYSPORT.xml:S1:12872:8	B-Severity
in	DYSPORT.xml:S1:12881:2	O
severity	DYSPORT.xml:S1:12884:8	O
and	DYSPORT.xml:S1:12893:3	O
resolved	DYSPORT.xml:S1:12897:8	O
over	DYSPORT.xml:S1:12906:4	O
several	DYSPORT.xml:S1:12911:7	O
weeks	DYSPORT.xml:S1:12919:5	O
.	DYSPORT.xml:S1:12924:1	O

[	DYSPORT.xml:S1:12926:1	O
seeDosage	DYSPORT.xml:S1:12929:9	O
and	DYSPORT.xml:S1:12939:3	O
Administration	DYSPORT.xml:S1:12943:14	O
(	DYSPORT.xml:S1:12958:1	O
2.3	DYSPORT.xml:S1:12959:3	O
)	DYSPORT.xml:S1:12962:1	O
]	DYSPORT.xml:S1:12965:1	O
.	DYSPORT.xml:S1:12966:1	O

Upper	DYSPORT.xml:S1:12976:5	O
Limb	DYSPORT.xml:S1:12982:4	O
Spasticity	DYSPORT.xml:S1:12987:10	O

Table	DYSPORT.xml:S1:13004:5	O
6	DYSPORT.xml:S1:13010:1	O
lists	DYSPORT.xml:S1:13012:5	O
the	DYSPORT.xml:S1:13018:3	O
most	DYSPORT.xml:S1:13022:4	O
frequently	DYSPORT.xml:S1:13027:10	O
reported	DYSPORT.xml:S1:13038:8	O
adverse	DYSPORT.xml:S1:13047:7	O
reactions	DYSPORT.xml:S1:13055:9	O
(	DYSPORT.xml:S1:13065:1	O
2%	DYSPORT.xml:S1:13068:2	O
)	DYSPORT.xml:S1:13070:1	O
in	DYSPORT.xml:S1:13072:2	O
any	DYSPORT.xml:S1:13075:3	O
DYSPORT	DYSPORT.xml:S1:13079:7	O
(	DYSPORT.xml:S1:13088:1	O
r	DYSPORT.xml:S1:13089:1	O
)	DYSPORT.xml:S1:13090:1	O
dose	DYSPORT.xml:S1:13093:4	O
group	DYSPORT.xml:S1:13098:5	O
and	DYSPORT.xml:S1:13104:3	O
more	DYSPORT.xml:S1:13108:4	O
frequent	DYSPORT.xml:S1:13113:8	O
than	DYSPORT.xml:S1:13122:4	O
placebo	DYSPORT.xml:S1:13127:7	O
in	DYSPORT.xml:S1:13135:2	O
double	DYSPORT.xml:S1:13138:6	O
blind	DYSPORT.xml:S1:13145:5	O
studies	DYSPORT.xml:S1:13151:7	O
evaluating	DYSPORT.xml:S1:13159:10	O
the	DYSPORT.xml:S1:13170:3	O
treatment	DYSPORT.xml:S1:13174:9	O
of	DYSPORT.xml:S1:13184:2	O
upper	DYSPORT.xml:S1:13187:5	O
limb	DYSPORT.xml:S1:13193:4	O
spasticity	DYSPORT.xml:S1:13198:10	O
in	DYSPORT.xml:S1:13209:2	O
adults	DYSPORT.xml:S1:13212:6	O
with	DYSPORT.xml:S1:13219:4	O
DYSPORT	DYSPORT.xml:S1:13224:7	O
(	DYSPORT.xml:S1:13233:1	O
r	DYSPORT.xml:S1:13234:1	O
)	DYSPORT.xml:S1:13235:1	O
.	DYSPORT.xml:S1:13238:1	O

Table	DYSPORT.xml:S1:13244:5	O
6	DYSPORT.xml:S1:13250:1	O
:	DYSPORT.xml:S1:13251:1	O
Most	DYSPORT.xml:S1:13253:4	O
Common	DYSPORT.xml:S1:13258:6	O
Adverse	DYSPORT.xml:S1:13265:7	O
Reactions	DYSPORT.xml:S1:13273:9	O
Observed	DYSPORT.xml:S1:13283:8	O
in	DYSPORT.xml:S1:13292:2	O
at	DYSPORT.xml:S1:13295:2	O
Least	DYSPORT.xml:S1:13298:5	O
2%	DYSPORT.xml:S1:13304:2	O
of	DYSPORT.xml:S1:13307:2	O
Patients	DYSPORT.xml:S1:13310:8	O
Treated	DYSPORT.xml:S1:13319:7	O
in	DYSPORT.xml:S1:13327:2	O
Pooled	DYSPORT.xml:S1:13330:6	O
,	DYSPORT.xml:S1:13336:1	O
Double	DYSPORT.xml:S1:13338:6	O
-	DYSPORT.xml:S1:13344:1	O
Blind	DYSPORT.xml:S1:13345:5	O
Trials	DYSPORT.xml:S1:13351:6	O
of	DYSPORT.xml:S1:13358:2	O
Patients	DYSPORT.xml:S1:13361:8	O
with	DYSPORT.xml:S1:13370:4	O
Upper	DYSPORT.xml:S1:13375:5	O
Limb	DYSPORT.xml:S1:13381:4	O
Spasticity	DYSPORT.xml:S1:13386:10	O
Reported	DYSPORT.xml:S1:13397:8	O
More	DYSPORT.xml:S1:13406:4	O
Frequently	DYSPORT.xml:S1:13411:10	O
than	DYSPORT.xml:S1:13422:4	O
with	DYSPORT.xml:S1:13427:4	O
Placebo	DYSPORT.xml:S1:13432:7	O

Adverse	DYSPORT.xml:S1:13442:7	O
Reaction	DYSPORT.xml:S1:13450:8	O
Preferred	DYSPORT.xml:S1:13460:9	O
Term	DYSPORT.xml:S1:13470:4	O
DYSPORT	DYSPORT.xml:S1:13499:7	O
(	DYSPORT.xml:S1:13508:1	O
r	DYSPORT.xml:S1:13509:1	O
)	DYSPORT.xml:S1:13510:1	O
Placebo	DYSPORT.xml:S1:13520:7	O

500	DYSPORT.xml:S1:13536:3	O
Units	DYSPORT.xml:S1:13540:5	O
(	DYSPORT.xml:S1:13545:1	O
N	DYSPORT.xml:S1:13546:1	O
197	DYSPORT.xml:S1:13548:3	O
)	DYSPORT.xml:S1:13551:1	O
1000	DYSPORT.xml:S1:13593:4	O
Units	DYSPORT.xml:S1:13598:5	O
(	DYSPORT.xml:S1:13603:1	O
N	DYSPORT.xml:S1:13604:1	O
194	DYSPORT.xml:S1:13606:3	O
)	DYSPORT.xml:S1:13609:1	O
(	DYSPORT.xml:S1:13616:1	O
N	DYSPORT.xml:S1:13617:1	O
279	DYSPORT.xml:S1:13619:3	O
)	DYSPORT.xml:S1:13622:1	O

Infections	DYSPORT.xml:S1:13638:10	O

and	DYSPORT.xml:S1:13649:3	O
infestations	DYSPORT.xml:S1:13653:12	O

Nasopharyngitis	DYSPORT.xml:S1:13749:15	B-AdverseReaction
4	DYSPORT.xml:S1:13811:1	O
1	DYSPORT.xml:S1:13828:1	O
1	DYSPORT.xml:S1:13845:1	O

Urinary	DYSPORT.xml:S1:13860:7	B-AdverseReaction
tract	DYSPORT.xml:S1:13868:5	I-AdverseReaction
infection	DYSPORT.xml:S1:13874:9	I-AdverseReaction
3	DYSPORT.xml:S1:13922:1	O
1	DYSPORT.xml:S1:13939:1	O
2	DYSPORT.xml:S1:13956:1	O

Influenza	DYSPORT.xml:S1:13971:9	B-AdverseReaction
1	DYSPORT.xml:S1:14033:1	O
2	DYSPORT.xml:S1:14050:1	O
1	DYSPORT.xml:S1:14067:1	O

Infection	DYSPORT.xml:S1:14082:9	B-AdverseReaction
1	DYSPORT.xml:S1:14144:1	O
2	DYSPORT.xml:S1:14161:1	O
1	DYSPORT.xml:S1:14178:1	O

Musculoskeletal	DYSPORT.xml:S1:14193:15	O
and	DYSPORT.xml:S1:14209:3	O
connective	DYSPORT.xml:S1:14213:10	O
tissue	DYSPORT.xml:S1:14224:6	O
disorders	DYSPORT.xml:S1:14231:9	O

Muscular	DYSPORT.xml:S1:14304:8	B-AdverseReaction
weakness	DYSPORT.xml:S1:14313:8	I-AdverseReaction
2	DYSPORT.xml:S1:14366:1	O
4	DYSPORT.xml:S1:14383:1	O
1	DYSPORT.xml:S1:14400:1	O

Pain	DYSPORT.xml:S1:14415:4	B-AdverseReaction
in	DYSPORT.xml:S1:14420:2	I-AdverseReaction
extremity	DYSPORT.xml:S1:14423:9	I-AdverseReaction
0	DYSPORT.xml:S1:14477:1	O
2	DYSPORT.xml:S1:14494:1	O
1	DYSPORT.xml:S1:14511:1	O

Musculoskeletal	DYSPORT.xml:S1:14526:15	B-AdverseReaction
pain	DYSPORT.xml:S1:14542:4	I-AdverseReaction
3	DYSPORT.xml:S1:14588:1	O
2	DYSPORT.xml:S1:14605:1	O
2	DYSPORT.xml:S1:14622:1	O

Back	DYSPORT.xml:S1:14637:4	B-AdverseReaction
pain	DYSPORT.xml:S1:14642:4	I-AdverseReaction
1	DYSPORT.xml:S1:14699:1	O
2	DYSPORT.xml:S1:14716:1	O
1	DYSPORT.xml:S1:14733:1	O

Nervous	DYSPORT.xml:S1:14748:7	O
system	DYSPORT.xml:S1:14756:6	O
disorders	DYSPORT.xml:S1:14763:9	O

Headache	DYSPORT.xml:S1:14859:8	B-AdverseReaction
1	DYSPORT.xml:S1:14921:1	O
2	DYSPORT.xml:S1:14938:1	O
1	DYSPORT.xml:S1:14955:1	O

Dizziness	DYSPORT.xml:S1:14970:9	B-AdverseReaction
3	DYSPORT.xml:S1:15032:1	O
1	DYSPORT.xml:S1:15049:1	O
1	DYSPORT.xml:S1:15066:1	O

Convulsion	DYSPORT.xml:S1:15081:10	B-AdverseReaction
2	DYSPORT.xml:S1:15143:1	O
2	DYSPORT.xml:S1:15160:1	O
1	DYSPORT.xml:S1:15177:1	O

Syncope	DYSPORT.xml:S1:15192:7	B-AdverseReaction
1	DYSPORT.xml:S1:15254:1	O
2	DYSPORT.xml:S1:15271:1	O
0	DYSPORT.xml:S1:15288:1	O

Hypoaesthesia	DYSPORT.xml:S1:15303:13	B-AdverseReaction
0	DYSPORT.xml:S1:15365:1	O
2	DYSPORT.xml:S1:15382:1	O
1	DYSPORT.xml:S1:15399:1	O

Partial	DYSPORT.xml:S1:15414:7	B-AdverseReaction
seizures	DYSPORT.xml:S1:15422:8	I-AdverseReaction
0	DYSPORT.xml:S1:15476:1	O
2	DYSPORT.xml:S1:15493:1	O
0	DYSPORT.xml:S1:15510:1	O

General	DYSPORT.xml:S1:15525:7	O
disorders	DYSPORT.xml:S1:15533:9	O
and	DYSPORT.xml:S1:15543:3	O
administration	DYSPORT.xml:S1:15547:14	O
site	DYSPORT.xml:S1:15562:4	O
conditions	DYSPORT.xml:S1:15567:10	O

Fatigue	DYSPORT.xml:S1:15637:7	B-AdverseReaction
2	DYSPORT.xml:S1:15699:1	O
2	DYSPORT.xml:S1:15716:1	O
0	DYSPORT.xml:S1:15733:1	O

Asthenia	DYSPORT.xml:S1:15748:8	B-AdverseReaction
2	DYSPORT.xml:S1:15810:1	O
1	DYSPORT.xml:S1:15827:1	O
1	DYSPORT.xml:S1:15844:1	O

Injury	DYSPORT.xml:S1:15859:6	O
,	DYSPORT.xml:S1:15865:1	O
poisoning	DYSPORT.xml:S1:15867:9	O
and	DYSPORT.xml:S1:15877:3	O
procedural	DYSPORT.xml:S1:15881:10	O
complications	DYSPORT.xml:S1:15892:13	O

Fall	DYSPORT.xml:S1:15970:4	B-AdverseReaction
2	DYSPORT.xml:S1:16032:1	O
3	DYSPORT.xml:S1:16049:1	O
2	DYSPORT.xml:S1:16066:1	O

Injury	DYSPORT.xml:S1:16081:6	B-AdverseReaction
2	DYSPORT.xml:S1:16143:1	O
2	DYSPORT.xml:S1:16160:1	O
1	DYSPORT.xml:S1:16177:1	O

Contusion	DYSPORT.xml:S1:16192:9	B-AdverseReaction
1	DYSPORT.xml:S1:16254:1	O
2	DYSPORT.xml:S1:16271:1	O
1	DYSPORT.xml:S1:16288:1	O

Gastrointestinal	DYSPORT.xml:S1:16303:16	O
disorders	DYSPORT.xml:S1:16320:9	O

Diarrhea	DYSPORT.xml:S1:16414:8	B-AdverseReaction
1	DYSPORT.xml:S1:16476:1	O
2	DYSPORT.xml:S1:16493:1	O
1	DYSPORT.xml:S1:16510:1	O

Nausea	DYSPORT.xml:S1:16525:6	B-AdverseReaction
2	DYSPORT.xml:S1:16587:1	O
1	DYSPORT.xml:S1:16604:1	O
1	DYSPORT.xml:S1:16621:1	O

Constipation	DYSPORT.xml:S1:16636:12	B-AdverseReaction
0	DYSPORT.xml:S1:16698:1	O
2	DYSPORT.xml:S1:16715:1	O
1	DYSPORT.xml:S1:16732:1	O

Investigation	DYSPORT.xml:S1:16747:13	O

Blood	DYSPORT.xml:S1:16858:5	B-AdverseReaction
triglycerides	DYSPORT.xml:S1:16864:13	I-AdverseReaction
increased	DYSPORT.xml:S1:16878:9	I-AdverseReaction
2	DYSPORT.xml:S1:16920:1	O
1	DYSPORT.xml:S1:16937:1	O
0	DYSPORT.xml:S1:16954:1	O

Respiratory	DYSPORT.xml:S1:16971:11	O
,	DYSPORT.xml:S1:16982:1	O
thoracic	DYSPORT.xml:S1:16984:8	O
and	DYSPORT.xml:S1:16993:3	O
mediastinal	DYSPORT.xml:S1:16997:11	O
disorders	DYSPORT.xml:S1:17009:9	O

Cough	DYSPORT.xml:S1:17080:5	B-AdverseReaction
1	DYSPORT.xml:S1:17142:1	O
2	DYSPORT.xml:S1:17159:1	O
1	DYSPORT.xml:S1:17176:1	O

Vascular	DYSPORT.xml:S1:17191:8	O
disorders	DYSPORT.xml:S1:17200:9	O

Hypertension	DYSPORT.xml:S1:17302:12	B-AdverseReaction
1	DYSPORT.xml:S1:17364:1	O
2	DYSPORT.xml:S1:17381:1	O
1	DYSPORT.xml:S1:17398:1	O

Psychiatric	DYSPORT.xml:S1:17413:11	O
disorders	DYSPORT.xml:S1:17425:9	O

Depression	DYSPORT.xml:S1:17524:10	B-AdverseReaction
2	DYSPORT.xml:S1:17586:1	O
3	DYSPORT.xml:S1:17603:1	O
1	DYSPORT.xml:S1:17620:1	O

Injection	DYSPORT.xml:S1:17646:9	O
Site	DYSPORT.xml:S1:17656:4	O
Reactions	DYSPORT.xml:S1:17661:9	O

Injection	DYSPORT.xml:S1:17677:9	B-AdverseReaction

site	DYSPORT.xml:S1:17687:4	I-AdverseReaction
reactions	DYSPORT.xml:S1:17692:9	I-AdverseReaction
(	DYSPORT.xml:S1:17702:1	O
e	DYSPORT.xml:S1:17703:1	O
.	DYSPORT.xml:S1:17704:1	O
g	DYSPORT.xml:S1:17705:1	O
.	DYSPORT.xml:S1:17706:1	O

pain	DYSPORT.xml:S1:17708:4	I-AdverseReaction
,	DYSPORT.xml:S1:17712:1	O
bruising	DYSPORT.xml:S1:17714:8	I-AdverseReaction
,	DYSPORT.xml:S1:17722:1	O
haemorrhage	DYSPORT.xml:S1:17724:11	I-AdverseReaction
,	DYSPORT.xml:S1:17735:1	O
injection	DYSPORT.xml:S1:17737:9	B-AdverseReaction
site	DYSPORT.xml:S1:17747:4	I-AdverseReaction
erythema	DYSPORT.xml:S1:17752:8	I-AdverseReaction
haematoma	DYSPORT.xml:S1:17761:9	I-AdverseReaction
etc	DYSPORT.xml:S1:17771:3	O
.	DYSPORT.xml:S1:17774:1	O
)	DYSPORT.xml:S1:17775:1	O

have	DYSPORT.xml:S1:17777:4	O
occurred	DYSPORT.xml:S1:17782:8	O
following	DYSPORT.xml:S1:17791:9	O
administration	DYSPORT.xml:S1:17801:14	O
of	DYSPORT.xml:S1:17816:2	O
DYSPORT	DYSPORT.xml:S1:17819:7	O
(	DYSPORT.xml:S1:17828:1	O
r	DYSPORT.xml:S1:17829:1	O
)	DYSPORT.xml:S1:17830:1	O
.	DYSPORT.xml:S1:17833:1	O

Less	DYSPORT.xml:S1:17843:4	O
Common	DYSPORT.xml:S1:17848:6	O
Adverse	DYSPORT.xml:S1:17855:7	O
Reactions	DYSPORT.xml:S1:17863:9	O

In	DYSPORT.xml:S1:17879:2	O
a	DYSPORT.xml:S1:17882:1	O
pooled	DYSPORT.xml:S1:17884:6	O
analysis	DYSPORT.xml:S1:17891:8	O
of	DYSPORT.xml:S1:17900:2	O
clinical	DYSPORT.xml:S1:17903:8	O
studies	DYSPORT.xml:S1:17912:7	O
,	DYSPORT.xml:S1:17919:1	O
adverse	DYSPORT.xml:S1:17921:7	O
reactions	DYSPORT.xml:S1:17929:9	O
with	DYSPORT.xml:S1:17939:4	O
an	DYSPORT.xml:S1:17944:2	O
incidence	DYSPORT.xml:S1:17947:9	O
of	DYSPORT.xml:S1:17957:2	O
less	DYSPORT.xml:S1:17960:4	O
than	DYSPORT.xml:S1:17965:4	O
2%	DYSPORT.xml:S1:17970:2	O
reported	DYSPORT.xml:S1:17973:8	O
in	DYSPORT.xml:S1:17982:2	O
DYSPORT	DYSPORT.xml:S1:17985:7	O
(	DYSPORT.xml:S1:17996:1	O
r	DYSPORT.xml:S1:17997:1	O
)	DYSPORT.xml:S1:17998:1	O
treatment	DYSPORT.xml:S1:18003:9	O
groups	DYSPORT.xml:S1:18013:6	O
included	DYSPORT.xml:S1:18020:8	O
dysphagia	DYSPORT.xml:S1:18029:9	B-AdverseReaction
0.5%	DYSPORT.xml:S1:18039:4	O
,	DYSPORT.xml:S1:18043:1	O
gait	DYSPORT.xml:S1:18045:4	B-AdverseReaction
disturbance	DYSPORT.xml:S1:18050:11	I-AdverseReaction
0.5%	DYSPORT.xml:S1:18062:4	O
,	DYSPORT.xml:S1:18066:1	O
hypertonia	DYSPORT.xml:S1:18068:10	B-AdverseReaction
0.5%	DYSPORT.xml:S1:18079:4	O
,	DYSPORT.xml:S1:18083:1	O
and	DYSPORT.xml:S1:18085:3	O
sensation	DYSPORT.xml:S1:18089:9	B-AdverseReaction
of	DYSPORT.xml:S1:18099:2	I-AdverseReaction
heaviness	DYSPORT.xml:S1:18102:9	I-AdverseReaction
0.3%	DYSPORT.xml:S1:18112:4	O
.	DYSPORT.xml:S1:18116:1	O

6.2	DYSPORT.xml:S1:18124:3	O
Postmarketing	DYSPORT.xml:S1:18128:13	O
Experience	DYSPORT.xml:S1:18142:10	O

Because	DYSPORT.xml:S1:18156:7	O
adverse	DYSPORT.xml:S1:18164:7	O
reactions	DYSPORT.xml:S1:18172:9	O
are	DYSPORT.xml:S1:18182:3	O
reported	DYSPORT.xml:S1:18186:8	O
voluntarily	DYSPORT.xml:S1:18195:11	O
from	DYSPORT.xml:S1:18207:4	O
a	DYSPORT.xml:S1:18212:1	O
population	DYSPORT.xml:S1:18214:10	O
of	DYSPORT.xml:S1:18225:2	O
uncertain	DYSPORT.xml:S1:18228:9	O
size	DYSPORT.xml:S1:18238:4	O
,	DYSPORT.xml:S1:18242:1	O
it	DYSPORT.xml:S1:18244:2	O
is	DYSPORT.xml:S1:18247:2	O
not	DYSPORT.xml:S1:18250:3	O
always	DYSPORT.xml:S1:18254:6	O
possible	DYSPORT.xml:S1:18261:8	O
to	DYSPORT.xml:S1:18270:2	O
reliably	DYSPORT.xml:S1:18273:8	O
estimate	DYSPORT.xml:S1:18282:8	O
their	DYSPORT.xml:S1:18291:5	O
frequency	DYSPORT.xml:S1:18297:9	O
or	DYSPORT.xml:S1:18307:2	O
establish	DYSPORT.xml:S1:18310:9	O
a	DYSPORT.xml:S1:18320:1	O
causal	DYSPORT.xml:S1:18322:6	O
relationship	DYSPORT.xml:S1:18329:12	O
to	DYSPORT.xml:S1:18342:2	O
drug	DYSPORT.xml:S1:18345:4	O
exposure	DYSPORT.xml:S1:18350:8	O
.	DYSPORT.xml:S1:18358:1	O

The	DYSPORT.xml:S1:18364:3	O
following	DYSPORT.xml:S1:18368:9	O
adverse	DYSPORT.xml:S1:18378:7	O
reactions	DYSPORT.xml:S1:18386:9	O
have	DYSPORT.xml:S1:18396:4	O
been	DYSPORT.xml:S1:18401:4	O
identified	DYSPORT.xml:S1:18406:10	O
during	DYSPORT.xml:S1:18417:6	O
post	DYSPORT.xml:S1:18424:4	O
-	DYSPORT.xml:S1:18428:1	O
approval	DYSPORT.xml:S1:18429:8	O
use	DYSPORT.xml:S1:18438:3	O
of	DYSPORT.xml:S1:18442:2	O
DYSPORT	DYSPORT.xml:S1:18445:7	O
(	DYSPORT.xml:S1:18454:1	O
r	DYSPORT.xml:S1:18455:1	O
)	DYSPORT.xml:S1:18456:1	O
:	DYSPORT.xml:S1:18459:1	O
vertigo	DYSPORT.xml:S1:18461:7	B-AdverseReaction
,	DYSPORT.xml:S1:18468:1	O
photophobia	DYSPORT.xml:S1:18470:11	B-AdverseReaction
,	DYSPORT.xml:S1:18481:1	O
influenza	DYSPORT.xml:S1:18483:9	B-AdverseReaction
-	DYSPORT.xml:S1:18492:1	I-AdverseReaction
like	DYSPORT.xml:S1:18493:4	I-AdverseReaction
illness	DYSPORT.xml:S1:18498:7	I-AdverseReaction
,	DYSPORT.xml:S1:18505:1	O
amyotrophy	DYSPORT.xml:S1:18507:10	B-AdverseReaction
,	DYSPORT.xml:S1:18517:1	O
burning	DYSPORT.xml:S1:18519:7	B-AdverseReaction
sensation	DYSPORT.xml:S1:18527:9	I-AdverseReaction
,	DYSPORT.xml:S1:18536:1	O
facial	DYSPORT.xml:S1:18538:6	B-AdverseReaction
paresis	DYSPORT.xml:S1:18545:7	I-AdverseReaction
,	DYSPORT.xml:S1:18552:1	O
hypoesthesia	DYSPORT.xml:S1:18554:12	B-AdverseReaction
,	DYSPORT.xml:S1:18566:1	O
erythema	DYSPORT.xml:S1:18568:8	B-AdverseReaction
,	DYSPORT.xml:S1:18576:1	O
and	DYSPORT.xml:S1:18578:3	O
excessive	DYSPORT.xml:S1:18582:9	B-AdverseReaction
granulation	DYSPORT.xml:S1:18592:11	I-AdverseReaction
tissue	DYSPORT.xml:S1:18604:6	I-AdverseReaction
.	DYSPORT.xml:S1:18610:1	O

6.3	DYSPORT.xml:S1:18618:3	O
Immunogenicity	DYSPORT.xml:S1:18622:14	O

As	DYSPORT.xml:S1:18640:2	O
with	DYSPORT.xml:S1:18643:4	O
all	DYSPORT.xml:S1:18648:3	O
therapeutic	DYSPORT.xml:S1:18652:11	O
proteins	DYSPORT.xml:S1:18664:8	O
,	DYSPORT.xml:S1:18672:1	O
there	DYSPORT.xml:S1:18674:5	O
is	DYSPORT.xml:S1:18680:2	O
a	DYSPORT.xml:S1:18683:1	O
potential	DYSPORT.xml:S1:18685:9	O
for	DYSPORT.xml:S1:18695:3	O
immunogenicity	DYSPORT.xml:S1:18699:14	O
.	DYSPORT.xml:S1:18713:1	O

The	DYSPORT.xml:S1:18719:3	O
incidence	DYSPORT.xml:S1:18723:9	O
of	DYSPORT.xml:S1:18733:2	O
antibody	DYSPORT.xml:S1:18736:8	O
formation	DYSPORT.xml:S1:18745:9	O
is	DYSPORT.xml:S1:18755:2	O
highly	DYSPORT.xml:S1:18758:6	O
dependent	DYSPORT.xml:S1:18765:9	O
on	DYSPORT.xml:S1:18775:2	O
the	DYSPORT.xml:S1:18778:3	O
sensitivity	DYSPORT.xml:S1:18782:11	O
and	DYSPORT.xml:S1:18794:3	O
specificity	DYSPORT.xml:S1:18798:11	O
of	DYSPORT.xml:S1:18810:2	O
the	DYSPORT.xml:S1:18813:3	O
assay	DYSPORT.xml:S1:18817:5	O
.	DYSPORT.xml:S1:18822:1	O

In	DYSPORT.xml:S1:18824:2	O
addition	DYSPORT.xml:S1:18827:8	O
,	DYSPORT.xml:S1:18835:1	O
the	DYSPORT.xml:S1:18837:3	O
observed	DYSPORT.xml:S1:18841:8	O
incidence	DYSPORT.xml:S1:18850:9	O
of	DYSPORT.xml:S1:18860:2	O
antibody	DYSPORT.xml:S1:18863:8	O
positivity	DYSPORT.xml:S1:18872:10	O
in	DYSPORT.xml:S1:18883:2	O
an	DYSPORT.xml:S1:18886:2	O
assay	DYSPORT.xml:S1:18889:5	O
may	DYSPORT.xml:S1:18895:3	O
be	DYSPORT.xml:S1:18899:2	O
influenced	DYSPORT.xml:S1:18902:10	O
by	DYSPORT.xml:S1:18913:2	O
several	DYSPORT.xml:S1:18916:7	O
factors	DYSPORT.xml:S1:18924:7	O
including	DYSPORT.xml:S1:18932:9	O
assay	DYSPORT.xml:S1:18942:5	O
methodology	DYSPORT.xml:S1:18948:11	O
,	DYSPORT.xml:S1:18959:1	O
sample	DYSPORT.xml:S1:18961:6	O
handling	DYSPORT.xml:S1:18968:8	O
,	DYSPORT.xml:S1:18976:1	O
timing	DYSPORT.xml:S1:18978:6	O
of	DYSPORT.xml:S1:18985:2	O
sample	DYSPORT.xml:S1:18988:6	O
collection	DYSPORT.xml:S1:18995:10	O
,	DYSPORT.xml:S1:19005:1	O
concomitant	DYSPORT.xml:S1:19007:11	O
medications	DYSPORT.xml:S1:19019:11	O
,	DYSPORT.xml:S1:19030:1	O
and	DYSPORT.xml:S1:19032:3	O
underlying	DYSPORT.xml:S1:19036:10	O
disease	DYSPORT.xml:S1:19047:7	O
.	DYSPORT.xml:S1:19054:1	O

For	DYSPORT.xml:S1:19056:3	O
these	DYSPORT.xml:S1:19060:5	O
reasons	DYSPORT.xml:S1:19066:7	O
,	DYSPORT.xml:S1:19073:1	O
comparison	DYSPORT.xml:S1:19075:10	O
of	DYSPORT.xml:S1:19086:2	O
the	DYSPORT.xml:S1:19089:3	O
incidence	DYSPORT.xml:S1:19093:9	O
of	DYSPORT.xml:S1:19103:2	O
antibodies	DYSPORT.xml:S1:19106:10	O
across	DYSPORT.xml:S1:19117:6	O
products	DYSPORT.xml:S1:19124:8	O
in	DYSPORT.xml:S1:19133:2	O
this	DYSPORT.xml:S1:19136:4	O
class	DYSPORT.xml:S1:19141:5	O
may	DYSPORT.xml:S1:19147:3	O
be	DYSPORT.xml:S1:19151:2	O
misleading	DYSPORT.xml:S1:19154:10	O
.	DYSPORT.xml:S1:19164:1	O

Cervical	DYSPORT.xml:S1:19174:8	O
Dystonia	DYSPORT.xml:S1:19183:8	O

About	DYSPORT.xml:S1:19198:5	O
3%	DYSPORT.xml:S1:19204:2	O
of	DYSPORT.xml:S1:19207:2	O
subjects	DYSPORT.xml:S1:19210:8	O
developed	DYSPORT.xml:S1:19219:9	O
antibodies	DYSPORT.xml:S1:19229:10	O
(	DYSPORT.xml:S1:19240:1	O
binding	DYSPORT.xml:S1:19241:7	O
or	DYSPORT.xml:S1:19249:2	O
neutralizing	DYSPORT.xml:S1:19252:12	O
)	DYSPORT.xml:S1:19264:1	O
over	DYSPORT.xml:S1:19266:4	O
time	DYSPORT.xml:S1:19271:4	O
with	DYSPORT.xml:S1:19276:4	O
DYSPORT	DYSPORT.xml:S1:19281:7	O
(	DYSPORT.xml:S1:19292:1	O
r	DYSPORT.xml:S1:19293:1	O
)	DYSPORT.xml:S1:19294:1	O
treatment	DYSPORT.xml:S1:19299:9	O
.	DYSPORT.xml:S1:19308:1	O

Glabellar	DYSPORT.xml:S1:19318:9	O
Lines	DYSPORT.xml:S1:19328:5	O

Testing	DYSPORT.xml:S1:19340:7	O
for	DYSPORT.xml:S1:19348:3	O
antibodies	DYSPORT.xml:S1:19352:10	O
to	DYSPORT.xml:S1:19363:2	O
DYSPORT	DYSPORT.xml:S1:19366:7	O
(	DYSPORT.xml:S1:19377:1	O
r	DYSPORT.xml:S1:19378:1	O
)	DYSPORT.xml:S1:19379:1	O
was	DYSPORT.xml:S1:19384:3	O
performed	DYSPORT.xml:S1:19388:9	O
for	DYSPORT.xml:S1:19398:3	O
1554	DYSPORT.xml:S1:19402:4	O
subjects	DYSPORT.xml:S1:19407:8	O
who	DYSPORT.xml:S1:19416:3	O
had	DYSPORT.xml:S1:19420:3	O
up	DYSPORT.xml:S1:19424:2	O
to	DYSPORT.xml:S1:19427:2	O
nine	DYSPORT.xml:S1:19430:4	O
cycles	DYSPORT.xml:S1:19435:6	O
of	DYSPORT.xml:S1:19442:2	O
treatment	DYSPORT.xml:S1:19445:9	O
.	DYSPORT.xml:S1:19454:1	O

Two	DYSPORT.xml:S1:19456:3	O
subjects	DYSPORT.xml:S1:19460:8	O
(	DYSPORT.xml:S1:19469:1	O
0.13%	DYSPORT.xml:S1:19470:5	O
)	DYSPORT.xml:S1:19475:1	O
tested	DYSPORT.xml:S1:19477:6	O
positive	DYSPORT.xml:S1:19484:8	O
for	DYSPORT.xml:S1:19493:3	O
binding	DYSPORT.xml:S1:19497:7	O
antibodies	DYSPORT.xml:S1:19505:10	O
at	DYSPORT.xml:S1:19516:2	O
baseline	DYSPORT.xml:S1:19519:8	O
.	DYSPORT.xml:S1:19527:1	O

Three	DYSPORT.xml:S1:19529:5	O
additional	DYSPORT.xml:S1:19535:10	O
subjects	DYSPORT.xml:S1:19546:8	O
tested	DYSPORT.xml:S1:19555:6	O
positive	DYSPORT.xml:S1:19562:8	O
for	DYSPORT.xml:S1:19571:3	O
binding	DYSPORT.xml:S1:19575:7	O
antibodies	DYSPORT.xml:S1:19583:10	O
after	DYSPORT.xml:S1:19594:5	O
receiving	DYSPORT.xml:S1:19600:9	O
DYSPORT	DYSPORT.xml:S1:19610:7	O
(	DYSPORT.xml:S1:19621:1	O
r	DYSPORT.xml:S1:19622:1	O
)	DYSPORT.xml:S1:19623:1	O
treatment	DYSPORT.xml:S1:19628:9	O
.	DYSPORT.xml:S1:19637:1	O

None	DYSPORT.xml:S1:19639:4	O
of	DYSPORT.xml:S1:19644:2	O
the	DYSPORT.xml:S1:19647:3	O
subjects	DYSPORT.xml:S1:19651:8	O
tested	DYSPORT.xml:S1:19660:6	O
positive	DYSPORT.xml:S1:19667:8	O
for	DYSPORT.xml:S1:19676:3	O
neutralizing	DYSPORT.xml:S1:19680:12	O
antibodies	DYSPORT.xml:S1:19693:10	O
.	DYSPORT.xml:S1:19703:1	O

Upper	DYSPORT.xml:S1:19713:5	O
Limb	DYSPORT.xml:S1:19719:4	O
Spasticity	DYSPORT.xml:S1:19724:10	O

From	DYSPORT.xml:S1:19741:4	O
230	DYSPORT.xml:S1:19746:3	O
subjects	DYSPORT.xml:S1:19750:8	O
treated	DYSPORT.xml:S1:19759:7	O
with	DYSPORT.xml:S1:19767:4	O
DYSPORT	DYSPORT.xml:S1:19772:7	O
(	DYSPORT.xml:S1:19781:1	O
r	DYSPORT.xml:S1:19782:1	O
)	DYSPORT.xml:S1:19783:1	O
and	DYSPORT.xml:S1:19786:3	O
tested	DYSPORT.xml:S1:19790:6	O
for	DYSPORT.xml:S1:19797:3	O
the	DYSPORT.xml:S1:19801:3	O
presence	DYSPORT.xml:S1:19805:8	O
of	DYSPORT.xml:S1:19814:2	O
binding	DYSPORT.xml:S1:19817:7	O
antibodies	DYSPORT.xml:S1:19825:10	O
,	DYSPORT.xml:S1:19835:1	O
5	DYSPORT.xml:S1:19837:1	O
subjects	DYSPORT.xml:S1:19839:8	O
were	DYSPORT.xml:S1:19848:4	O
positive	DYSPORT.xml:S1:19853:8	O
at	DYSPORT.xml:S1:19862:2	O
baseline	DYSPORT.xml:S1:19865:8	O
and	DYSPORT.xml:S1:19874:3	O
17	DYSPORT.xml:S1:19878:2	O
developed	DYSPORT.xml:S1:19881:9	O
antibodies	DYSPORT.xml:S1:19891:10	O
after	DYSPORT.xml:S1:19902:5	O
treatment	DYSPORT.xml:S1:19908:9	O
.	DYSPORT.xml:S1:19917:1	O

Among	DYSPORT.xml:S1:19919:5	O
those	DYSPORT.xml:S1:19925:5	O
17	DYSPORT.xml:S1:19931:2	O
subjects	DYSPORT.xml:S1:19934:8	O
,	DYSPORT.xml:S1:19942:1	O
10	DYSPORT.xml:S1:19944:2	O
subjects	DYSPORT.xml:S1:19947:8	O
developed	DYSPORT.xml:S1:19956:9	O
neutralizing	DYSPORT.xml:S1:19966:12	O
antibodies	DYSPORT.xml:S1:19979:10	O
.	DYSPORT.xml:S1:19989:1	O

An	DYSPORT.xml:S1:19991:2	O
additional	DYSPORT.xml:S1:19994:10	O
51	DYSPORT.xml:S1:20005:2	O
subjects	DYSPORT.xml:S1:20008:8	O
from	DYSPORT.xml:S1:20017:4	O
a	DYSPORT.xml:S1:20022:1	O
separate	DYSPORT.xml:S1:20024:8	O
repeat	DYSPORT.xml:S1:20033:6	O
dose	DYSPORT.xml:S1:20040:4	O
study	DYSPORT.xml:S1:20045:5	O
were	DYSPORT.xml:S1:20051:4	O
tested	DYSPORT.xml:S1:20056:6	O
for	DYSPORT.xml:S1:20063:3	O
the	DYSPORT.xml:S1:20067:3	O
presence	DYSPORT.xml:S1:20071:8	O
of	DYSPORT.xml:S1:20080:2	O
neutralizing	DYSPORT.xml:S1:20083:12	O
antibodies	DYSPORT.xml:S1:20096:10	O
only	DYSPORT.xml:S1:20107:4	O
.	DYSPORT.xml:S1:20111:1	O

None	DYSPORT.xml:S1:20113:4	O
of	DYSPORT.xml:S1:20118:2	O
the	DYSPORT.xml:S1:20121:3	O
subjects	DYSPORT.xml:S1:20125:8	O
tested	DYSPORT.xml:S1:20134:6	O
positive	DYSPORT.xml:S1:20141:8	O
.	DYSPORT.xml:S1:20149:1	O

In	DYSPORT.xml:S1:20151:2	O
total	DYSPORT.xml:S1:20154:5	O
,	DYSPORT.xml:S1:20159:1	O
from	DYSPORT.xml:S1:20161:4	O
the	DYSPORT.xml:S1:20166:3	O
281	DYSPORT.xml:S1:20170:3	O
subjects	DYSPORT.xml:S1:20174:8	O
treated	DYSPORT.xml:S1:20183:7	O
in	DYSPORT.xml:S1:20191:2	O
the	DYSPORT.xml:S1:20194:3	O
long	DYSPORT.xml:S1:20198:4	O
-	DYSPORT.xml:S1:20202:1	O
term	DYSPORT.xml:S1:20203:4	O
studies	DYSPORT.xml:S1:20208:7	O
and	DYSPORT.xml:S1:20216:3	O
tested	DYSPORT.xml:S1:20220:6	O
for	DYSPORT.xml:S1:20227:3	O
the	DYSPORT.xml:S1:20231:3	O
presence	DYSPORT.xml:S1:20235:8	O
of	DYSPORT.xml:S1:20244:2	O
neutralizing	DYSPORT.xml:S1:20247:12	O
antibodies	DYSPORT.xml:S1:20260:10	O
,	DYSPORT.xml:S1:20270:1	O
3.6%	DYSPORT.xml:S1:20272:4	O
developed	DYSPORT.xml:S1:20277:9	O
neutralizing	DYSPORT.xml:S1:20287:12	O
antibodies	DYSPORT.xml:S1:20300:10	O
after	DYSPORT.xml:S1:20311:5	O
treatment	DYSPORT.xml:S1:20317:9	O
.	DYSPORT.xml:S1:20326:1	O

In	DYSPORT.xml:S1:20332:2	O
the	DYSPORT.xml:S1:20335:3	O
presence	DYSPORT.xml:S1:20339:8	O
of	DYSPORT.xml:S1:20348:2	O
binding	DYSPORT.xml:S1:20351:7	O
and	DYSPORT.xml:S1:20359:3	O
neutralizing	DYSPORT.xml:S1:20363:12	O
antibodies	DYSPORT.xml:S1:20376:10	O
to	DYSPORT.xml:S1:20387:2	O
DYSPORT	DYSPORT.xml:S1:20390:7	O
(	DYSPORT.xml:S1:20399:1	O
r	DYSPORT.xml:S1:20400:1	O
)	DYSPORT.xml:S1:20401:1	O
some	DYSPORT.xml:S1:20404:4	O
patients	DYSPORT.xml:S1:20409:8	O
continue	DYSPORT.xml:S1:20418:8	O
to	DYSPORT.xml:S1:20427:2	O
experience	DYSPORT.xml:S1:20430:10	O
clinical	DYSPORT.xml:S1:20441:8	O
benefit	DYSPORT.xml:S1:20450:7	O
.	DYSPORT.xml:S1:20457:1	O
\n\n	DYSPORT.xml:S2:0:2	O
BOXED	DYSPORT.xml:S2:6:5	O
WARNING	DYSPORT.xml:S2:12:7	O
:	DYSPORT.xml:S2:19:1	O
WARNING	DYSPORT.xml:S2:21:7	O
:	DYSPORT.xml:S2:28:1	O
DISTANT	DYSPORT.xml:S2:30:7	B-AdverseReaction
SPREAD	DYSPORT.xml:S2:38:6	I-AdverseReaction
OF	DYSPORT.xml:S2:45:2	I-AdverseReaction
TOXIN	DYSPORT.xml:S2:48:5	I-AdverseReaction
EFFECT	DYSPORT.xml:S2:54:6	I-AdverseReaction
\n\n	DYSPORT.xml:S2:60:2	O
WARNING	DYSPORT.xml:S2:64:7	O
:	DYSPORT.xml:S2:71:1	O
DISTANT	DYSPORT.xml:S2:73:7	B-AdverseReaction
SPREAD	DYSPORT.xml:S2:81:6	I-AdverseReaction
OF	DYSPORT.xml:S2:88:2	I-AdverseReaction
TOXIN	DYSPORT.xml:S2:91:5	I-AdverseReaction
EFFECT	DYSPORT.xml:S2:97:6	I-AdverseReaction
\n\n	DYSPORT.xml:S2:103:2	O
Postmarketing	DYSPORT.xml:S2:109:13	O
reports	DYSPORT.xml:S2:123:7	O
indicate	DYSPORT.xml:S2:131:8	O
that	DYSPORT.xml:S2:140:4	O
the	DYSPORT.xml:S2:145:3	O
effects	DYSPORT.xml:S2:149:7	O
of	DYSPORT.xml:S2:157:2	O
DYSPORT	DYSPORT.xml:S2:160:7	O
(	DYSPORT.xml:S2:167:1	O
r	DYSPORT.xml:S2:168:1	O
)	DYSPORT.xml:S2:169:1	O
and	DYSPORT.xml:S2:171:3	O
all	DYSPORT.xml:S2:175:3	O
botulinum	DYSPORT.xml:S2:179:9	O
toxin	DYSPORT.xml:S2:189:5	O
products	DYSPORT.xml:S2:195:8	O
may	DYSPORT.xml:S2:204:3	B-Factor
spread	DYSPORT.xml:S2:208:6	B-AdverseReaction
from	DYSPORT.xml:S2:215:4	O
the	DYSPORT.xml:S2:220:3	O
area	DYSPORT.xml:S2:224:4	O
of	DYSPORT.xml:S2:229:2	O
injection	DYSPORT.xml:S2:232:9	O
to	DYSPORT.xml:S2:242:2	O
produce	DYSPORT.xml:S2:245:7	O
symptoms	DYSPORT.xml:S2:253:8	O
consistent	DYSPORT.xml:S2:262:10	O
with	DYSPORT.xml:S2:273:4	O
botulinum	DYSPORT.xml:S2:278:9	O
toxin	DYSPORT.xml:S2:288:5	I-AdverseReaction
effects	DYSPORT.xml:S2:294:7	I-AdverseReaction
.	DYSPORT.xml:S2:301:1	O

These	DYSPORT.xml:S2:303:5	O
may	DYSPORT.xml:S2:309:3	B-Factor
include	DYSPORT.xml:S2:313:7	O
asthenia	DYSPORT.xml:S2:321:8	B-AdverseReaction
,	DYSPORT.xml:S2:329:1	O
generalized	DYSPORT.xml:S2:331:11	B-AdverseReaction
muscle	DYSPORT.xml:S2:343:6	I-AdverseReaction
weakness	DYSPORT.xml:S2:350:8	I-AdverseReaction
,	DYSPORT.xml:S2:358:1	O
diplopia	DYSPORT.xml:S2:360:8	B-AdverseReaction
,	DYSPORT.xml:S2:368:1	O
blurred	DYSPORT.xml:S2:370:7	B-AdverseReaction
vision	DYSPORT.xml:S2:378:6	I-AdverseReaction
,	DYSPORT.xml:S2:384:1	O
ptosis	DYSPORT.xml:S2:386:6	B-AdverseReaction
,	DYSPORT.xml:S2:392:1	O
dysphagia	DYSPORT.xml:S2:394:9	B-AdverseReaction
,	DYSPORT.xml:S2:403:1	O
dysphonia	DYSPORT.xml:S2:405:9	B-AdverseReaction
,	DYSPORT.xml:S2:414:1	O
dysarthria	DYSPORT.xml:S2:416:10	B-AdverseReaction
,	DYSPORT.xml:S2:426:1	O
urinary	DYSPORT.xml:S2:428:7	B-AdverseReaction
incontinence	DYSPORT.xml:S2:436:12	I-AdverseReaction
and	DYSPORT.xml:S2:449:3	O
breathing	DYSPORT.xml:S2:453:9	B-AdverseReaction
difficulties	DYSPORT.xml:S2:463:12	I-AdverseReaction
.	DYSPORT.xml:S2:475:1	O

These	DYSPORT.xml:S2:477:5	O
symptoms	DYSPORT.xml:S2:483:8	O
have	DYSPORT.xml:S2:492:4	O
been	DYSPORT.xml:S2:497:4	O
reported	DYSPORT.xml:S2:502:8	O
hours	DYSPORT.xml:S2:511:5	O
to	DYSPORT.xml:S2:517:2	O
weeks	DYSPORT.xml:S2:520:5	O
after	DYSPORT.xml:S2:526:5	O
injection	DYSPORT.xml:S2:532:9	O
.	DYSPORT.xml:S2:541:1	O

Swallowing	DYSPORT.xml:S2:543:10	B-AdverseReaction
and	DYSPORT.xml:S2:554:3	O
breathing	DYSPORT.xml:S2:558:9	B-AdverseReaction
difficulties	DYSPORT.xml:S2:568:12	I-AdverseReaction
can	DYSPORT.xml:S2:581:3	O
be	DYSPORT.xml:S2:585:2	O
life	DYSPORT.xml:S2:588:4	O
threatening	DYSPORT.xml:S2:593:11	O
and	DYSPORT.xml:S2:605:3	O
there	DYSPORT.xml:S2:609:5	O
have	DYSPORT.xml:S2:615:4	O
been	DYSPORT.xml:S2:620:4	O
reports	DYSPORT.xml:S2:625:7	O
of	DYSPORT.xml:S2:633:2	O
death	DYSPORT.xml:S2:636:5	B-AdverseReaction
.	DYSPORT.xml:S2:641:1	O

The	DYSPORT.xml:S2:643:3	O
risk	DYSPORT.xml:S2:647:4	O
of	DYSPORT.xml:S2:652:2	O
symptoms	DYSPORT.xml:S2:655:8	O
is	DYSPORT.xml:S2:664:2	O
probably	DYSPORT.xml:S2:667:8	O
greatest	DYSPORT.xml:S2:676:8	O
in	DYSPORT.xml:S2:685:2	O
children	DYSPORT.xml:S2:688:8	O
treated	DYSPORT.xml:S2:697:7	O
for	DYSPORT.xml:S2:705:3	O
spasticity	DYSPORT.xml:S2:709:10	O
but	DYSPORT.xml:S2:720:3	O
symptoms	DYSPORT.xml:S2:724:8	O
can	DYSPORT.xml:S2:733:3	O
also	DYSPORT.xml:S2:737:4	O
occur	DYSPORT.xml:S2:742:5	O
in	DYSPORT.xml:S2:748:2	O
adults	DYSPORT.xml:S2:751:6	O
treated	DYSPORT.xml:S2:758:7	O
for	DYSPORT.xml:S2:766:3	O
spasticity	DYSPORT.xml:S2:770:10	O
and	DYSPORT.xml:S2:781:3	O
other	DYSPORT.xml:S2:785:5	O
conditions	DYSPORT.xml:S2:791:10	O
,	DYSPORT.xml:S2:801:1	O
particularly	DYSPORT.xml:S2:803:12	O
in	DYSPORT.xml:S2:816:2	O
those	DYSPORT.xml:S2:819:5	O
patients	DYSPORT.xml:S2:825:8	O
who	DYSPORT.xml:S2:834:3	O
have	DYSPORT.xml:S2:838:4	O
underlying	DYSPORT.xml:S2:843:10	O
conditions	DYSPORT.xml:S2:854:10	O
that	DYSPORT.xml:S2:865:4	O
would	DYSPORT.xml:S2:870:5	O
predispose	DYSPORT.xml:S2:876:10	O
them	DYSPORT.xml:S2:887:4	O
to	DYSPORT.xml:S2:892:2	O
these	DYSPORT.xml:S2:895:5	O
symptoms	DYSPORT.xml:S2:901:8	O
.	DYSPORT.xml:S2:909:1	O

In	DYSPORT.xml:S2:911:2	O
unapproved	DYSPORT.xml:S2:914:10	O
uses	DYSPORT.xml:S2:925:4	O
,	DYSPORT.xml:S2:929:1	O
including	DYSPORT.xml:S2:931:9	O
spasticity	DYSPORT.xml:S2:941:10	O
in	DYSPORT.xml:S2:952:2	O
children	DYSPORT.xml:S2:955:8	O
,	DYSPORT.xml:S2:963:1	O
and	DYSPORT.xml:S2:965:3	O
in	DYSPORT.xml:S2:969:2	O
approved	DYSPORT.xml:S2:972:8	O
indications	DYSPORT.xml:S2:981:11	O
,	DYSPORT.xml:S2:992:1	O
cases	DYSPORT.xml:S2:994:5	O
of	DYSPORT.xml:S2:1000:2	O
spread	DYSPORT.xml:S2:1003:6	O
of	DYSPORT.xml:S2:1010:2	O
effect	DYSPORT.xml:S2:1013:6	O
have	DYSPORT.xml:S2:1020:4	O
been	DYSPORT.xml:S2:1025:4	O
reported	DYSPORT.xml:S2:1030:8	O
at	DYSPORT.xml:S2:1039:2	O
doses	DYSPORT.xml:S2:1042:5	O
comparable	DYSPORT.xml:S2:1048:10	O
to	DYSPORT.xml:S2:1059:2	O
or	DYSPORT.xml:S2:1062:2	O
lower	DYSPORT.xml:S2:1065:5	O
than	DYSPORT.xml:S2:1071:4	O
the	DYSPORT.xml:S2:1076:3	O
maximum	DYSPORT.xml:S2:1080:7	O
recommended	DYSPORT.xml:S2:1088:11	O
total	DYSPORT.xml:S2:1100:5	O
dose	DYSPORT.xml:S2:1106:4	O
.	DYSPORT.xml:S2:1110:1	O

[	DYSPORT.xml:S2:1112:1	O
see	DYSPORT.xml:S2:1115:3	O
Warnings	DYSPORT.xml:S2:1119:8	O
and	DYSPORT.xml:S2:1128:3	O
Precautions	DYSPORT.xml:S2:1132:11	O
(	DYSPORT.xml:S2:1144:1	O
5.2	DYSPORT.xml:S2:1145:3	O
)	DYSPORT.xml:S2:1148:1	O
]	DYSPORT.xml:S2:1151:1	O
\n\n\n\n	DYSPORT.xml:S2:1154:4	O
WARNING	DYSPORT.xml:S2:1161:7	O
:	DYSPORT.xml:S2:1168:1	O
DISTANT	DYSPORT.xml:S2:1170:7	B-AdverseReaction
SPREAD	DYSPORT.xml:S2:1178:6	I-AdverseReaction
OF	DYSPORT.xml:S2:1185:2	I-AdverseReaction
TOXIN	DYSPORT.xml:S2:1188:5	I-AdverseReaction
EFFECT	DYSPORT.xml:S2:1194:6	I-AdverseReaction
\n\n\n\n	DYSPORT.xml:S2:1200:4	O
See	DYSPORT.xml:S2:1207:3	O
full	DYSPORT.xml:S2:1211:4	O
prescribing	DYSPORT.xml:S2:1216:11	O
information	DYSPORT.xml:S2:1228:11	O
for	DYSPORT.xml:S2:1240:3	O
complete	DYSPORT.xml:S2:1244:8	O
boxed	DYSPORT.xml:S2:1253:5	O
warning	DYSPORT.xml:S2:1259:7	O
\n\n\n\n	DYSPORT.xml:S2:1269:4	O
The	DYSPORT.xml:S2:1276:3	O
effects	DYSPORT.xml:S2:1280:7	O
of	DYSPORT.xml:S2:1288:2	O
DYSPORT	DYSPORT.xml:S2:1291:7	O
(	DYSPORT.xml:S2:1298:1	O
r	DYSPORT.xml:S2:1299:1	O
)	DYSPORT.xml:S2:1300:1	O
and	DYSPORT.xml:S2:1302:3	O
all	DYSPORT.xml:S2:1306:3	O
botulinum	DYSPORT.xml:S2:1310:9	O
toxin	DYSPORT.xml:S2:1320:5	O
products	DYSPORT.xml:S2:1326:8	O
may	DYSPORT.xml:S2:1335:3	B-Factor
spread	DYSPORT.xml:S2:1339:6	B-AdverseReaction
from	DYSPORT.xml:S2:1346:4	O
the	DYSPORT.xml:S2:1351:3	O
area	DYSPORT.xml:S2:1355:4	O
of	DYSPORT.xml:S2:1360:2	O
injection	DYSPORT.xml:S2:1363:9	O
to	DYSPORT.xml:S2:1373:2	O
produce	DYSPORT.xml:S2:1376:7	O
symptoms	DYSPORT.xml:S2:1384:8	O
consistent	DYSPORT.xml:S2:1393:10	O
with	DYSPORT.xml:S2:1404:4	O
botulinum	DYSPORT.xml:S2:1409:9	O
toxin	DYSPORT.xml:S2:1419:5	I-AdverseReaction
effects	DYSPORT.xml:S2:1425:7	I-AdverseReaction
.	DYSPORT.xml:S2:1432:1	O

These	DYSPORT.xml:S2:1434:5	O
symptoms	DYSPORT.xml:S2:1440:8	O
have	DYSPORT.xml:S2:1449:4	O
been	DYSPORT.xml:S2:1454:4	O
reported	DYSPORT.xml:S2:1459:8	O
hours	DYSPORT.xml:S2:1468:5	O
to	DYSPORT.xml:S2:1474:2	O
weeks	DYSPORT.xml:S2:1477:5	O
after	DYSPORT.xml:S2:1483:5	O
injection	DYSPORT.xml:S2:1489:9	O
.	DYSPORT.xml:S2:1498:1	O

Swallowing	DYSPORT.xml:S2:1500:10	B-AdverseReaction
and	DYSPORT.xml:S2:1511:3	O
breathing	DYSPORT.xml:S2:1515:9	B-AdverseReaction
difficulties	DYSPORT.xml:S2:1525:12	I-AdverseReaction
can	DYSPORT.xml:S2:1538:3	O
be	DYSPORT.xml:S2:1542:2	O
life	DYSPORT.xml:S2:1545:4	O
threatening	DYSPORT.xml:S2:1550:11	O
and	DYSPORT.xml:S2:1562:3	O
there	DYSPORT.xml:S2:1566:5	O
have	DYSPORT.xml:S2:1572:4	O
been	DYSPORT.xml:S2:1577:4	O
reports	DYSPORT.xml:S2:1582:7	O
of	DYSPORT.xml:S2:1590:2	O
death	DYSPORT.xml:S2:1593:5	B-AdverseReaction
.	DYSPORT.xml:S2:1598:1	O

The	DYSPORT.xml:S2:1600:3	O
risk	DYSPORT.xml:S2:1604:4	O
of	DYSPORT.xml:S2:1609:2	O
symptoms	DYSPORT.xml:S2:1612:8	O
is	DYSPORT.xml:S2:1621:2	O
probably	DYSPORT.xml:S2:1624:8	O
greatest	DYSPORT.xml:S2:1633:8	O
in	DYSPORT.xml:S2:1642:2	O
children	DYSPORT.xml:S2:1645:8	O
treated	DYSPORT.xml:S2:1654:7	O
for	DYSPORT.xml:S2:1662:3	O
spasticity	DYSPORT.xml:S2:1666:10	O
but	DYSPORT.xml:S2:1677:3	O
symptoms	DYSPORT.xml:S2:1681:8	O
can	DYSPORT.xml:S2:1690:3	O
also	DYSPORT.xml:S2:1694:4	O
occur	DYSPORT.xml:S2:1699:5	O
in	DYSPORT.xml:S2:1705:2	O
adults	DYSPORT.xml:S2:1708:6	O
,	DYSPORT.xml:S2:1714:1	O
particularly	DYSPORT.xml:S2:1716:12	O
in	DYSPORT.xml:S2:1729:2	O
those	DYSPORT.xml:S2:1732:5	O
patients	DYSPORT.xml:S2:1738:8	O
who	DYSPORT.xml:S2:1747:3	O
have	DYSPORT.xml:S2:1751:4	O
underlying	DYSPORT.xml:S2:1756:10	O
conditions	DYSPORT.xml:S2:1767:10	O
that	DYSPORT.xml:S2:1778:4	O
would	DYSPORT.xml:S2:1783:5	O
predispose	DYSPORT.xml:S2:1789:10	O
them	DYSPORT.xml:S2:1800:4	O
to	DYSPORT.xml:S2:1805:2	O
these	DYSPORT.xml:S2:1808:5	O
symptoms	DYSPORT.xml:S2:1814:8	O
.	DYSPORT.xml:S2:1822:1	O
\n	DYSPORT.xml:S2:1825:1	O
5	DYSPORT.xml:S3:4:1	O
WARNINGS	DYSPORT.xml:S3:6:8	O
AND	DYSPORT.xml:S3:15:3	O
PRECAUTIONS	DYSPORT.xml:S3:19:11	O

EXCERPT	DYSPORT.xml:S3:35:7	O
:	DYSPORT.xml:S3:42:1	O
The	DYSPORT.xml:S3:50:3	O
potency	DYSPORT.xml:S3:54:7	O
Units	DYSPORT.xml:S3:62:5	O
of	DYSPORT.xml:S3:68:2	O
DYSPORT	DYSPORT.xml:S3:71:7	O
(	DYSPORT.xml:S3:80:1	O
r	DYSPORT.xml:S3:81:1	O
)	DYSPORT.xml:S3:82:1	O
are	DYSPORT.xml:S3:85:3	O
not	DYSPORT.xml:S3:89:3	O
interchangeable	DYSPORT.xml:S3:93:15	O
with	DYSPORT.xml:S3:109:4	O
other	DYSPORT.xml:S3:114:5	O
preparations	DYSPORT.xml:S3:120:12	O
of	DYSPORT.xml:S3:133:2	O
botulinum	DYSPORT.xml:S3:136:9	O
toxin	DYSPORT.xml:S3:146:5	O
products	DYSPORT.xml:S3:152:8	O
and	DYSPORT.xml:S3:161:3	O
,	DYSPORT.xml:S3:164:1	O
therefore	DYSPORT.xml:S3:166:9	O
,	DYSPORT.xml:S3:175:1	O
units	DYSPORT.xml:S3:177:5	O
of	DYSPORT.xml:S3:183:2	O
biological	DYSPORT.xml:S3:186:10	O
activity	DYSPORT.xml:S3:197:8	O
of	DYSPORT.xml:S3:206:2	O
DYSPORT	DYSPORT.xml:S3:209:7	O
(	DYSPORT.xml:S3:218:1	O
r	DYSPORT.xml:S3:219:1	O
)	DYSPORT.xml:S3:220:1	O
cannot	DYSPORT.xml:S3:223:6	O
be	DYSPORT.xml:S3:230:2	O
compared	DYSPORT.xml:S3:233:8	O
to	DYSPORT.xml:S3:242:2	O
or	DYSPORT.xml:S3:245:2	O
converted	DYSPORT.xml:S3:248:9	O
into	DYSPORT.xml:S3:258:4	O
units	DYSPORT.xml:S3:263:5	O
of	DYSPORT.xml:S3:269:2	O
any	DYSPORT.xml:S3:272:3	O
other	DYSPORT.xml:S3:276:5	O
botulinum	DYSPORT.xml:S3:282:9	O
toxin	DYSPORT.xml:S3:292:5	O
products	DYSPORT.xml:S3:298:8	O
(	DYSPORT.xml:S3:307:1	O
5.1	DYSPORT.xml:S3:308:3	O
)	DYSPORT.xml:S3:311:1	O

Recommended	DYSPORT.xml:S3:319:11	O
dose	DYSPORT.xml:S3:331:4	O
and	DYSPORT.xml:S3:336:3	O
frequency	DYSPORT.xml:S3:340:9	O
of	DYSPORT.xml:S3:350:2	O
administration	DYSPORT.xml:S3:353:14	O
should	DYSPORT.xml:S3:368:6	O
not	DYSPORT.xml:S3:375:3	O
be	DYSPORT.xml:S3:379:2	O
exceeded	DYSPORT.xml:S3:382:8	O
(	DYSPORT.xml:S3:391:1	O
5.4	DYSPORT.xml:S3:392:3	O
)	DYSPORT.xml:S3:395:1	O

Immediate	DYSPORT.xml:S3:402:9	O
medical	DYSPORT.xml:S3:412:7	O
attention	DYSPORT.xml:S3:420:9	O
may	DYSPORT.xml:S3:430:3	O
be	DYSPORT.xml:S3:434:2	O
required	DYSPORT.xml:S3:437:8	O
in	DYSPORT.xml:S3:446:2	O
cases	DYSPORT.xml:S3:449:5	O
of	DYSPORT.xml:S3:455:2	O
respiratory	DYSPORT.xml:S3:458:11	B-AdverseReaction
,	DYSPORT.xml:S3:469:1	O
speech	DYSPORT.xml:S3:471:6	B-AdverseReaction
or	DYSPORT.xml:S3:478:2	O
swallowing	DYSPORT.xml:S3:481:10	B-AdverseReaction
difficulties	DYSPORT.xml:S3:492:12	I-AdverseReaction
(	DYSPORT.xml:S3:505:1	O
5.3	DYSPORT.xml:S3:506:3	O
)	DYSPORT.xml:S3:509:1	O

Concomitant	DYSPORT.xml:S3:516:11	O
neuromuscular	DYSPORT.xml:S3:528:13	O
disorder	DYSPORT.xml:S3:542:8	O
may	DYSPORT.xml:S3:551:3	O
exacerbate	DYSPORT.xml:S3:555:10	O
clinical	DYSPORT.xml:S3:566:8	O
effects	DYSPORT.xml:S3:575:7	O
of	DYSPORT.xml:S3:583:2	O
treatment	DYSPORT.xml:S3:586:9	O
(	DYSPORT.xml:S3:596:1	O
5.5	DYSPORT.xml:S3:597:3	O
)	DYSPORT.xml:S3:600:1	O

DYSPORT	DYSPORT.xml:S3:607:7	O
(	DYSPORT.xml:S3:617:1	O
r	DYSPORT.xml:S3:618:1	O
)	DYSPORT.xml:S3:619:1	O
contains	DYSPORT.xml:S3:623:8	O
human	DYSPORT.xml:S3:632:5	O
albumin	DYSPORT.xml:S3:638:7	O
.	DYSPORT.xml:S3:645:1	O

There	DYSPORT.xml:S3:647:5	O
is	DYSPORT.xml:S3:653:2	O
a	DYSPORT.xml:S3:656:1	O
risk	DYSPORT.xml:S3:658:4	B-Factor
for	DYSPORT.xml:S3:663:3	O
transmission	DYSPORT.xml:S3:667:12	O
of	DYSPORT.xml:S3:680:2	O
Creutzfeldt	DYSPORT.xml:S3:683:11	B-AdverseReaction
-	DYSPORT.xml:S3:694:1	I-AdverseReaction
Jakob	DYSPORT.xml:S3:695:5	I-AdverseReaction
disease	DYSPORT.xml:S3:701:7	I-AdverseReaction
(	DYSPORT.xml:S3:709:1	O
CJD	DYSPORT.xml:S3:710:3	B-AdverseReaction
)	DYSPORT.xml:S3:713:1	O
however	DYSPORT.xml:S3:715:7	O
,	DYSPORT.xml:S3:722:1	O
no	DYSPORT.xml:S3:724:2	B-Negation
cases	DYSPORT.xml:S3:727:5	O
of	DYSPORT.xml:S3:733:2	O
transmission	DYSPORT.xml:S3:736:12	I-Negation
of	DYSPORT.xml:S3:749:2	O
viral	DYSPORT.xml:S3:752:5	B-AdverseReaction
diseases	DYSPORT.xml:S3:758:8	I-AdverseReaction
or	DYSPORT.xml:S3:767:2	O
CJD	DYSPORT.xml:S3:770:3	B-AdverseReaction
have	DYSPORT.xml:S3:774:4	O
ever	DYSPORT.xml:S3:779:4	O
been	DYSPORT.xml:S3:784:4	O
identified	DYSPORT.xml:S3:789:10	O
for	DYSPORT.xml:S3:800:3	O
albumin	DYSPORT.xml:S3:804:7	O
(	DYSPORT.xml:S3:812:1	O
5.6	DYSPORT.xml:S3:813:3	O
)	DYSPORT.xml:S3:816:1	O

5.1	DYSPORT.xml:S3:827:3	O

Lack	DYSPORT.xml:S3:831:4	O
of	DYSPORT.xml:S3:836:2	O
Interchangeability	DYSPORT.xml:S3:839:18	O
between	DYSPORT.xml:S3:858:7	O
Botulinum	DYSPORT.xml:S3:866:9	O
Toxin	DYSPORT.xml:S3:876:5	O
Products	DYSPORT.xml:S3:882:8	O

The	DYSPORT.xml:S3:894:3	O
potency	DYSPORT.xml:S3:898:7	O
Units	DYSPORT.xml:S3:906:5	O
of	DYSPORT.xml:S3:912:2	O
DYSPORT	DYSPORT.xml:S3:915:7	O
(	DYSPORT.xml:S3:924:1	O
r	DYSPORT.xml:S3:925:1	O
)	DYSPORT.xml:S3:926:1	O
are	DYSPORT.xml:S3:929:3	O
specific	DYSPORT.xml:S3:933:8	O
to	DYSPORT.xml:S3:942:2	O
the	DYSPORT.xml:S3:945:3	O
preparation	DYSPORT.xml:S3:949:11	O
and	DYSPORT.xml:S3:961:3	O
assay	DYSPORT.xml:S3:965:5	O
method	DYSPORT.xml:S3:971:6	O
utilized	DYSPORT.xml:S3:978:8	O
.	DYSPORT.xml:S3:986:1	O

They	DYSPORT.xml:S3:988:4	O
are	DYSPORT.xml:S3:993:3	O
not	DYSPORT.xml:S3:997:3	O
interchangeable	DYSPORT.xml:S3:1001:15	O
with	DYSPORT.xml:S3:1017:4	O
other	DYSPORT.xml:S3:1022:5	O
preparations	DYSPORT.xml:S3:1028:12	O
of	DYSPORT.xml:S3:1041:2	O
botulinum	DYSPORT.xml:S3:1044:9	O
toxin	DYSPORT.xml:S3:1054:5	O
products	DYSPORT.xml:S3:1060:8	O
and	DYSPORT.xml:S3:1069:3	O
,	DYSPORT.xml:S3:1072:1	O
therefore	DYSPORT.xml:S3:1074:9	O
,	DYSPORT.xml:S3:1083:1	O
units	DYSPORT.xml:S3:1085:5	O
of	DYSPORT.xml:S3:1091:2	O
biological	DYSPORT.xml:S3:1094:10	O
activity	DYSPORT.xml:S3:1105:8	O
of	DYSPORT.xml:S3:1114:2	O
DYSPORT	DYSPORT.xml:S3:1117:7	O
(	DYSPORT.xml:S3:1126:1	O
r	DYSPORT.xml:S3:1127:1	O
)	DYSPORT.xml:S3:1128:1	O
cannot	DYSPORT.xml:S3:1131:6	O
be	DYSPORT.xml:S3:1138:2	O
compared	DYSPORT.xml:S3:1141:8	O
to	DYSPORT.xml:S3:1150:2	O
or	DYSPORT.xml:S3:1153:2	O
converted	DYSPORT.xml:S3:1156:9	O
into	DYSPORT.xml:S3:1166:4	O
units	DYSPORT.xml:S3:1171:5	O
of	DYSPORT.xml:S3:1177:2	O
any	DYSPORT.xml:S3:1180:3	O
other	DYSPORT.xml:S3:1184:5	O
botulinum	DYSPORT.xml:S3:1190:9	O
toxin	DYSPORT.xml:S3:1200:5	O
products	DYSPORT.xml:S3:1206:8	O
assessed	DYSPORT.xml:S3:1215:8	O
with	DYSPORT.xml:S3:1224:4	O
any	DYSPORT.xml:S3:1229:3	O
other	DYSPORT.xml:S3:1233:5	O
specific	DYSPORT.xml:S3:1239:8	O
assay	DYSPORT.xml:S3:1248:5	O
method	DYSPORT.xml:S3:1254:6	O
[	DYSPORT.xml:S3:1261:1	O
seeDescription	DYSPORT.xml:S3:1264:14	O
(	DYSPORT.xml:S3:1279:1	O
11	DYSPORT.xml:S3:1280:2	O
)	DYSPORT.xml:S3:1282:1	O
]	DYSPORT.xml:S3:1285:1	O
.	DYSPORT.xml:S3:1286:1	O

5.2	DYSPORT.xml:S3:1294:3	O
Spread	DYSPORT.xml:S3:1298:6	O
of	DYSPORT.xml:S3:1305:2	O
Toxin	DYSPORT.xml:S3:1308:5	O
Effect	DYSPORT.xml:S3:1314:6	O

Post	DYSPORT.xml:S3:1324:4	O
-	DYSPORT.xml:S3:1328:1	O
marketing	DYSPORT.xml:S3:1329:9	O
safety	DYSPORT.xml:S3:1339:6	O
data	DYSPORT.xml:S3:1346:4	O
from	DYSPORT.xml:S3:1351:4	O
DYSPORT	DYSPORT.xml:S3:1356:7	O
(	DYSPORT.xml:S3:1367:1	O
r	DYSPORT.xml:S3:1368:1	O
)	DYSPORT.xml:S3:1369:1	O
and	DYSPORT.xml:S3:1374:3	O
other	DYSPORT.xml:S3:1378:5	O
approved	DYSPORT.xml:S3:1384:8	O
botulinum	DYSPORT.xml:S3:1393:9	O
toxins	DYSPORT.xml:S3:1403:6	O
suggest	DYSPORT.xml:S3:1410:7	O
that	DYSPORT.xml:S3:1418:4	O
botulinum	DYSPORT.xml:S3:1423:9	O
toxin	DYSPORT.xml:S3:1433:5	B-AdverseReaction
effects	DYSPORT.xml:S3:1439:7	I-AdverseReaction
may	DYSPORT.xml:S3:1447:3	B-Factor
,	DYSPORT.xml:S3:1450:1	O
in	DYSPORT.xml:S3:1452:2	O
some	DYSPORT.xml:S3:1455:4	O
cases	DYSPORT.xml:S3:1460:5	O
,	DYSPORT.xml:S3:1465:1	O
be	DYSPORT.xml:S3:1467:2	O
observed	DYSPORT.xml:S3:1470:8	O
beyond	DYSPORT.xml:S3:1479:6	I-AdverseReaction
the	DYSPORT.xml:S3:1486:3	I-AdverseReaction
site	DYSPORT.xml:S3:1490:4	I-AdverseReaction
of	DYSPORT.xml:S3:1495:2	I-AdverseReaction
local	DYSPORT.xml:S3:1498:5	I-AdverseReaction
injection	DYSPORT.xml:S3:1504:9	I-AdverseReaction
.	DYSPORT.xml:S3:1513:1	O

The	DYSPORT.xml:S3:1515:3	O
symptoms	DYSPORT.xml:S3:1519:8	O
are	DYSPORT.xml:S3:1528:3	O
consistent	DYSPORT.xml:S3:1532:10	O
with	DYSPORT.xml:S3:1543:4	O
the	DYSPORT.xml:S3:1548:3	O
mechanism	DYSPORT.xml:S3:1552:9	O
of	DYSPORT.xml:S3:1562:2	O
action	DYSPORT.xml:S3:1565:6	O
of	DYSPORT.xml:S3:1572:2	O
botulinum	DYSPORT.xml:S3:1575:9	O
toxin	DYSPORT.xml:S3:1585:5	O
and	DYSPORT.xml:S3:1591:3	O
may	DYSPORT.xml:S3:1595:3	B-Factor
include	DYSPORT.xml:S3:1599:7	O
asthenia	DYSPORT.xml:S3:1607:8	B-AdverseReaction
,	DYSPORT.xml:S3:1615:1	O
generalized	DYSPORT.xml:S3:1617:11	B-AdverseReaction
muscle	DYSPORT.xml:S3:1629:6	I-AdverseReaction
weakness	DYSPORT.xml:S3:1636:8	I-AdverseReaction
,	DYSPORT.xml:S3:1644:1	O
diplopia	DYSPORT.xml:S3:1646:8	B-AdverseReaction
,	DYSPORT.xml:S3:1654:1	O
blurred	DYSPORT.xml:S3:1656:7	B-AdverseReaction
vision	DYSPORT.xml:S3:1664:6	I-AdverseReaction
,	DYSPORT.xml:S3:1670:1	O
ptosis	DYSPORT.xml:S3:1672:6	B-AdverseReaction
,	DYSPORT.xml:S3:1678:1	O
dysphagia	DYSPORT.xml:S3:1680:9	B-AdverseReaction
,	DYSPORT.xml:S3:1689:1	O
dysphonia	DYSPORT.xml:S3:1691:9	B-AdverseReaction
,	DYSPORT.xml:S3:1700:1	O
dysarthria	DYSPORT.xml:S3:1702:10	B-AdverseReaction
,	DYSPORT.xml:S3:1712:1	O
urinary	DYSPORT.xml:S3:1714:7	B-AdverseReaction
incontinence	DYSPORT.xml:S3:1722:12	I-AdverseReaction
and	DYSPORT.xml:S3:1735:3	O
breathing	DYSPORT.xml:S3:1739:9	B-AdverseReaction
difficulties	DYSPORT.xml:S3:1749:12	I-AdverseReaction
.	DYSPORT.xml:S3:1761:1	O

These	DYSPORT.xml:S3:1763:5	O
symptoms	DYSPORT.xml:S3:1769:8	O
have	DYSPORT.xml:S3:1778:4	O
been	DYSPORT.xml:S3:1783:4	O
reported	DYSPORT.xml:S3:1788:8	O
hours	DYSPORT.xml:S3:1797:5	O
to	DYSPORT.xml:S3:1803:2	O
weeks	DYSPORT.xml:S3:1806:5	O
after	DYSPORT.xml:S3:1812:5	O
injection	DYSPORT.xml:S3:1818:9	O
.	DYSPORT.xml:S3:1827:1	O

Swallowing	DYSPORT.xml:S3:1829:10	B-AdverseReaction
and	DYSPORT.xml:S3:1840:3	O
breathing	DYSPORT.xml:S3:1844:9	B-AdverseReaction
difficulties	DYSPORT.xml:S3:1854:12	I-AdverseReaction
can	DYSPORT.xml:S3:1867:3	O
be	DYSPORT.xml:S3:1871:2	O
life	DYSPORT.xml:S3:1874:4	O
threatening	DYSPORT.xml:S3:1879:11	O
and	DYSPORT.xml:S3:1891:3	O
there	DYSPORT.xml:S3:1895:5	O
have	DYSPORT.xml:S3:1901:4	O
been	DYSPORT.xml:S3:1906:4	O
reports	DYSPORT.xml:S3:1911:7	O
of	DYSPORT.xml:S3:1919:2	O
death	DYSPORT.xml:S3:1922:5	B-AdverseReaction
related	DYSPORT.xml:S3:1928:7	O
to	DYSPORT.xml:S3:1936:2	O
spread	DYSPORT.xml:S3:1939:6	B-AdverseReaction
of	DYSPORT.xml:S3:1946:2	I-AdverseReaction
toxin	DYSPORT.xml:S3:1949:5	I-AdverseReaction
effects	DYSPORT.xml:S3:1955:7	I-AdverseReaction
.	DYSPORT.xml:S3:1962:1	O

The	DYSPORT.xml:S3:1964:3	O
risk	DYSPORT.xml:S3:1968:4	O
of	DYSPORT.xml:S3:1973:2	O
the	DYSPORT.xml:S3:1976:3	O
symptoms	DYSPORT.xml:S3:1980:8	O
is	DYSPORT.xml:S3:1989:2	O
probably	DYSPORT.xml:S3:1992:8	O
greatest	DYSPORT.xml:S3:2001:8	O
in	DYSPORT.xml:S3:2010:2	O
children	DYSPORT.xml:S3:2013:8	O
treated	DYSPORT.xml:S3:2022:7	O
for	DYSPORT.xml:S3:2030:3	O
spasticity	DYSPORT.xml:S3:2034:10	O
but	DYSPORT.xml:S3:2045:3	O
symptoms	DYSPORT.xml:S3:2049:8	O
can	DYSPORT.xml:S3:2058:3	O
also	DYSPORT.xml:S3:2062:4	O
occur	DYSPORT.xml:S3:2067:5	O
in	DYSPORT.xml:S3:2073:2	O
adults	DYSPORT.xml:S3:2076:6	O
treated	DYSPORT.xml:S3:2083:7	O
for	DYSPORT.xml:S3:2091:3	O
spasticity	DYSPORT.xml:S3:2095:10	O
and	DYSPORT.xml:S3:2106:3	O
other	DYSPORT.xml:S3:2110:5	O
conditions	DYSPORT.xml:S3:2116:10	O
,	DYSPORT.xml:S3:2126:1	O
and	DYSPORT.xml:S3:2128:3	O
particularly	DYSPORT.xml:S3:2132:12	O
in	DYSPORT.xml:S3:2145:2	O
those	DYSPORT.xml:S3:2148:5	O
patients	DYSPORT.xml:S3:2154:8	O
who	DYSPORT.xml:S3:2163:3	O
have	DYSPORT.xml:S3:2167:4	O
underlying	DYSPORT.xml:S3:2172:10	O
conditions	DYSPORT.xml:S3:2183:10	O
that	DYSPORT.xml:S3:2194:4	O
would	DYSPORT.xml:S3:2199:5	O
predispose	DYSPORT.xml:S3:2205:10	O
them	DYSPORT.xml:S3:2216:4	O
to	DYSPORT.xml:S3:2221:2	O
these	DYSPORT.xml:S3:2224:5	O
symptoms	DYSPORT.xml:S3:2230:8	O
.	DYSPORT.xml:S3:2238:1	O

In	DYSPORT.xml:S3:2240:2	O
unapproved	DYSPORT.xml:S3:2243:10	O
uses	DYSPORT.xml:S3:2254:4	O
,	DYSPORT.xml:S3:2258:1	O
including	DYSPORT.xml:S3:2260:9	O
spasticity	DYSPORT.xml:S3:2270:10	O
in	DYSPORT.xml:S3:2281:2	O
children	DYSPORT.xml:S3:2284:8	O
and	DYSPORT.xml:S3:2293:3	O
in	DYSPORT.xml:S3:2297:2	O
approved	DYSPORT.xml:S3:2300:8	O
indications	DYSPORT.xml:S3:2309:11	O
,	DYSPORT.xml:S3:2320:1	O
symptoms	DYSPORT.xml:S3:2322:8	O
consistent	DYSPORT.xml:S3:2331:10	O
with	DYSPORT.xml:S3:2342:4	O
spread	DYSPORT.xml:S3:2347:6	B-AdverseReaction
of	DYSPORT.xml:S3:2354:2	I-AdverseReaction
toxin	DYSPORT.xml:S3:2357:5	I-AdverseReaction
effect	DYSPORT.xml:S3:2363:6	I-AdverseReaction
have	DYSPORT.xml:S3:2370:4	O
been	DYSPORT.xml:S3:2375:4	O
reported	DYSPORT.xml:S3:2380:8	O
at	DYSPORT.xml:S3:2389:2	O
doses	DYSPORT.xml:S3:2392:5	O
comparable	DYSPORT.xml:S3:2398:10	O
to	DYSPORT.xml:S3:2409:2	O
or	DYSPORT.xml:S3:2412:2	O
lower	DYSPORT.xml:S3:2415:5	O
than	DYSPORT.xml:S3:2421:4	O
the	DYSPORT.xml:S3:2426:3	O
maximum	DYSPORT.xml:S3:2430:7	O
recommended	DYSPORT.xml:S3:2438:11	O
total	DYSPORT.xml:S3:2450:5	O
dose	DYSPORT.xml:S3:2456:4	O
.	DYSPORT.xml:S3:2460:1	O

5.3	DYSPORT.xml:S3:2468:3	O
Dysphagia	DYSPORT.xml:S3:2472:9	O
and	DYSPORT.xml:S3:2482:3	O
Breathing	DYSPORT.xml:S3:2486:9	O
Difficulties	DYSPORT.xml:S3:2496:12	O

Treatment	DYSPORT.xml:S3:2512:9	O
with	DYSPORT.xml:S3:2522:4	O
DYSPORT	DYSPORT.xml:S3:2527:7	O
(	DYSPORT.xml:S3:2538:1	O
r	DYSPORT.xml:S3:2539:1	O
)	DYSPORT.xml:S3:2540:1	O
and	DYSPORT.xml:S3:2545:3	O
other	DYSPORT.xml:S3:2549:5	O
botulinum	DYSPORT.xml:S3:2555:9	O
toxin	DYSPORT.xml:S3:2565:5	O
products	DYSPORT.xml:S3:2571:8	O
can	DYSPORT.xml:S3:2580:3	B-Factor
result	DYSPORT.xml:S3:2584:6	O
in	DYSPORT.xml:S3:2591:2	O
swallowing	DYSPORT.xml:S3:2594:10	B-AdverseReaction
or	DYSPORT.xml:S3:2605:2	O
breathing	DYSPORT.xml:S3:2608:9	B-AdverseReaction
difficulties	DYSPORT.xml:S3:2618:12	I-AdverseReaction
.	DYSPORT.xml:S3:2630:1	O

Patients	DYSPORT.xml:S3:2632:8	O
with	DYSPORT.xml:S3:2641:4	O
pre	DYSPORT.xml:S3:2646:3	O
-	DYSPORT.xml:S3:2649:1	O
existing	DYSPORT.xml:S3:2651:8	O
swallowing	DYSPORT.xml:S3:2660:10	O
or	DYSPORT.xml:S3:2671:2	O
breathing	DYSPORT.xml:S3:2674:9	O
difficulties	DYSPORT.xml:S3:2684:12	O
may	DYSPORT.xml:S3:2697:3	O
be	DYSPORT.xml:S3:2701:2	O
more	DYSPORT.xml:S3:2704:4	O
susceptible	DYSPORT.xml:S3:2709:11	O
to	DYSPORT.xml:S3:2721:2	O
these	DYSPORT.xml:S3:2724:5	O
complications	DYSPORT.xml:S3:2730:13	O
.	DYSPORT.xml:S3:2743:1	O

In	DYSPORT.xml:S3:2745:2	O
most	DYSPORT.xml:S3:2748:4	O
cases	DYSPORT.xml:S3:2753:5	O
,	DYSPORT.xml:S3:2758:1	O
this	DYSPORT.xml:S3:2760:4	O
is	DYSPORT.xml:S3:2765:2	O
a	DYSPORT.xml:S3:2768:1	O
consequence	DYSPORT.xml:S3:2770:11	O
of	DYSPORT.xml:S3:2782:2	O
weakening	DYSPORT.xml:S3:2785:9	O
of	DYSPORT.xml:S3:2795:2	O
muscles	DYSPORT.xml:S3:2798:7	O
in	DYSPORT.xml:S3:2806:2	O
the	DYSPORT.xml:S3:2809:3	O
area	DYSPORT.xml:S3:2813:4	O
of	DYSPORT.xml:S3:2818:2	O
injection	DYSPORT.xml:S3:2821:9	O
that	DYSPORT.xml:S3:2831:4	O
are	DYSPORT.xml:S3:2836:3	O
involved	DYSPORT.xml:S3:2840:8	O
in	DYSPORT.xml:S3:2849:2	O
breathing	DYSPORT.xml:S3:2852:9	O
or	DYSPORT.xml:S3:2862:2	O
swallowing	DYSPORT.xml:S3:2865:10	O
.	DYSPORT.xml:S3:2875:1	O

When	DYSPORT.xml:S3:2877:4	O
distant	DYSPORT.xml:S3:2882:7	O
effects	DYSPORT.xml:S3:2890:7	O
occur	DYSPORT.xml:S3:2898:5	O
,	DYSPORT.xml:S3:2903:1	O
additional	DYSPORT.xml:S3:2905:10	O
respiratory	DYSPORT.xml:S3:2916:11	O
muscles	DYSPORT.xml:S3:2928:7	O
may	DYSPORT.xml:S3:2936:3	O
be	DYSPORT.xml:S3:2940:2	O
involved	DYSPORT.xml:S3:2943:8	O
[	DYSPORT.xml:S3:2952:1	O
seeWarnings	DYSPORT.xml:S3:2955:11	O
and	DYSPORT.xml:S3:2967:3	O
Precautions	DYSPORT.xml:S3:2971:11	O
(	DYSPORT.xml:S3:2983:1	O
5.2	DYSPORT.xml:S3:2984:3	O
)	DYSPORT.xml:S3:2987:1	O
]	DYSPORT.xml:S3:2990:1	O
.	DYSPORT.xml:S3:2991:1	O

Deaths	DYSPORT.xml:S3:2997:6	B-AdverseReaction
as	DYSPORT.xml:S3:3004:2	O
a	DYSPORT.xml:S3:3007:1	O
complication	DYSPORT.xml:S3:3009:12	O
of	DYSPORT.xml:S3:3022:2	O
severe	DYSPORT.xml:S3:3025:6	B-Severity
dysphagia	DYSPORT.xml:S3:3032:9	B-AdverseReaction
have	DYSPORT.xml:S3:3042:4	O
been	DYSPORT.xml:S3:3047:4	O
reported	DYSPORT.xml:S3:3052:8	O
after	DYSPORT.xml:S3:3061:5	O
treatment	DYSPORT.xml:S3:3067:9	O
with	DYSPORT.xml:S3:3077:4	O
botulinum	DYSPORT.xml:S3:3082:9	O
toxin	DYSPORT.xml:S3:3092:5	O
.	DYSPORT.xml:S3:3097:1	O

Dysphagia	DYSPORT.xml:S3:3099:9	B-AdverseReaction
may	DYSPORT.xml:S3:3109:3	O
persist	DYSPORT.xml:S3:3113:7	O
for	DYSPORT.xml:S3:3121:3	O
several	DYSPORT.xml:S3:3125:7	O
weeks	DYSPORT.xml:S3:3133:5	O
,	DYSPORT.xml:S3:3138:1	O
and	DYSPORT.xml:S3:3140:3	O
require	DYSPORT.xml:S3:3144:7	O
use	DYSPORT.xml:S3:3152:3	O
of	DYSPORT.xml:S3:3156:2	O
a	DYSPORT.xml:S3:3159:1	O
feeding	DYSPORT.xml:S3:3161:7	O
tube	DYSPORT.xml:S3:3169:4	O
to	DYSPORT.xml:S3:3174:2	O
maintain	DYSPORT.xml:S3:3177:8	O
adequate	DYSPORT.xml:S3:3186:8	O
nutrition	DYSPORT.xml:S3:3195:9	O
and	DYSPORT.xml:S3:3205:3	O
hydration	DYSPORT.xml:S3:3209:9	O
.	DYSPORT.xml:S3:3218:1	O

Aspiration	DYSPORT.xml:S3:3220:10	B-AdverseReaction
may	DYSPORT.xml:S3:3231:3	B-Factor
result	DYSPORT.xml:S3:3235:6	O
from	DYSPORT.xml:S3:3242:4	O
severe	DYSPORT.xml:S3:3247:6	B-Severity
dysphagia	DYSPORT.xml:S3:3254:9	B-AdverseReaction
and	DYSPORT.xml:S3:3264:3	O
is	DYSPORT.xml:S3:3268:2	O
a	DYSPORT.xml:S3:3271:1	O
particular	DYSPORT.xml:S3:3273:10	O
risk	DYSPORT.xml:S3:3284:4	O
when	DYSPORT.xml:S3:3289:4	O
treating	DYSPORT.xml:S3:3294:8	O
patients	DYSPORT.xml:S3:3303:8	O
in	DYSPORT.xml:S3:3312:2	O
whom	DYSPORT.xml:S3:3315:4	O
swallowing	DYSPORT.xml:S3:3320:10	O
or	DYSPORT.xml:S3:3331:2	O
respiratory	DYSPORT.xml:S3:3334:11	O
function	DYSPORT.xml:S3:3346:8	O
is	DYSPORT.xml:S3:3355:2	O
already	DYSPORT.xml:S3:3358:7	O
compromised	DYSPORT.xml:S3:3366:11	O
.	DYSPORT.xml:S3:3377:1	O

Treatment	DYSPORT.xml:S3:3383:9	O
of	DYSPORT.xml:S3:3393:2	O
cervical	DYSPORT.xml:S3:3396:8	O
dystonia	DYSPORT.xml:S3:3405:8	O
with	DYSPORT.xml:S3:3414:4	O
botulinum	DYSPORT.xml:S3:3419:9	O
toxins	DYSPORT.xml:S3:3429:6	O
may	DYSPORT.xml:S3:3436:3	B-Factor
weaken	DYSPORT.xml:S3:3440:6	B-AdverseReaction
neck	DYSPORT.xml:S3:3447:4	I-AdverseReaction
muscles	DYSPORT.xml:S3:3452:7	I-AdverseReaction
that	DYSPORT.xml:S3:3460:4	O
serve	DYSPORT.xml:S3:3465:5	O
as	DYSPORT.xml:S3:3471:2	O
accessory	DYSPORT.xml:S3:3474:9	O
muscles	DYSPORT.xml:S3:3484:7	O
of	DYSPORT.xml:S3:3492:2	O
ventilation	DYSPORT.xml:S3:3495:11	O
.	DYSPORT.xml:S3:3506:1	O

This	DYSPORT.xml:S3:3508:4	O
may	DYSPORT.xml:S3:3513:3	B-Factor
result	DYSPORT.xml:S3:3517:6	O
in	DYSPORT.xml:S3:3524:2	O
a	DYSPORT.xml:S3:3527:1	O
critical	DYSPORT.xml:S3:3529:8	B-Severity
loss	DYSPORT.xml:S3:3538:4	B-AdverseReaction
of	DYSPORT.xml:S3:3543:2	I-AdverseReaction
breathing	DYSPORT.xml:S3:3546:9	I-AdverseReaction
capacity	DYSPORT.xml:S3:3556:8	I-AdverseReaction
in	DYSPORT.xml:S3:3565:2	O
patients	DYSPORT.xml:S3:3568:8	O
with	DYSPORT.xml:S3:3577:4	O
respiratory	DYSPORT.xml:S3:3582:11	O
disorders	DYSPORT.xml:S3:3594:9	O
who	DYSPORT.xml:S3:3604:3	O
may	DYSPORT.xml:S3:3608:3	O
have	DYSPORT.xml:S3:3612:4	O
become	DYSPORT.xml:S3:3617:6	O
dependent	DYSPORT.xml:S3:3624:9	O
upon	DYSPORT.xml:S3:3634:4	O
these	DYSPORT.xml:S3:3639:5	O
accessory	DYSPORT.xml:S3:3645:9	O
muscles	DYSPORT.xml:S3:3655:7	O
.	DYSPORT.xml:S3:3662:1	O

There	DYSPORT.xml:S3:3664:5	O
have	DYSPORT.xml:S3:3670:4	O
been	DYSPORT.xml:S3:3675:4	O
post	DYSPORT.xml:S3:3680:4	O
-	DYSPORT.xml:S3:3684:1	O
marketing	DYSPORT.xml:S3:3685:9	O
reports	DYSPORT.xml:S3:3695:7	O
of	DYSPORT.xml:S3:3703:2	O
serious	DYSPORT.xml:S3:3706:7	B-Severity
breathing	DYSPORT.xml:S3:3714:9	B-AdverseReaction
difficulties	DYSPORT.xml:S3:3724:12	I-AdverseReaction
,	DYSPORT.xml:S3:3736:1	O
including	DYSPORT.xml:S3:3738:9	O
respiratory	DYSPORT.xml:S3:3748:11	B-AdverseReaction
failure	DYSPORT.xml:S3:3760:7	I-AdverseReaction
.	DYSPORT.xml:S3:3767:1	O

Patients	DYSPORT.xml:S3:3773:8	B-Factor
treated	DYSPORT.xml:S3:3782:7	O
with	DYSPORT.xml:S3:3790:4	O
botulinum	DYSPORT.xml:S3:3795:9	O
toxin	DYSPORT.xml:S3:3805:5	O
may	DYSPORT.xml:S3:3811:3	O
require	DYSPORT.xml:S3:3815:7	O
immediate	DYSPORT.xml:S3:3823:9	O
medical	DYSPORT.xml:S3:3833:7	O
attention	DYSPORT.xml:S3:3841:9	O
should	DYSPORT.xml:S3:3851:6	O
they	DYSPORT.xml:S3:3858:4	O
develop	DYSPORT.xml:S3:3863:7	O
problems	DYSPORT.xml:S3:3871:8	O
with	DYSPORT.xml:S3:3880:4	O
swallowing	DYSPORT.xml:S3:3885:10	O
,	DYSPORT.xml:S3:3895:1	O
speech	DYSPORT.xml:S3:3897:6	O
or	DYSPORT.xml:S3:3904:2	O
respiratory	DYSPORT.xml:S3:3907:11	O
disorders	DYSPORT.xml:S3:3919:9	O
.	DYSPORT.xml:S3:3928:1	O

These	DYSPORT.xml:S3:3930:5	O
reactions	DYSPORT.xml:S3:3936:9	O
can	DYSPORT.xml:S3:3946:3	O
occur	DYSPORT.xml:S3:3950:5	O
within	DYSPORT.xml:S3:3956:6	O
hours	DYSPORT.xml:S3:3963:5	O
to	DYSPORT.xml:S3:3969:2	O
weeks	DYSPORT.xml:S3:3972:5	O
after	DYSPORT.xml:S3:3978:5	O
injection	DYSPORT.xml:S3:3984:9	O
with	DYSPORT.xml:S3:3994:4	O
botulinum	DYSPORT.xml:S3:3999:9	O
toxin	DYSPORT.xml:S3:4009:5	O
[	DYSPORT.xml:S3:4015:1	O
seeWarnings	DYSPORT.xml:S3:4018:11	O
and	DYSPORT.xml:S3:4030:3	O
Precautions	DYSPORT.xml:S3:4034:11	O
(	DYSPORT.xml:S3:4046:1	O
5.2	DYSPORT.xml:S3:4047:3	O
)	DYSPORT.xml:S3:4050:1	O
,	DYSPORT.xml:S3:4051:1	O
Adverse	DYSPORT.xml:S3:4052:7	O
Reactions	DYSPORT.xml:S3:4060:9	O
(	DYSPORT.xml:S3:4070:1	O
6.1	DYSPORT.xml:S3:4071:3	O
)	DYSPORT.xml:S3:4074:1	O
,	DYSPORT.xml:S3:4075:1	O
Clinical	DYSPORT.xml:S3:4076:8	O
Pharmacology	DYSPORT.xml:S3:4085:12	O
(	DYSPORT.xml:S3:4098:1	O
12.2	DYSPORT.xml:S3:4099:4	O
)	DYSPORT.xml:S3:4103:1	O
]	DYSPORT.xml:S3:4106:1	O
.	DYSPORT.xml:S3:4107:1	O

5.4	DYSPORT.xml:S3:4115:3	O
Facial	DYSPORT.xml:S3:4119:6	O
Anatomy	DYSPORT.xml:S3:4126:7	O
in	DYSPORT.xml:S3:4134:2	O
the	DYSPORT.xml:S3:4137:3	O
Treatment	DYSPORT.xml:S3:4141:9	O
of	DYSPORT.xml:S3:4151:2	O
Glabellar	DYSPORT.xml:S3:4154:9	O
Lines	DYSPORT.xml:S3:4164:5	O

Caution	DYSPORT.xml:S3:4173:7	O
should	DYSPORT.xml:S3:4181:6	O
be	DYSPORT.xml:S3:4188:2	O
exercised	DYSPORT.xml:S3:4191:9	O
when	DYSPORT.xml:S3:4201:4	O
administering	DYSPORT.xml:S3:4206:13	O
DYSPORT	DYSPORT.xml:S3:4220:7	O
(	DYSPORT.xml:S3:4231:1	O
r	DYSPORT.xml:S3:4232:1	O
)	DYSPORT.xml:S3:4233:1	O
to	DYSPORT.xml:S3:4238:2	O
patients	DYSPORT.xml:S3:4241:8	O
with	DYSPORT.xml:S3:4250:4	O
surgical	DYSPORT.xml:S3:4255:8	O
alterations	DYSPORT.xml:S3:4264:11	O
to	DYSPORT.xml:S3:4276:2	O
the	DYSPORT.xml:S3:4279:3	O
facial	DYSPORT.xml:S3:4283:6	O
anatomy	DYSPORT.xml:S3:4290:7	O
,	DYSPORT.xml:S3:4297:1	O
excessive	DYSPORT.xml:S3:4299:9	O
weakness	DYSPORT.xml:S3:4309:8	O
or	DYSPORT.xml:S3:4318:2	O
atrophy	DYSPORT.xml:S3:4321:7	O
in	DYSPORT.xml:S3:4329:2	O
the	DYSPORT.xml:S3:4332:3	O
target	DYSPORT.xml:S3:4336:6	O
muscle	DYSPORT.xml:S3:4343:6	O
(	DYSPORT.xml:S3:4349:1	O
s	DYSPORT.xml:S3:4350:1	O
)	DYSPORT.xml:S3:4351:1	O
,	DYSPORT.xml:S3:4352:1	O
marked	DYSPORT.xml:S3:4354:6	O
facial	DYSPORT.xml:S3:4361:6	O
asymmetry	DYSPORT.xml:S3:4368:9	O
,	DYSPORT.xml:S3:4377:1	O
inflammation	DYSPORT.xml:S3:4379:12	O
at	DYSPORT.xml:S3:4392:2	O
the	DYSPORT.xml:S3:4395:3	O
injection	DYSPORT.xml:S3:4399:9	O
site	DYSPORT.xml:S3:4409:4	O
(	DYSPORT.xml:S3:4413:1	O
s	DYSPORT.xml:S3:4414:1	O
)	DYSPORT.xml:S3:4415:1	O
,	DYSPORT.xml:S3:4416:1	O
ptosis	DYSPORT.xml:S3:4418:6	O
,	DYSPORT.xml:S3:4424:1	O
excessive	DYSPORT.xml:S3:4426:9	O
dermatochalasis	DYSPORT.xml:S3:4436:15	O
,	DYSPORT.xml:S3:4451:1	O
deep	DYSPORT.xml:S3:4453:4	O
dermal	DYSPORT.xml:S3:4458:6	O
scarring	DYSPORT.xml:S3:4465:8	O
,	DYSPORT.xml:S3:4473:1	O
thick	DYSPORT.xml:S3:4475:5	O
sebaceous	DYSPORT.xml:S3:4481:9	O
skin	DYSPORT.xml:S3:4491:4	O
[	DYSPORT.xml:S3:4496:1	O
seeDosage	DYSPORT.xml:S3:4499:9	O
and	DYSPORT.xml:S3:4509:3	O
Administration	DYSPORT.xml:S3:4513:14	O
(	DYSPORT.xml:S3:4528:1	O
2.3	DYSPORT.xml:S3:4529:3	O
]	DYSPORT.xml:S3:4534:1	O
or	DYSPORT.xml:S3:4536:2	O
the	DYSPORT.xml:S3:4539:3	O
inability	DYSPORT.xml:S3:4543:9	O
to	DYSPORT.xml:S3:4553:2	O
substantially	DYSPORT.xml:S3:4556:13	O
lessen	DYSPORT.xml:S3:4570:6	O
glabellar	DYSPORT.xml:S3:4577:9	O
lines	DYSPORT.xml:S3:4587:5	O
by	DYSPORT.xml:S3:4593:2	O
physically	DYSPORT.xml:S3:4596:10	O
spreading	DYSPORT.xml:S3:4607:9	O
them	DYSPORT.xml:S3:4617:4	O
apart	DYSPORT.xml:S3:4622:5	O
[	DYSPORT.xml:S3:4628:1	O
seeClinical	DYSPORT.xml:S3:4631:11	O
Studies	DYSPORT.xml:S3:4643:7	O
(	DYSPORT.xml:S3:4651:1	O
14.2	DYSPORT.xml:S3:4652:4	O
)	DYSPORT.xml:S3:4656:1	O
]	DYSPORT.xml:S3:4659:1	O
.	DYSPORT.xml:S3:4660:1	O

Do	DYSPORT.xml:S3:4666:2	O
not	DYSPORT.xml:S3:4669:3	O
exceed	DYSPORT.xml:S3:4673:6	O
the	DYSPORT.xml:S3:4680:3	O
recommended	DYSPORT.xml:S3:4684:11	O
dosage	DYSPORT.xml:S3:4696:6	O
and	DYSPORT.xml:S3:4703:3	O
frequency	DYSPORT.xml:S3:4707:9	O
of	DYSPORT.xml:S3:4717:2	O
administration	DYSPORT.xml:S3:4720:14	O
of	DYSPORT.xml:S3:4735:2	O
DYSPORT	DYSPORT.xml:S3:4738:7	B-Factor
(	DYSPORT.xml:S3:4749:1	O
r	DYSPORT.xml:S3:4750:1	O
)	DYSPORT.xml:S3:4751:1	O
.	DYSPORT.xml:S3:4756:1	O

In	DYSPORT.xml:S3:4758:2	O
clinical	DYSPORT.xml:S3:4761:8	O
trials	DYSPORT.xml:S3:4770:6	O
,	DYSPORT.xml:S3:4776:1	O
subjects	DYSPORT.xml:S3:4778:8	O
who	DYSPORT.xml:S3:4787:3	O
received	DYSPORT.xml:S3:4791:8	O
a	DYSPORT.xml:S3:4800:1	O
higher	DYSPORT.xml:S3:4802:6	O
dose	DYSPORT.xml:S3:4809:4	O
of	DYSPORT.xml:S3:4814:2	O
DYSPORT	DYSPORT.xml:S3:4817:7	O
(	DYSPORT.xml:S3:4828:1	O
r	DYSPORT.xml:S3:4829:1	O
)	DYSPORT.xml:S3:4830:1	O
had	DYSPORT.xml:S3:4835:3	O
an	DYSPORT.xml:S3:4839:2	O
increased	DYSPORT.xml:S3:4842:9	O
incidence	DYSPORT.xml:S3:4852:9	O
of	DYSPORT.xml:S3:4862:2	O
eyelid	DYSPORT.xml:S3:4865:6	B-AdverseReaction
ptosis	DYSPORT.xml:S3:4872:6	I-AdverseReaction
.	DYSPORT.xml:S3:4878:1	O

5.5	DYSPORT.xml:S3:4886:3	O
Pre	DYSPORT.xml:S3:4890:3	O
-	DYSPORT.xml:S3:4893:1	O
existing	DYSPORT.xml:S3:4894:8	O
Neuromuscular	DYSPORT.xml:S3:4903:13	O
Disorders	DYSPORT.xml:S3:4917:9	O

Individuals	DYSPORT.xml:S3:4930:11	O
with	DYSPORT.xml:S3:4942:4	O
peripheral	DYSPORT.xml:S3:4947:10	O
motor	DYSPORT.xml:S3:4958:5	O
neuropathic	DYSPORT.xml:S3:4964:11	O
diseases	DYSPORT.xml:S3:4976:8	O
,	DYSPORT.xml:S3:4984:1	O
amyotrophic	DYSPORT.xml:S3:4986:11	O
lateral	DYSPORT.xml:S3:4998:7	O
sclerosis	DYSPORT.xml:S3:5006:9	O
or	DYSPORT.xml:S3:5016:2	O
neuromuscular	DYSPORT.xml:S3:5019:13	O
junction	DYSPORT.xml:S3:5033:8	O
disorders	DYSPORT.xml:S3:5042:9	O
(	DYSPORT.xml:S3:5052:1	O
e	DYSPORT.xml:S3:5053:1	O
.	DYSPORT.xml:S3:5054:1	O
g	DYSPORT.xml:S3:5055:1	O
.	DYSPORT.xml:S3:5056:1	O
,	DYSPORT.xml:S3:5057:1	O
myasthenia	DYSPORT.xml:S3:5059:10	O
gravis	DYSPORT.xml:S3:5070:6	O
or	DYSPORT.xml:S3:5077:2	O
Lambert	DYSPORT.xml:S3:5080:7	O
-	DYSPORT.xml:S3:5087:1	O
Eaton	DYSPORT.xml:S3:5088:5	O
syndrome	DYSPORT.xml:S3:5094:8	O
)	DYSPORT.xml:S3:5102:1	O
should	DYSPORT.xml:S3:5104:6	O
be	DYSPORT.xml:S3:5111:2	O
monitored	DYSPORT.xml:S3:5114:9	O
particularly	DYSPORT.xml:S3:5124:12	O
closely	DYSPORT.xml:S3:5137:7	O
when	DYSPORT.xml:S3:5145:4	O
given	DYSPORT.xml:S3:5150:5	O
botulinum	DYSPORT.xml:S3:5156:9	O
toxin	DYSPORT.xml:S3:5166:5	O
.	DYSPORT.xml:S3:5171:1	O

Patients	DYSPORT.xml:S3:5173:8	O
with	DYSPORT.xml:S3:5182:4	O
neuromuscular	DYSPORT.xml:S3:5187:13	O
disorders	DYSPORT.xml:S3:5201:9	O
may	DYSPORT.xml:S3:5211:3	O
be	DYSPORT.xml:S3:5215:2	O
at	DYSPORT.xml:S3:5218:2	O
increased	DYSPORT.xml:S3:5221:9	O
risk	DYSPORT.xml:S3:5231:4	B-Factor
of	DYSPORT.xml:S3:5236:2	O
clinically	DYSPORT.xml:S3:5239:10	O
significant	DYSPORT.xml:S3:5250:11	O
effects	DYSPORT.xml:S3:5262:7	O
including	DYSPORT.xml:S3:5270:9	O
severe	DYSPORT.xml:S3:5280:6	B-Severity
dysphagia	DYSPORT.xml:S3:5287:9	B-AdverseReaction
and	DYSPORT.xml:S3:5297:3	O
respiratory	DYSPORT.xml:S3:5301:11	B-AdverseReaction
compromise	DYSPORT.xml:S3:5313:10	I-AdverseReaction
from	DYSPORT.xml:S3:5324:4	O
typical	DYSPORT.xml:S3:5329:7	O
doses	DYSPORT.xml:S3:5337:5	O
of	DYSPORT.xml:S3:5343:2	O
DYSPORT	DYSPORT.xml:S3:5346:7	O
(	DYSPORT.xml:S3:5357:1	O
r	DYSPORT.xml:S3:5358:1	O
)	DYSPORT.xml:S3:5359:1	O
[	DYSPORT.xml:S3:5364:1	O
seeAdverse	DYSPORT.xml:S3:5367:10	O
Reactions	DYSPORT.xml:S3:5378:9	O
(	DYSPORT.xml:S3:5388:1	O
6.1	DYSPORT.xml:S3:5389:3	O
)	DYSPORT.xml:S3:5392:1	O
]	DYSPORT.xml:S3:5395:1	O
.	DYSPORT.xml:S3:5396:1	O

5.6	DYSPORT.xml:S3:5404:3	O
Human	DYSPORT.xml:S3:5408:5	O
Albumin	DYSPORT.xml:S3:5414:7	O

This	DYSPORT.xml:S3:5425:4	O
product	DYSPORT.xml:S3:5430:7	O
contains	DYSPORT.xml:S3:5438:8	O
albumin	DYSPORT.xml:S3:5447:7	O
,	DYSPORT.xml:S3:5454:1	O
a	DYSPORT.xml:S3:5456:1	O
derivative	DYSPORT.xml:S3:5458:10	O
of	DYSPORT.xml:S3:5469:2	O
human	DYSPORT.xml:S3:5472:5	O
blood	DYSPORT.xml:S3:5478:5	O
.	DYSPORT.xml:S3:5483:1	O

Based	DYSPORT.xml:S3:5485:5	O
on	DYSPORT.xml:S3:5491:2	O
effective	DYSPORT.xml:S3:5494:9	O
donor	DYSPORT.xml:S3:5504:5	O
screening	DYSPORT.xml:S3:5510:9	O
and	DYSPORT.xml:S3:5520:3	O
product	DYSPORT.xml:S3:5524:7	O
manufacturing	DYSPORT.xml:S3:5532:13	O
processes	DYSPORT.xml:S3:5546:9	O
,	DYSPORT.xml:S3:5555:1	O
it	DYSPORT.xml:S3:5557:2	O
carries	DYSPORT.xml:S3:5560:7	O
an	DYSPORT.xml:S3:5568:2	O
extremely	DYSPORT.xml:S3:5571:9	O
remote	DYSPORT.xml:S3:5581:6	O
risk	DYSPORT.xml:S3:5588:4	B-Factor
for	DYSPORT.xml:S3:5593:3	O
transmission	DYSPORT.xml:S3:5597:12	O
of	DYSPORT.xml:S3:5610:2	O
viral	DYSPORT.xml:S3:5613:5	B-AdverseReaction
diseases	DYSPORT.xml:S3:5619:8	I-AdverseReaction
.	DYSPORT.xml:S3:5627:1	O

A	DYSPORT.xml:S3:5629:1	O
theoretical	DYSPORT.xml:S3:5631:11	O
risk	DYSPORT.xml:S3:5643:4	B-Factor
for	DYSPORT.xml:S3:5648:3	O
transmission	DYSPORT.xml:S3:5652:12	O
of	DYSPORT.xml:S3:5665:2	O
Creutzfeldt	DYSPORT.xml:S3:5668:11	B-AdverseReaction
-	DYSPORT.xml:S3:5679:1	I-AdverseReaction
Jakob	DYSPORT.xml:S3:5680:5	I-AdverseReaction
disease	DYSPORT.xml:S3:5686:7	I-AdverseReaction
(	DYSPORT.xml:S3:5694:1	O
CJD	DYSPORT.xml:S3:5695:3	B-AdverseReaction
)	DYSPORT.xml:S3:5698:1	O
is	DYSPORT.xml:S3:5700:2	O
also	DYSPORT.xml:S3:5703:4	O
considered	DYSPORT.xml:S3:5708:10	O
extremely	DYSPORT.xml:S3:5719:9	O
remote	DYSPORT.xml:S3:5729:6	O
.	DYSPORT.xml:S3:5735:1	O

No	DYSPORT.xml:S3:5737:2	B-Negation
cases	DYSPORT.xml:S3:5740:5	O
of	DYSPORT.xml:S3:5746:2	O
transmission	DYSPORT.xml:S3:5749:12	I-Negation
of	DYSPORT.xml:S3:5762:2	O
viral	DYSPORT.xml:S3:5765:5	B-AdverseReaction
diseases	DYSPORT.xml:S3:5771:8	I-AdverseReaction
or	DYSPORT.xml:S3:5780:2	O
CJD	DYSPORT.xml:S3:5783:3	B-AdverseReaction
have	DYSPORT.xml:S3:5787:4	O
ever	DYSPORT.xml:S3:5792:4	O
been	DYSPORT.xml:S3:5797:4	O
reported	DYSPORT.xml:S3:5802:8	O
for	DYSPORT.xml:S3:5811:3	O
albumin	DYSPORT.xml:S3:5815:7	O
.	DYSPORT.xml:S3:5822:1	O

5.7	DYSPORT.xml:S3:5830:3	O
Intradermal	DYSPORT.xml:S3:5834:11	O
Immune	DYSPORT.xml:S3:5846:6	O
Reaction	DYSPORT.xml:S3:5853:8	O

The	DYSPORT.xml:S3:5865:3	O
possibility	DYSPORT.xml:S3:5869:11	O
of	DYSPORT.xml:S3:5881:2	O
an	DYSPORT.xml:S3:5884:2	O
immune	DYSPORT.xml:S3:5887:6	O
reaction	DYSPORT.xml:S3:5894:8	O
when	DYSPORT.xml:S3:5903:4	O
injected	DYSPORT.xml:S3:5908:8	O
intradermally	DYSPORT.xml:S3:5917:13	O
is	DYSPORT.xml:S3:5931:2	O
unknown	DYSPORT.xml:S3:5934:7	O
.	DYSPORT.xml:S3:5941:1	O

The	DYSPORT.xml:S3:5943:3	O
safety	DYSPORT.xml:S3:5947:6	O
of	DYSPORT.xml:S3:5954:2	O
DYSPORT	DYSPORT.xml:S3:5957:7	O
(	DYSPORT.xml:S3:5968:1	O
r	DYSPORT.xml:S3:5969:1	O
)	DYSPORT.xml:S3:5970:1	O
for	DYSPORT.xml:S3:5975:3	O
the	DYSPORT.xml:S3:5979:3	O
treatment	DYSPORT.xml:S3:5983:9	O
of	DYSPORT.xml:S3:5993:2	O
hyperhidrosis	DYSPORT.xml:S3:5996:13	O
has	DYSPORT.xml:S3:6010:3	O
not	DYSPORT.xml:S3:6014:3	O
been	DYSPORT.xml:S3:6018:4	O
established	DYSPORT.xml:S3:6023:11	O
.	DYSPORT.xml:S3:6034:1	O

DYSPORT	DYSPORT.xml:S3:6036:7	O
(	DYSPORT.xml:S3:6045:1	O
r	DYSPORT.xml:S3:6046:1	O
)	DYSPORT.xml:S3:6047:1	O
is	DYSPORT.xml:S3:6050:2	O
approved	DYSPORT.xml:S3:6053:8	O
only	DYSPORT.xml:S3:6062:4	O
for	DYSPORT.xml:S3:6067:3	O
intramuscular	DYSPORT.xml:S3:6071:13	O
injection	DYSPORT.xml:S3:6085:9	O
.	DYSPORT.xml:S3:6095:1	O
